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Abstract
Atherosclerotic and restenotic lesions develop in the blood vessel wall as a result of
chronic inflammatory and uncontrolled proliferative responses to injury.
Glucocorticoids are steroid hormones which exert both anti-inflammatory and
anti-proliferative actions in the body, and can interact directly with the vascular wall.
The effect of these hormones is controlled, in part, by the tissue-specific pre-receptor
generation of active steroid by the enzyme 11 P-hydroxysteroid dehydrogenase 1
(lip-HSDl). Whilst administration of exogenous glucocorticoids can inhibit
restenosis, it is not known whether the availability of endogenous glucocorticoids
influences the vascular response to injury. We hypothesised that endogenous
glucocorticoids will directly inhibit vascular lesion formation, and that this effect
will be modulated by 1 lp-HSDl.
In order to study the influence of glucocorticoids on vascular lesion formation, a
model of intra-luminal, wire-induced vascular injury in the mouse femoral artery was
developed. This model caused extensive stretching of the arterial wall and
denudation of the endothelium, followed by the time-dependent formation of smooth
muscle-rich neointimal lesions.
The effects of exogenous glucocorticoids on lesion development were assessed using
different methods of administration. Systemic administration of dexamethasone by
sub-cutaneous injection (lmg/kg/day, 21 days) reduced the size of smooth
muscle-rich lesions after injury, but also promoted the formation of large thrombotic
lesions. These occluded the lumen, leading to a similar reduction in luminal diameter
to that seen in vehicle-treated controls. In contrast, local application of Cortisol at the
vessel wall via sustained release from an implanted pellet (21 days), significantly
reduced neointimal lesion growth when compared to contra-lateral vehicle controls,
without the development of thrombotic lesions. The influence of endogenous
glucocorticoid activity on neointimal proliferation in the femoral artery was assessed
using administration of a glucocorticoid receptor antagonist (RU38486, via
implanted pellet for 21 days) or via selective pharmacological inhibition of
lip-HSDl (60mg/kg/day via oral gavage, 14 days) and the use of mice with
transgenic disruption of 1 ip-HSDl. Neither glucocorticoid receptor antagonism nor
i
1 lp-HSDl inhibition or deletion significantly altered neointimal lesion development
after injury.
These results indicate that exogenous glucocorticoids do inhibit neointimal
proliferation in this model but their effectiveness depends upon whether they are
administered systemically or locally at the vessel wall. Furthermore, it was
demonstrated that metabolism of endogenous glucocorticoids within the artery wall
does not significantly regulate neointimal proliferation in response to injury.
Therefore, whereas the manipulation of endogenous glucocorticoid generation in the
vessel wall may not represent a novel therapeutic target, the application of
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Cardiovascular disease is the single biggest cause of death and disability in
developed countries. Central to its pathogenesis is the development of arterial
lesions, a process thought to occur in response to chronic injury of the vascular wall.
Since localised inflammation and cellular proliferation are key features of this
vascular response to injury, pharmacological manipulations of inflammation and
proliferation have been identified as potential therapeutic approaches to modulating
lesion development. Glucocorticoid hormones have widely-recognised
anti-inflammatory and anti-proliferative properties which appear to make them ideal
candidates for inhibition of vascular lesion development. However, although
administration of glucocorticoids to experimental animals does inhibit the growth of
vascular lesions in some models, systemic excess or increased tissue sensitivity to
these hormones in humans is associated with increased cardiovascular risk (e.g.
central obesity, insulin resistance, dyslipidemia and hypertension). Recent
demonstrations that glucocorticoid activity is regulated by pre-receptor metabolism
in target tissues, and indications that modulation of this pathway can reduce
cardiovascular risk, make it increasingly important to clarify the mechanisms through
which glucocorticoids regulate vascular remodelling in response to injury. This will
improve our understanding of both the role of endogenous glucocorticoids in
regulating cardiovascular risk and lesion pathogenesis, and the therapeutic potential
of manipulating glucocorticoid activity for the treatment of cardiovascular disease.
This introduction will consider the mechanisms that contribute to arterial
remodelling in response to injury, the physiological role of glucocorticoids and the
evidence that glucocorticoid activity regulates development of vascular lesions.
1.1 The vascular response to injury
Vascular lesion development in response to injury is implicated in a variety of
conditions (including atherosclerosis, restenosis and chronic graft rejection) and its
clinical significance is indisputable. Diseases of the heart and circulatory system
(cardiovascular disease or CVD) are the principle cause of death in the developed
world, including the United States, Europe and much of Asia (Ross 1999). In the
United Kingdom CVD, leading to myocardial infarction, heart failure, stroke and
peripheral vascular disease, is responsible for 36% of all deaths each year
(www.heartstats.org). About half of these deaths are caused by coronary heart
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disease (CHD), a condition which is itself the most common cause of death in the
U.K., affecting almost 2.6 million people in this country (www.heartstats.org).
Although mortality from CHD is currently falling, death rates in the U.K. are still
amongst the highest in Western Europe, whilst morbidity from this condition is rising
(www.heartstats.org). Furthermore, the rapid increase in the incidence of
cardiovascular risk factors, such as obesity and diabetes, threatens to reverse the
current decrease in CHD-related mortality. Consequently, CVD continues to
command a high cost in terms of human suffering and economic burden. It is
essential to improve current understanding of the factors that contribute to the
development of CVD and identify new therapeutic options for treatment of this
condition. CHD is caused by the formation of lipid-laden atherosclerotic lesions in
the coronary circulation. In order to understand the vascular remodelling that occurs
during atherogenesis, it is necessary to consider the structure of the healthy arterial
wall and the functional role of its component layers.
1.1.1 The structure of the normal artery wall
The healthy arterial wall comprises three distinct layers (Figure 1.1a).
1.1.1.1 Tunica intima
The innermost layer of the arterial wall, which lines the vascular lumen,
predominantly consists of a monolayer of endothelial cells seated on a basement
membrane, and is separated from the tunica media by the internal elastic lamina
(IEL). In some arteries, the intima can be more extensive, containing focal
accumulations of modified vascular smooth muscle cells (VSMCs) (Stary 1990).
Intimal thickening occurs during normal development and aging (Velican & Velican
1976). The endothelial cells are crucial to the regulation of vascular tone, as they can
release a variety of vasodilators (e.g. nitric oxide (NO), prostacyclin (Furchgott &
Zawadzki 1980; Ignarro et al. 1987; Palmer et al. 1987)) and vasoconstrictors (e.g.
endothelin-1, thromboxane). In addition, the endothelium acts as a barrier between
the blood and pro-thrombotic components of the vascular wall, and is an important
modulator of inflammation and new blood vessel growth (Levick 2003).
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Figure 1.1: Structure of the artery wall in health and disease
(a) Transverse section of a normal mouse femoral artery. The tunica adventitia (A) lies
outside of the external elastic lamina (EEL, marked by white arrow heads), while the tunica
media (M) lies between the EEL and internal elastic lamina (IEL, marked by filled arrow
heads). The tunica intima (I) is difficult to see in this artery, since it consists of only a
monolayer of endothelial cells lining the surface of the lumen (L). Red blood cells (RBCs) are
present in the lumen of the artery.
(b) Transverse section of the brachiocephalic artery from an Apolipoprotein E deficient
mouse, which is susceptible to the development of atherosclerosis when fed a high fat diet.
In this high fat-fed animal, an atherosclerotic lesion blocks the lumen of the artery. The lesion
contains fibrous material and sites of lipid incorporation (*), and the luminal surface is
covered by a fibrous cap. Medial remodelling is also evident in this artery.
Scale bar = 100 pm. Both sections are stained with the United States trichrome histological




The middle layer of the vessel wall consists of VSMCs and supporting extracellular
matrix (ECM). Medial VSMCs respond to stimulation by blood-borne signals,
factors released by the endothelium and neurotransmitters released by nerve endings
to regulate luminal diameter. In this way they regulate vascular tone and, hence,
blood flow and pressure. The ECM consists of concentric sheets of elastin that
enable the vessel to expand and recoil, in order to accommodate blood ejected from
the heart and convert pulsatile flow in arteries close to the heart into a continuous
flow through more distal arteries (Levick 2003). The ECM also contains collagen,
which is important in the maintenance of vessel shape and integrity, and prevents
over-expansion of the artery wall (Levick 2003).
1.1.1.3 Tunica adventitia
The outermost layer of the vessel wall is separated from the media by the external
elastic lamina (EEL). It consists of connective tissue, VSMCs, fibroblasts and
macrophages. The adventitia can also contain nerve cells and small blood vessels
(vasa vasorum), which supply the vessel wall with nutrients (Levick 2003). This
layer gives the blood vessel stability and strength, and connects it to surrounding
tissues. In addition to its supportive role, the adventitia can also regulate vascular
structure and function. For example, NO can be released from the adventitia via the
action of inducible nitric oxide synthase (iNOS) (Muller et al. 2000) and neuronal
nitric oxide synthase (nNOS) (Pluta 2006). In addition, perivascular adventitial fat
can influence vascular function through the release of an (as yet unidentified)
adventitial-derived relaxing factor (Dubrovska et al. 2004) and vasoactive
adipocytokines (a mechanism that may contribute to the relationship between
visceral obesity and vascular disease (Yudkin et al. 2005)). The adventitia may also
influence vascular remodelling, as it has been proposed that proliferation and
migration of adventitial fibroblasts contributes to the development of atherosclerotic
lesions (Xu et al. 2007).
1.1.2 Atherosclerosis
As mentioned above, atherosclerosis is the most clinically significant manifestation
of vascular lesion development. Atherosclerosis is primarily a disease of the large
and medium-sized elastic and muscular arteries, and is characterised by the
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accumulation of lipids and fibrous material within the arterial wall (Figure 1.1b).
Development of atherosclerotic lesions (or plaques) usually occurs silently, over
several decades, and throughout the vascular network. When symptoms do occur
they are predominantly due to interruption of the blood supply, with their precise
nature dependent upon the site of lesion development. For example, arterial
occlusion in the coronary circulation results in loss of blood supply to the
myocardium, which can produce angina or myocardial infarction, the hallmarks of
CHD. The mechanisms underlying interruption of blood flow in atherosclerotic
arteries can include gradual occlusion of the lumen by an expanding lesion, and
spasm of the arterial wall. However, the current opinion is that rupture of unstable
plaques, leading to acute and potentially occlusive thrombosis, is the most clinically
significant mechanism of vascular occlusion associated with atherosclerosis
(Weissberg 2000).
Atherosclerotic plaques are classically described on the basis of pathological studies
(Stary 1989; Wissler 1992; Badimon et al. 1993) and are usually divided into three
main types of lesion (Ross & Glomset 1976a; Ross & Glomset 1976b): the fatty
streak, the fibrous plaque and the complicated lesion. They are predominantly intimal
in nature (Wissler 1992), although their development is often accompanied by medial
remodelling or atrophy (Davies & Woolf 1993).
1.1.2.1 The fatty streak
The fatty streak is commonly observed in early life, and can be found in the aorta of
virtually every child from the age of 10 years, regardless of race, sex or environment
(Stary 1983). It is characterised by its yellow colour, due to lipid deposition in the
artery wall, and often occurs at vascular branch points and sites of pre-existing
'cushions' of intimal VSMCs (Ross & Glomset 1976a). Although originally
described as focal accumulations of lipid-containing smooth muscle cells and
macrophages (Ross & Glomset 1976a), the fatty streak has more recently been
described as an inflammatory lesion (Ross 1999), consisting primarily of
macrophages and T lymphocytes (Stary et al. 1994). These lesions cause little or no
obstruction, produce no clinical symptoms, and are only detected at post mortem.
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1.1.2.2 The fibrous plaque
The fibrous plaque is characteristic of progressing atherosclerosis. It consists
principally of a lipid-laden core, often containing some necrotic material, covered by
a fibrous cap of VSMCs, collagen fibres and proteoglycans (Badimon et al. 1993).
The development of fibrous plaques in anatomical locations associated with fatty
streaks in earlier life (Leary 1951; Robertson et al. 1963), and the suggestion that
fibrous plaques are preceded by an intermediate (or fibrofatty) lesion (Wissler 1992),
prompted the proposal that fatty streaks are the precursors of fibrous plaques (McGill
1984). More recently, however, it has been proposed that the process of plaque
development is dynamic, with lesions in a constant, but clinically silent, flux between
formation and regression (Weissberg 2000).
1.1.2.3 The complicated lesion
The complicated lesion distinguishes advanced atherosclerosis and can be thought of
as a fibrous plaque that has undergone necrosis, calcification, rupture and focal
thrombosis (Wissler 1992). As described above, the clinical consequences of
atherosclerosis have been attributed to progressive occlusion of the vascular lumen
which, in the coronary circulation, can cause chronic stable angina. However, lesion
development does not always lead to vascular occlusion, as atherosclerotic arteries
can undergo outward remodelling, or compensatory enlargement, to accommodate
lesion growth (Figure 1.2) (Glagov et al. 1987). During this process, which involves
the degradation and deposition of ECM molecules (Ward et al. 2000), an increase in
cross-sectional area within the EEL preserves luminal patency as the lesion expands;
this continues until later stages of the disease. Consequently, large lesions can be
asymptomatic, and are not visible using imaging techniques such as angiography,
which are based on measurement of the lumen.
It is now widely accepted that plaque rupture and consequent thrombosis (Weissberg
2000) are the more clinically significant mechanisms of vascular occlusion. In this
model, plaque stability is not determined primarily by size or degree of luminal
obstruction, but by composition. Collagen provides most of the biomechanical
strength of the fibrous cap, and plaques with a thick cap are more able to resist local





Figure 1.2: Artery remodelling during vascular lesion growth
During the growth of atherosclerotic lesions (indicated by black area), an increase in vessel
area via outward remodelling can preserve luminal patency. If no artery remodelling occurs
during vascular lesion growth, luminal area is decreased. During vascular healing after
plaque rupture, or restenosis in response to injury caused by coronary revascularisation
interventions, inward remodelling of the vessel wall may occur. This causes a reduction in
vessel area which, along with vascular lesion growth, decreases luminal area. Adapted from
(Ward etal. 2000).
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However, a high content of inflammatory cells and a lack of VSMCs, particularly at
the edges (or shoulder regions) of a plaque, can contribute to instability (Lendon et
al. 1991; van der Wal et al. 1994). Therefore, the likelihood of rupture is greatest in
lesions with a large lipid pool and a thin fibrous cap, containing more inflammatory
cells than VSMCs and collagen (Libby 2000). Over the last ten years, these
observations have led to the new paradigm which proposes that 'vulnerable' lesions
provide the greatest risk of morbidity and mortality from atherosclerosis (Weissberg
2000). Therefore, the development of interventions which increase lesion stability
represents a current area of investigation for the treatment of atherosclerosis. For
example, the therapeutic benefit of treating existing atherosclerosis with statins is
thought to be due, at least in part, to their ability to increase plaque stability (Libby &
Aikawa 2003).
1.1.2.4 Pathogenesis of atherosclerosis: the response to injury hypothesis
The slow and silent development of atherosclerosis has made it difficult to study;
consequently, its pathogenesis is not completely understood. The most widely
accepted hypothesis proposes that lesion development is the result of an excessive
wound-healing response to injury in the blood vessel wall. This hypothesis
developed from the work of Von Rokitansky and Virchow in the mid 19th century,
was refined and compared with alternative hypotheses by Ross & Glomset in 1976
(Ross & Glomset 1976a; Ross & Glomset 1976b), and has subsequently been
extensively updated and revised (Ross 1986; Ross 1993; Ross 1999).
Initiation of vascular injury. The response-to-injury hypothesis proposes that
atherosclerosis begins as the result of a wound-healing response that has spiralled out
of control. This process is influenced by genetic pre-disposition to the condition, and
occurs in response to injury induced by local formation of harmful compounds after
exposure to risk factors for atherosclerosis (which include cigarette smoking,
diabetes mellitus, hyperlipidemia and hypertension). Initially, damage to the
endothelium stimulates an inflammatory response, and the incorporation of lipid into
the vascular wall, leading to fatty streak formation.
The initiating injury (the precise nature of which remains unclear) induces
endothelial dysfunction, including an increase in endothelial cell adhesiveness and
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permeability, allowing plasma constituents to pass into the sub-endothelial space.
Increased adhesiveness is mediated by expression of surface-bound cell adhesion
molecules such as P-selectin (Johnson et al. 1997) and vascular cell adhesion
molecule-1 (VCAM-1) (Li et al. 1993). Monocytes and lymphocytes adhere to the
endothelium and migrate into the sub-endothelial space in response to
chemoattractant chemokines such as macrophage chemoattractant protein-1 (MCP-1)
(Gu et al. 1998). Increased transport of lipids across the endothelium also occurs,
during which lipid oxidation can occur. Monocytes within the intima mature into
macrophages, under the influence of MCP-1 and macrophage colony-stimulating
factor (M-CSF) (Smith et al. 1995). Macrophages accumulate oxidized lipid via
uptake through scavenger receptors to become foam cells (Brown & Goldstein
1983), which are the hallmark of the fatty streak. Activated macrophages and T cells
express a variety of cytokines (such as interferon y (IFNy), tumour necrosis factor a
and P (TNFa/ P), and interleukin-1 (IL-1)) that recruit and activate further
leukocytes, and stimulate endothelial cells and VSMCs within the vessel wall to
produce additional inflammatory mediators (Libby 2000). These processes lead to
the reversible formation of a fatty streak, containing lipid and leukocytes. However,
with continued exposure to risk factors for atherosclerosis, this inflammatory
response can not effectively interrupt and repair chronic injury to the vessel wall, and
it continues indefinitely.
Fibrous plaque development. Lesion progression involves both propagation of the
initial inflammatory response, and additional, excessive wound-healing responses in
the arterial wall. Continued injury and inflammation produces a cascade of
proliferative and chemotactic factors that promote activation of VSMCs, and their
migration to, and proliferation in, the intima. This results in the development of a
fibrous plaque with a smooth muscle cell-rich cap. VSMCs within the intimal lesion
change phenotype from a 'contractile' state into a 'synthetic' state and secrete ECM
components, which contribute to cap formation (Chamley-Campbell & Campbell
1981). The predisposition for lesions to develop at sites with pre-existing 'cushions'
of intimal VSMCs makes it difficult to determine the origin of the VSMCs that form
the fibrous cap (Ross & Glomset 1976a). Indeed, it is not clear whether these
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VSMCs originate predominantly in the intima or the media, or, alternatively, are
derived from cells circulating in the blood (Dzau et al. 2002).
Proliferation and migration of VSMCs is stimulated by a variety of growth factors
(including platelet derived growth factor (PDGF) (Ferns et al. 1991), basic fibroblast
growth factor (bFGF) (Lindner & Reidy 1991), insulin-like growth factor (IGF)
(Bornfeldt et al. 1992; Bornfeldt et al. 1994), epidermal growth factor (EGF)
(Mitsumata et al. 1994) and angiotensin II (Geisterfer et al. 1988; Berk et al. 1989))
released by vascular and inflammatory cells within the lesion. Increased expression
of cytokines, such as TNFa and IL-1, by leukocytes also contributes to the induction
of VSMC proliferation (Ikeda et al. 1990; Fukumoto et al. 1997; Selzman et al.
1999).
The original hypothesis that VSMC proliferation was a key initiating event during
atherogenesis (Ross & Glomset 1976a; Ross & Glomset 1976b) has given way to the
belief that it represents an important reparative response to inflammation. VSMC
migration and proliferation at the site of injury, with subsequent release of ECM
proteins such as collagen and elastin, is central to the production of a fibrous cap
(Newby & Zaltsman 2000). This cap separates the highly thrombogenic lipid core of
the plaque from the blood, and also confers structural stability to the lesion, and
therefore prevents plaque rupture and focal thrombosis.
Progression to complicated lesion. Further expansion and development of the fibrous
plaque will produce a complicated lesion with characteristic necrosis, calcification,
thinning of the fibrous cap and protrusion into the lumen (Wissler 1992). This may
be accompanied by loss of overlying endothelial cells, thrombosis on the lesion
surface, Assuring and plaque rupture.
Continuation of the inflammatory response, which increases the numbers of
macrophages and T lymphocytes in the lesion, exacerbates the release of hydrolytic
enzymes, chemokines, cytokines, and growth factors (Ross 1999). This causes
further damage and, eventually, focal necrosis. For example, inflammatory cytokines
such as IFNy can induce macrophage apoptosis, contributing to the development of a
necrotic core (Inagaki et al. 2002). The lesion increases in size and becomes
structurally modified, with the fibrous cap covering a core of lipid and necrotic
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tissue. Generation of this characteristic advanced, complicated lesion is often
accompanied by loss of outward remodelling (Figure 1.2) of the vessel wall (Glagov
et al. 1987). As a result, the lesion protrudes into the vascular lumen and restricts
blood flow. These advanced lesions may be subject to silent, non-occlusive episodes
of plaque rupture and thrombosis (Weissberg 2000), resulting in platelet adhesion
and activation, PDGF release and thrombin formation. PDGF and thrombin act to
cause further VSMC recruitment, proliferation and ECM synthesis (Fingerle et al.
1989; Ferns et al. 1991; Kanthou et al. 1995; Molloy et al. 1996), and thus stimulate
the formation of a new fibrous cap over the thrombus. In this way, atherosclerotic
plaques can grow in size due to repeated episodes of rupture and repair (Weissberg
2000).
As discussed above, many clinical consequences of atherosclerosis are the result of
plaque rupture and occlusive thrombosis (Libby 1995). Thrombosis occurs when
plaque contents come into contact with circulating clotting factors. Tissue factor is
the main mediator of thrombosis in atheroma. It is produced by macrophages in
response to stimulation by T cell-derived CD40 (Mach et al. 1997), and also by
endothelial cells (Bevilacqua et al. 1984) and VSMCs (Schecter et al. 1997) exposed
to inflammatory cytokines such as IL-1 and TNFa, highlighting a link between
inflammation and thrombosis in atherosclerosis (Libby & Simon 2001). Resultant
clots can produce sudden occlusion of the vascular lumen which, in the coronary
arteries, leads to myocardial infarction.
The susceptibility of plaque shoulder regions to rupture is increased when
inflammatory cell content is high in these areas (Davies 1996). Inflammatory cells
can decrease plaque stability in several ways: (i) inflammatory cytokines can
increase the expression ofmatrix metalloproteinase (MMP) enzymes, which degrade
collagen in the cap (Galis et al. 1994a), and activated macrophages within the lesion
can produce these enzymes (Galis et al. 1994b), (ii) T cells can provoke activation of
macrophages, and MMP production, by cell-cell contact through CD40 ligand (Mach
et al. 1997), (iii) inflammatory cytokines such as IFNy inhibit VSMC proliferation
and collagen synthesis (Amento et al. 1991), and (iv) the inflammatory cytokines
IFNy, IL-1 (3 and TNFa all induce apoptosis in VSMCs (Geng et al. 1996), whilst
activated macrophages can induce VSMC apoptosis by direct cell-cell contact (Boyle
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et al. 2001). In this way inflammation plays an active role in mediating plaque
stability.
1.1.2.5 Current treatments for atherosclerosis
Treatment options for atherosclerosis can be broadly divided into primary
prevention, secondary prevention and treatment of symptoms. Lifestyle change
(including weight loss, dietary modification, stopping smoking and increased
exercise) is an important aspect of primary prevention. In patients with established
disease (or those with an increased risk of developing atheroma), these strategies can
be augmented by pharmacological treatments (for example, to improve plasma lipid
profiles or reduce blood pressure). Medical interventions (including vasodilators
such as sublingual glyceryl trinitrate) are also used for the treatment of clinical
complications of CHD, such as stable and unstable angina. Thrombolytic and
anti-platelet drugs are used to treat myocardial infarction, in an attempt to open the
blocked coronary artery.
Surgical intervention is often necessary in patients with severe angina or obstruction
of the coronary circulation. Essentially, this involves bypassing the occluded area
using a coronary artery bypass graft (CABG) formed from the great saphenous vein
or the internal mammary artery (Favaloro 1968). Alternatively, an internal thoracic
artery can be anastomosed with the blocked coronary artery. A less invasive
alternative to CABG is percutaneous coronary intervention (PCI), based on the
technique of percutaneous transluminal balloon angioplasty originally introduced by
Andreas Gruntzig (Gruntzig et al. 1979). This procedure has grown in importance,
and has been developed by the introduction of laser catheters, atherectomy catheters
and stents. Its aim is to widen the arterial lumen and improve blood flow to tissue
downstream of the atherosclerotic lesion, via the insertion of an intra-luminal device.
This is achieved by compression or removal of the plaque, and can also involve
stretching of the artery wall (Gruntzig et al. 1979). PCI was greatly improved by the
introduction of coronary stents, which act as a scaffold to hold the artery open, and
has become an increasingly important interventional approach to arterial occlusion.
Indeed, in 2005 over 70,000 PCI procedures were carried out in the U.K. alone
(www.heartstats.org). The rise in the use of PCI has occurred despite the procedure
being limited by some significant acute and chronic complications. The most
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important of these is chronic restenosis, which involves inward remodelling of the
arterial wall (Figure 1.2) and the growth of fibroproliferative neointimal lesions in
response to vascular injury, and so leads to re-occlusion of the arterial lumen.
Interestingly, the neointimal development involved in restenosis has provided a
useful model for investigating the mechanisms of arterial lesion formation in
response to vascular injury (discussed below in section 1.1.4).
1.1.3 Restenosis
Initial success using balloon angioplasty for the revascularisation of atherosclerotic
arteries has been limited by three major complications (Serruys et al. 1988): (i) acute
dissection of the artery wall (requiring emergency CABG), (ii) acute re-occlusion
due to elastic recoil, and (iii) chronic restenosis, which generally occurs in 30-50%
of patients within 6 months of the initial procedure (Serruys et al. 1988; Bourassa et
al. 1989). The introduction of intra-coronary stents has been highly effective in
reducing these complications, by decreasing the need for emergency CABG (Al et al.
2000) and reducing early elastic recoil and chronic inward remodelling in nearly all
patients (Fischman et al. 1994; Hoffmann et al. 1996). In-stent restenosis, however,
remains a significant problem, affecting approximately 20% of patients (Welt &
Rogers 2002). This is perhaps not surprising, since stents have been shown to induce
increased proliferation of VSMCs (Edelman & Rogers 1996) and the creation of a
more intense and prolonged inflammatory state (Welt & Rogers 2002). Therefore,
stents can actually cause an increase in neointimal lesion formation.
Restenosis is the re-occlusion of an artery following PCI for the treatment of
atherosclerosis. It involves the rapid development of fibroproliferative neointimal
lesions in response to the acute injury caused by revascularisation. Since PCI
techniques can produce severe damage to the vessel wall (including endothelial
denudation, transient stretching, and medial fracture (Edelman & Rogers 1996)) the
inflammatory and proliferative response to injury is more rapid than in
atherosclerosis. The use of stents can cause a more vigorous neointimal response as
this induces deep, focal trauma to the media at sites where the struts penetrate into
the vessel wall (Edelman & Rogers 1996). Indeed, the extent of this injury predicts
subsequent neointimal lesion formation (Schwartz et al. 1992b). In addition, the stent
also produces a permanent mechanical stretch on the artery wall, and remains as
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foreign material in the vessel, triggering an inflammatory response (Welt & Rogers
2002). Understanding the pathogenesis of the neointimal lesion formation that
underpins restenosis is important for the development of new anti-restenotic
treatments. However, neointimal proliferation also provides a rapid model for
investigating the mechanisms regulating the vascular response to injury.
1.1.3.1 Pathogenesis of neointimal lesion formation
The formation of neointimal lesions after revascularisation of a plaque-bearing artery
during restenosis has a similar mechanism to the neointimal proliferation which is
induced in response to experimental mechanical injury of a previously normal artery.
In addition, both processes incorporate components of the chronic wound-healing
response to the less severe injury that is central to atherosclerosis. Neointimal
proliferation comprises a complex series of events involving cells of the artery wall
and blood (VSMCs, endothelial cells, leukocytes and platelets). In a simplified
model (Lee et al. 1993), neointimal lesions are thought to form in three phases
(Figure 1.3). The first, acute phase involves the interaction of platelets, thrombin and
leukocytes with the site of injury, the subsequent release of a range of biologically
active signals, and the resulting activation of VSMCs. A second, intermediate phase
follows, characterised by proliferation of VSMCs and their migration to the intima.
A final, chronic phase involves phenotypic modulation of intimal VSMCs, which
produce large amounts of ECM molecules, contributing to the formation of a
fibroproliferative neointimal lesion.
Endothelial damage and medial stretch injury expose the underlying ECM of the
vessel wall, which induces the adhesion of platelets. Activation of tissue factor and
thrombin generation (Fager 1995) causes further platelet activation and the release of
PDGF, which acts as a potent chemoattractant for VSMCs during lesion
development (Fingerle et al. 1989; Ferns et al. 1991). In addition to PDGF, various
other growth factors up-regulated after vascular injury have been implicated in
inducing VSMC proliferation, including: bFGF (released directly from injured
VSMCs) (Lindner & Reidy 1991; Olson et al. 1992), IGF-1 (Cercek et al. 1990;

















I <^>\ Endothelial cell (^) Inflammatory cell Thrombin
Vascular smooth muscle cell Q Platelet Extracellular matrix
Figure 1.3: Neointimal lesion formation in response to vascular injury
Acute vascular injury causes endothelial denudation and damage to the underlying media
(hatched area). Lesion formation is initiated by interaction of platelets, thrombin and
inflammatory cells with the site of injury, and the release of various biologically active signals
(a). These factors stimulate the proliferation and migration of VSMCs in the neointima, and
further activation of inflammation (b). Finally, VSMCs in the intima secrete extracellular
matrix molecules to produce a stable fibrous lesion (c). Re-endothelialisation may also occur.
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endothelin-1 (Weissberg et al. 1990) and angiotensin II (Powell et al. 1989; Daemen
et al. 1991). Whilst thrombin generated in response to injury can act as a mitogen for
VSMCs, the development of platelet-rich mural thrombi over stent struts is also
thought to act as a 'scaffold', into which inflammatory cells and VSMCs migrate
(Edelman & Rogers 1996). In addition to growth factors, other mediators involved in
ECM remodelling, such as heperanases and proteases, are activated after vascular
injury. For example, MMPs are up-regulated after balloon angioplasty (Bendeck et
al. 1994; Zempo et al. 1994; Southgate et al. 1996), and contribute to VSMC
migration by degrading ECM molecules (Jackson & Reidy 1992).
The recruitment of leukocytes induced by endothelial denudation or medial damage,
and subsequent activation of inflammatory mechanisms, plays a key role in
neointimal lesion development (Wainwright et al. 2001; Welt & Rogers 2002;
Toutouzas et al. 2004). Studies using animal models show that leukocyte infiltration
into the vessel wall occurs rapidly following injury, with neutrophils observed within
6-24 hours (Cole et al. 1987; Welt et al. 2000), and T lymphocytes (Tanaka et al.
1993) and monocytes (Miller et al. 1996) appearing after 2-14 days. Inflammatory
cell recruitment and infiltration is mediated by: (i) interactions with surface
molecules on adherent platelets (P-selectin, Mac-1) at the site of injury (Diacovo et
al. 1996), (ii) release of chemokines such as MCP-1 (Rollins 1996) and IL-8 (Webb
et al. 1993) from VSMCs, endothelial cells and leukocytes at the site of injury, and
(iii) up-regulation of endothelial adhesion molecules (Tanaka et al. 1993; Kennedy et
al. 2000a). The central role of this inflammatory response in subsequent lesion
development is illustrated by the demonstration that leukocyte depletion virtually
abolishes neointimal formation following balloon angioplasty in rabbits (Miller et al.
2001).
Clinical evidence also supports a critical role of inflammation in neointimal lesion
formation during restenosis. Leukocytes are activated in patients within 24-48 hours
of angioplasty (De Servi & et al. 1990; Steg et al. 1993), with marked increases in
the plasma concentrations of leukocyte- and endothelium-derived soluble adhesion
molecules evident (Inoue et al. 1996; Neumann et al. 1996; Mickelson et al. 1996;
Serrano, Jr. et al. 1997; Inoue et al. 2003). Furthermore, elevated plasma levels of
cytokines and chemokines (Pietersma et al. 1995; Flojo et al. 2000; Suzuki et al.
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2000; Cipollone et al. 2001) and C-reactive protein (CRP) (Gaspardone et al. 1998;
Gottsauner-Wolf et al. 2000; Almagor et al. 2003) predict a high risk of restenosis.
Circulating monocyte counts after stenting show a positive correlation with
neointimal lesion area 6 months after PCI (Fukuda et al. 2004). Interestingly, in
patients with a genetic polymorphism resulting in increased production of the natural
antagonist of IL-1 (IL-lra), there is a lower risk of restenosis (Kastrati et al. 2000).
Expression of platelet and leukocyte surface adhesion molecules are increased by
coronary stent implantation when compared with balloon angioplasty (Inoue et al.
2000), which may explain the increased neointimal lesion formation seen after
stenting. In pathological studies, markers of inflammation in arterial tissue correlate
strongly with restenosis after angioplasty or stenting (Moreno et al. 1996; Farb et al.
2002). In addition to inflammatory responses triggered by PCI, the inflammatory
status of the underlying atherosclerotic plaque being treated must also be taken into
account. Indeed, correlations between pre-interventional inflammatory activation and
post-interventional restenosis or adverse cardiac events have been found in several
sub-groups of patients (Toutouzas et al. 2004).
There are several mechanisms by which activated inflammatory cells may contribute
to neointimal lesion formation. These cells release a wide range of vasoactive
substances, including cytokines, chemokines, growth factors, proteolytic enzymes
and oxygen-derived free radicals, all ofwhich can contribute to the vascular response
to injury. The expression of the cytokines TNFa (Tanaka et al. 1996) and IL-1 (3
(Wang et al. 2000) is increased after balloon angioplasty in animal models; these
cytokines induce smooth muscle cell proliferation in vitro (Ikeda et al. 1990;
Selzman et al. 1999) and neointimal lesion growth in normal porcine coronary
arteries (Fukumoto et al. 1997). Furthermore, the anti-inflammatory cytokine IL-10
attenuated macrophage infiltration and VSMC proliferation after balloon injury or
stenting in rabbits (Feldman et al. 2000). Cytokine release also causes the further
activation of leukocytes, and an increase in the adhesiveness of endothelial cells,
promoting leukocyte adherence and migration into the intima (Furie & McHugh
1989; Moser et al. 1989; Miller et al. 2005).
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1.1.4 Models for studying the vascular response to injury
The development of atherosclerosis without symptoms and over several decades
makes investigation of lesion generation in humans extremely difficult (reviewed in
(Toutouzas et al. 2004)). Information on lesion pathology obtained from
post-mortem and atherectomy specimens provides only a 'snapshot' in development.
Vascular imaging techniques (e.g. angiography, intra-vascular ultrasound, magnetic
resonance imaging (MRI), positron emission tomography (PET)) can provide
information on luminal narrowing and vascular lesion size, but give little or no
information on the molecular, biochemical and cellular events involved in lesion
formation. However, current advances in techniques such as MRI may allow a more
detailed cellular and molecular characterisation of atherosclerosis in the near future
(Canet-Soulas & Letourneur 2007). Vascular imaging can confirm the success or
failure of anti-atherosclerotic and anti-restenotic treatments, but provides no
information on the processes involved in the outcome (Toutouzas et al. 2004). In
addition, many imaging techniques are invasive and so would be impractical and
unethical to repeat frequently in longitudinal studies. Longitudinal studies are also
hampered by the extended duration of lesion development, and the fact that the
insidious development of atherosclerosis makes it difficult to identify a suitable
patient population. As a consequence, clinical studies require large groups of patients
and a long time-scale, making them labour intensive and expensive. They can also be
difficult to control (due to environmental and genetic differences between
individuals) and, if data are acquired from patients selected for coronary
revascularisation, a bias towards high-risk subjects can be introduced (Toutouzas et
al. 2004).
The practical obstacles to clinical investigations into the pathogenesis of
atherosclerosis and restenosis have resulted in much of our knowledge of these
processes being gained from animal models of vascular lesion formation. The
advantage of animal models is that lesion development can be induced more rapidly
than in humans, and conditions can be controlled more closely than in clinical studies
(Smith & Breslow 1997). However, it is important to acknowledge that no animal
model provides a perfect reproduction of vascular lesion development in humans.
Indeed, specific features of different animal models will determine their suitability
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for a particular investigation, and need to be considered carefully when extrapolating
findings to the condition in humans.
1.1.4.1 Choice of species
Species used in experimental models of vascular lesion formation can be broadly
divided into large animals, such as the pig, dog and non-human primate, and small
animals, including the rabbit, rat and mouse (Mehta et al. 1996; Narayanaswamy et
al. 2000). The main advantages of large animals are their relative physiological
similarity to humans and the ability to assess clinically relevant arteries (i.e. the
coronary circulation). Practical factors that limit the use of these species include
lower availability compared with small animals, higher purchase and maintenance
costs and greater difficulties associated with husbandry and handling. In addition,
lesion development may be slower than in small animals and, significantly, there
may be increased ethical concerns (particularly with the use of primates). Small
animals are increasingly favoured as they are readily available, cost relatively little to
purchase and house, are easy to handle and their small size reduces the amount of
drug needed for intervention studies. The rapid growth of lesions allows a quick
assessment of therapeutic agents, and it is possible to include large numbers in each
group for more powerful statistical analysis. Practical disadvantages include the
small size of arteries studied, the need to assess lesion formation in arteries that are
not as relevant to the clinical situation (e.g. femoral, iliac), and poor replication of
the condition in humans. However, perhaps the most significant advantage of using
small animals, in particular mice, for investigations of lesion growth stems from
developments in gene targeting techniques. Over the last decade, this has resulted in
the generation of an array of transgenic and knock-out mice (Allayee et al. 2003).
Transgenic techniques have been used to generate mice that are prone to the
development of atherosclerosis, such as the low density lipoprotein (LDL) receptor
and Apolipoprotein E (ApoE) knockout mice (Breslow 1993). Furthermore, these
techniques make it possible to assess lesion development in animals with transgenic
deletion of key factors involved in the vascular response to injury. This allows the
molecular mechanisms involved in arterial lesion formation to be investigated at a
genetic level.
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1.1.4.2 Choice of disease model
Animal models of vascular lesion development have been generated which replicate
features of atherosclerosis, induce neointimal proliferation in previously normal
arteries, or attempt to model neointimal lesion development during restenosis.
Classically, atherogenesis has been induced in pigs, primates and rabbits by
prolonged feeding with a high cholesterol diet (although some animals, such as the
Watanabe heritable hyperlipidemic rabbit, develop spontaneous lesions (Watanabe
1980)). However, the lesions that form in rabbits rarely advance beyond the fatty
streak stage (Prior et al. 1961), and so only replicate the early stages of
atherosclerosis. In addition, rats and mice do not even develop these early lesions of
atherosclerosis when fed a high-fat diet (Vesselinovitch & Wissler 1968), as a result
of differences in lipid handling compared with humans (Paigen et al. 1994). Despite
this, the mouse has become an increasingly popular model of atherosclerosis,
following the introduction of single gene deletion strains which can develop
hypercholesterolemia and atherosclerotic lesions. The two most widely-used murine
models of atherosclerosis are the ApoE deficient (Piedrahita et al. 1992) and LDL
receptor knockout (Ishibashi et al. 1993) mice. The former spontaneously develop
atherosclerotic lesions that can be exacerbated by feeding a high fat 'western' diet
(Paigen et al. 1987). ApoE serves as a ligand for LDL receptor-mediated removal of
chylomicrons and very low density lipoproteins (VLDL) from the blood.
Consequently, mice lacking ApoE develop hypercholesterolemia and atherosclerotic
lesions (Plump et al. 1992; Zhang et al. 1992) which are morphologically similar to
human lesions and occur at similar sites in the vasculature (Nakashima et al. 1994;
Reddick et al. 1994; VanderLaan et al. 2004). Similarly, LDL receptor knockout
mice are hypercholesterolemic (Ishibashi et al. 1993) and develop lipid-laden lesions
with a necrotic core when fed a high-fat diet (Ishibashi et al. 1994). These two strains
are now the basis of many investigations into the mechanisms of atherosclerotic
lesion formation.
Neointimal proliferation can be induced in animal models by acute injury to the
artery wall, and this approach has been used in a variety of different species (Mehta
et al. 1996; Narayanaswamy et al. 2000; Xu 2004; Wang et al. 2006). These models
mimic the injury caused to the blood vessel wall by angioplasty and stenting, in the
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absence of a pre-existing atherosclerotic lesion, and induce the rapid development of
a fibroproliferative lesion. Consequently, they can be used as a tool to study specific
biological factors, such as the role of inflammation in the vascular response to injury
and the mechanisms of VSMC proliferation and migration during lesion formation.
These models have also been used extensively to assess the therapeutic potential of
anti-restenotic interventions.
Attempts have been made to improve study of the pathogenesis and treatment of
restenosis in mice by combining models of atherosclerosis and acute injury
(Leidenfrost et al. 2003; Weingartner et al. 2005), in which injury is performed in
arteries with existing lesions. This is important as it is likely that the arterial response
to injury differs in diseased vessels (Carmeliet et al. 1998). Inevitably, however,
these models are technically more demanding and their validity is doubtful given that
the initial atherosclerotic lesion is likely to be a fatty streak (Lardenoye et al. 2000;
Ivan et al. 2002), rather then the advanced lesion that would be subjected to PCI in a
patient. This combination of atherogenesis and mechanical injury has also been used
in rabbits to produce lesions that more closely resemble human plaques (Abela et al.
1995; Skinner et al. 1995; Aikawa et al. 1998). However, this advantage is offset by
the complexity of the model (high fat feeding combined with repeated intra-luminal
injury) and the time required for lesions to develop (9-12 months).
1.1.4.3 Induction of acute injury to the arterial wall
Animal models of acute vascular injury use a variety of techniques to damage the
wall and induce neointimal proliferation in several different arteries. These were
originally developed in large animals (primarily pigs and dogs), and subsequently
applied to smaller species (rabbits and rats). More recently, they have been refined
for use in mice. This has occurred despite the anatomical and physiological
differences between mice and humans, and the structural differences of the mouse
arterial wall (which is thin, with only 2-3 layers of VSMCs, few intimal VSMCs and
a narrow lumen (Carmeliet et al. 1998)). The four most commonly used techniques
in the mouse (Table 1.1) are: (i) intra-luminal mechanical injury, (ii) arterial ligation,
(iii) electrical injury, and (iv) cuff placement. Each model induces either
intra-vascular or perivascular injury, which results in the generation of an
inflammatory response followed by neointimal proliferation.
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Mechanical injury Ligation Electrical injury Cuff placement
Endothelial removal Yes No Yes No
Medial injury Yes No Yes No
Blood flow Not changed Changed Not changed Not changed
Thrombotic involvement Some Possible High None
Inflammatory response Medium Low Extensive Low
Difficulty of surgery Hard Low Low Medium
Examples of genes studied P-selectin, VEGF,ApoE, ApoA-1
MMP-2 and -
9, eNOS
PAI-1 IL-1 ra, VLDLR
Table 1.1: Comparing four different models of vascular injury in the mouse
The most commonly used models of arterial injury in the mouse are intra-luminal mechanical
injury (Lindner et al. 1993; Sata et al. 2000), ligation of the carotid artery (Kumar & Lindner
1997), electrical injury across the wall of the femoral artery (Carmeliet et al. 1997c) and cuff
placement around the femoral artery (Moroi et al. 1998). Components of the injury induced
and surgical difficulty for each model are compared. Examples of genes with a role in the
response to injury studied using each model are also given. P-selectin (Smyth et al. 2001),
VEGF: vascular endothelial growth factor (Hutter et al. 2004), ApoE: apolipoprotein E (De et
al. 1997b; Weingartner et al. 2005), ApoA-1: apolipoprotein A-1 (De et al. 1997b), MMP:
matrix metalloproteinase (Kuzuya et al. 2003; Galis et al. 2002), eNOS: endothelial nitric
oxide synthase (Kawashima et al. 2001), PAI-1: plasminogen activator inhibitor-1 (Carmeliet
et al. 1997b), IL-1 ra: interleukin-1 receptor antagonist (Isoda et al. 2003), VLDLR: very low
density lipoprotein receptor (Tacken et al. 2002). Adapted from (Xu 2004; Wang et al. 2006).
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Intra-luminal mechanical injury. This method was originally introduced in the
mouse by Lindner et al, using a flexible guidewire inserted into the common carotid
artery (Lindner et al. 1993). Subsequently, it was applied to the femoral artery
(Roque et al. 2000; Sata et al. 2000) whilst more recently, a method of balloon injury
to the mouse aorta has been developed (Petrov et al. 2005). Intra-luminal injury
causes endothelial denudation, and stretches the artery wall inducing disruption of
the IEL and damage to VSMCs in the media. Early responses to injury include the
adherence of platelets and neutrophils to the artery surface (Lindner et al. 1993;
Roque et al. 2000; Petrov et al. 2005), and medial cell apoptosis (Sata et al. 2000;
Petrov et al. 2005). Neointimal lesions are first evident from 7-8 days after injury
(Lindner et al. 1993; Sata et al. 2000), and continue to grow in size until around 28
days, after which time they stabilise (Sata et al. 2000). These lesions are VSMC-rich
(Lindner et al. 1993; Sata et al. 2000; Petrov et al. 2005), and become
re-endothelialised from about 3 weeks after injury (Lindner et al. 1993; Sata et al.
2000).
In models of intra-luminal vascular injury, it is important that the artery targeted is:
(i) relatively accessible, (ii) free from branches, (iii) large enough in diameter to
introduce an intra-vascular device, and (iv) long enough to provide a sufficient area
for lesion growth. The mouse carotid artery produces only a relatively small
neointimal proliferative response to intra-luminal injury, with lesions around 2-3
cells thick (Lindner et al. 1993). In addition, these lesions are less reproducible and
have a higher inter-animal variability than reported for models of femoral artery
injury (Sata et al. 2000). This may be due in part to the challenging surgery involved
in cannulating the carotid artery, which also increases the risk of complications such
as stroke. In contrast, femoral arteries produce large, occlusive neointimal lesions in
response to injury, with less adventitial remodelling than is seen in the carotid artery
(Lindner et al. 1993; Sata et al. 2000). Aortic angioplasty in the mouse has two main
advantages over other models; it involves the use of a balloon catheter as in the
clinical setting, and allows the recovery of sufficient quantities of intact ribonucleic
acid (RNA) from injured vessels for molecular analysis (Petrov et al. 2005).
However, unlike the carotid and femoral arteries, this model does not permit the use
of a contra-lateral artery as a control.
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Artery ligation. Kumar and Lindner developed a ligation model using the mouse
carotid artery (Kumar & Lindner 1997). Ligation of the common carotid artery, at its
bifurcation into the internal and external carotid arteries, is thought to induce
remodelling in response to altered shear stress on the vessel wall (Kohler et al. 1991;
Geary et al. 1994). Large, concentric VSMC-rich neointimal lesions develop 2-4
weeks after ligation (Kumar & Lindner 1997) without the extensive endothelial cell
removal, mechanical trauma and thrombosis produced by intra-luminal injury. Early
platelet and leukocyte infiltration, and medial VSMC death are followed by luminal
narrowing, caused in part by neointimal lesion growth and in part by inward
remodelling of the artery wall (Kumar & Lindner 1997). The main advantage of this
model is that the surgery required is relatively simple, and gives good reproducibility
and less variation in lesion development than occurs after wire injury of the carotid
artery. The pathogenesis of lesion formation remains unclear but it is possible that
changes in blood flow alter the expression of adhesion molecules and chemokines by
endothelial cells and leukocytes, leading to the observed influx of inflammatory cells
and the activation of an inflammatory response (Carmeliet et al. 1998).
Electrical injury. Passing an electrical current through the wall of the femoral artery
produces severe damage, killing many cells across the vessel wall, including
endothelial cells, VSMCs and adventitial fibroblasts (Carmeliet et al. 1997c). Early
platelet- and fibrin-rich thrombosis, and removal of necrotic material by leukocyte
infiltration, is followed by the proliferation and migration of VSMCs from regions of
the vessel wall bordering the site of injury. This results in the formation of a
re-endothelialised neointimal lesion 2 weeks after injury. Adventitial and outward
vascular remodelling also take place, which prevents luminal narrowing despite
neointimal growth. The main advantage of this procedure is that it avoids the
technical challenge of inserting intra-vascular devices.
Cuffplacement. Models of cuff placement used in the rat and rabbit were adapted
for use in mice (Moroi et al. 1998). The femoral artery is isolated and loosely
sheathed with polyethylene tubing, which does not restrict blood flow. A neointimal
lesion is evident after 14 days, comprising VSMCs, with minimal thrombosis, cell
death or endothelial cell denudation. The mechanisms leading to lesion formation are
incompletely understood but studies in rabbits have indicated that it may result from
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endothelial cell activation, distortion of the artery, vasospasm, increased blood flow
velocity, blockage of lymphatic drainage, damage to adventitial nerves and vasa
vasorum (causing hypoxia of the media) or toxicity of the cuff (Kockx et al. 1992). It
has been suggested that leukocytes play a central role in activation of the VSMC
response (Carmeliet et al. 1998). This model can be extended by using drug-eluting
cuffs, to allow local drug administration during lesion formation (Pires et al. 2005).
Other models. Acute vascular injury in the mouse has also been induced via
endothelial denudation by air-drying the carotid artery (Simon et al. 2000), and
endothelial denudation and occlusive thrombus generation by injection of rose
bengal and irradiation of the femoral artery (Kikuchi et al. 1998). In addition, several
mouse models of vein grafting have been introduced (Xu 2004), which allow the
study ofmechanisms of neointimal hyperplasia after CABG.
1.1.4.4 Advantages and disadvantages of animal models of vascular lesion
formation
The main advantages of larger animal models are their susceptibility to experimental
atherosclerosis, their physiological similarity to humans, accessibility of a clinically
relevant artery, and a vascular remodelling process which is similar to that seen in
humans. For example, pigs (Buchwald et al. 1992), and some non-human primates
(Strong et al. 1994; Fincham et al. 1998), develop atherosclerosis in response to
dietary manipulation; however dogs do not (Lafont & Faxon 1998). (The similarity
of canine and human coronary artery morphology has led to dogs being used
primarily for testing interventional cardiology devices (Roubin et al. 1987; Schatz et
al. 1987)). In addition, the response to vascular injury and neointimal lesion
composition in pigs (Schwartz et al. 1990), dogs (Lafont & Faxon 1998) and
primates (Geary et al. 1996) is also very similar to that seen in humans.
The clinical relevance of large animal models is demonstrated by their ability to
predict the effect of therapeutic interventions in humans. For example, the success of
both probucol (Setsuda et al. 1993; Watanabe et al. 1996) and irradiation (Teirstein
et al. 1997; Condado et al. 1997) in clinical trials was consistent with reduced
neointimal growth in porcine models (Schneider et al. 1993; Waksman et al. 1995).
However, this consistency with clinical studies is not always seen, with the
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anti-proliferative action of low molecular weight heparin observed in pigs (Buchwald
et al. 1992), not recapitulated in baboons (Geary et al. 1995) or humans (Faxon et al.
1994). This type of discrepancy is probably due to physiological differences between
species. In pigs, for example, the haemostatic system differs from that in humans
(Johnson et al. 1999), whilst in primates it is more similar to humans (Hanson 1991).
The major drawback of small animal models is that they have failed to predict the
effectiveness of a number of pharmacological interventions in clinical trials
(reviewed in (Johnson et al. 1999)), having produced both false positive and false
negative results. For example, although angiotensin converting enzyme (ACE)
inhibitors reduced neointimal lesion formation in rats (Powell et al. 1989) and rabbits
(Shibutani et al. 1994), clinical studies found no effect on restenosis in humans
(Faxon 1995). Several possibilities have been suggested to explain this shortcoming,
including differences in: (i) species, (ii) size of artery used, (ii) structure of artery
used (elastic vs. muscular), (iv) the protocol of drug administration and, (iv) the
method used to assess outcome (Johnson et al. 1999). Alternatively, the poor
predictive ability of small animal models may be attributable to their failure to
replicate the pathophysiology of neointimal growth during restenosis in humans. For
example, in the well-characterised model of balloon injury to the rat carotid artery
(Clowes et al. 1983) the response to injury is limited to VSMC proliferation and
migration, with no involvement of thrombosis and the absence of an underlying
atherosclerotic lesion (Mehta et al. 1996). Similarly, although hyperlipidemic rabbits
develop atherosclerotic lesions (Block et al. 1980) these are mainly composed of
foam cells, and lack other features (e.g. fibromuscular caps) of human plaques (Prior
et al. 1961). Indeed, the neointimal lesions that develop after balloon injury in
hyperlipidemic rabbits tend to be lipid-rich with a scarcity ofVSMCs (Johnson et al.
1999).
Thus, large animal models, such as the atherosclerotic pig, produce the best
representation of neointimal formation during restenosis in humans and, therefore,
are valuable for pre-clinical validation of potential therapeutic strategies (Johnson et
al. 1999). Small animal models, in contrast, are useful in the experimental study of
specific components involved in the vascular response to injury (such as mechanisms
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of inflammation or VSMC proliferation); however, results must be interpreted with
caution when extrapolating to the human conditions of restenosis and atherosclerosis.
1.1.4.5 Mechanistic insights from murine models of neointimal lesion
development
The powerful combination of genetic manipulation and arterial injury in the mouse
has provided important insights into the cellular and molecular mechanisms of
neointimal proliferation (Table 1.1). A role for inflammation, including activation of
adhesion molecules, has been confirmed with the demonstration that lesion size is
increased by deletion of IL-lra (Isoda et al. 2003), but reduced in the absence of
P-selectin (Smyth et al. 2001). Similarly, NO synthesis has been shown to regulate
lesion formation; eNOS deletion is associated with increased lesion size (Moroi et al.
1998) whilst over-expression of this enzyme results in smaller lesions (Kawashima et
al. 2001). Other processes that have been addressed include the action of MMPs
(with deletion ofMMP-2 (Kuzuya et al. 2003) or MMP-9 (Galis et al. 2002) causing
a reduction in lesion size), growth factors (over-expression of vascular endothelial
growth factor (VEGF) protects against neointimal formation (Hutter et al. 2004)) and
the fibrinolytic system (showing that urokinase and plasminogen activator inhibitor-1
modulate lesion development (Carmeliet et al. 1997a; Carmeliet et al. 1997b)).
Mouse models have also been used to address the suggestion that circulating
progenitor cells contribute to lesion formation (Hibbert et al. 2003). This work has
shown that the origin of neointimal cells is dependent upon the initial injury model
(Tanaka et al. 2003). After wire-induced injury a significant number of neointimal
and medial cells are derived from the bone marrow; fewer cells of this lineage are
observed after ligation and bone marrow-derived cells are seldom observed in the
arterial wall after cuff placement.
The role of plasma lipids in neointimal lesion formation has been addressed, for
example by genetic deletion of the VLDL receptor (Tacken et al. 2002), which
increased neointimal proliferation, and by gene transfer of apolipoprotein A-l
(ApoA-1), which increased high density lipoprotein (HDL) and attenuated lesion
development (De et al. 1997b). An alternative approach has been to perform arterial
injury in atherosclerosis prone (ApoE knockout) mice, which develop larger lesions
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than controls (De et al. 1997b; Weingartner et al. 2005). Therefore, these studies
indicate that dyslipidemia exacerbates lesion development following arterial injury.
1.1.5 Targeting inflammation in the treatment of vascular lesions
Various approaches for the treatment of vascular lesion development have been
attempted, such as targeting VSMC proliferation, platelet adhesion and activation,
and the generation of thrombin. However, the volume of evidence showing that
chronic vascular injury produces a cascade of inflammatory and proliferative signals
has led to a general acceptance over the last twenty years that vascular disease is an
inflammatory condition (Ross 1999; Wainwright et al. 2001; Libby et al. 2002).
Given this central role for inflammation, it seems logical that anti-inflammatory
interventions would be effective inhibitors of atherogenesis and neointimal lesion
development.
Inhibition of leukocyte adhesion and platelet interaction after vascular injury has
been successful in animals. Indeed, attenuation of intercellular adhesion molecule-1
(ICAM-1) (Yasukawa et al. 1997), Mac-1 (Rogers et al. 1998) and P-selectin
(Hayashi et al. 2000) binding with monoclonal antibodies reduces neointimal
formation in a range of animal models. Furthermore, the response to injury is
inhibited in ICAM-1 (Zou et al. 2000) and Mac-1 (Simon et al. 2000) deficient mice.
This work is consistent with many clinical trials that have focused on the prevention
of restenosis using anti-inflammatory approaches. Due to their pleiotropic mode of
action, statins exert well-described anti-inflammatory effects in the vasculature
(Forrester & Libby 2007), and have been administered systemically for the treatment
of restenosis. Improvements in both clinical and angiographic outcomes have been
observed after statin treatment (Mulder et al. 2000; Walter et al. 2000; Walter et al.
2001a), even in patients with normal cholesterol levels (Serruys et al. 2002). Several
agents have also been administered locally at the vessel wall. For example, coating
stents with agents such as the immunosuppressant drug sirolimus (Suzuki et al. 2001;
Morice et al. 2002) and the mitotic inhibitor paclitaxel (Park et al. 2003; Stone et al.
2004), which also has anti-inflammatory properties, has been found to reduce
neointimal inflammation and lesion formation. Since the inflammatory response to
injury is prolonged after stenting, the use of stents as a platform for the sustained
delivery of anti-inflammatory drugs is very attractive. Therefore, although some
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previous trials have found a lack of efficacy when investigating the effect of potential
anti-inflammatory agents on restenosis (Ellis et al. 1989), a better understanding of
both the biological response to injury and the pharmacokinetics and
pharmacodynamics of certain agents has resulted in more recent clinical successes
with agents such as sirolimus and paclitaxel.
The potential benefit of targeting local inflammation for prevention of vascular
lesion formation suggests that glucocorticoids may provide a therapeutic option, as
these hormones have well-described anti-inflammatory effects. In addition,
glucocorticoids are anti-proliferative, which could also contribute to reduced lesion
development. Furthermore, since glucocorticoids are endogenous hormones, their
activity, metabolism and availability in the vessel wall may be an important influence
during the vascular response to injury. For these reasons, the current investigation
focuses on the effect of glucocorticoids on the vascular response to injury, and so a
detailed review of the biology of these hormones is appropriate.
1.2 Glucocorticoids
Glucocorticoids (Cortisol (F) in man and corticosterone (B) in rodents) are steroid
hormones synthesised from cholesterol in the adrenal cortex, and released from the
adrenal gland into the systemic circulation.
1.2.1 Physiological actions of glucocorticoids
Glucocorticoids exert wide-ranging effects in the body, and regulate a number of
important metabolic and homeostatic processes. They influence the cardiovascular,
immune and central nervous systems, and have effects during growth and
development. The most important physiological role of glucocorticoids is thought to
be during the stress response (Munck et al. 1984), during which increased levels of
hormone alter metabolism to increase blood glucose levels, thus preparing the body
for the 'fight or flight' response. The main metabolic effects of glucocorticoids in
organs such as the liver, adipose tissue, and muscle are to increase the conversion of
stored energy (in glycogen, triglycerides and protein) into fuel (glucose, free fatty
acids and amino acids) for mitochondrial oxidation; thereby opposing the effects of
insulin (Dallman et al. 1993). They also induce the differentiation of pre-adipocyte
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stromal cells into mature adipocytes (Hauner et al. 1987), promoting the
accumulation of lipid. The physiological roles of these hormones have been clarified
by clinical observations of the symptoms of adrenal disease. Glucocorticoid excess
(e.g. in Cushing's syndrome) is characterised by central obesity, insulin resistance,
hyperglycemia and hypertension. In contrast, glucocorticoid insufficiency (e.g. in
Addison's disease) causes weight loss, loss of appetite, hypoglycemia and postural
hypotension.
1.2.1.1 Anti-inflammatory and immunosuppressive actions
The anti-inflammatory and immunosuppressive effects of glucocorticoids are well
described, and account for their most common therapeutic applications in the
treatment of inflammation, autoimmune disease and the prevention of rejection of
transplanted organs.
Endogenous glucocorticoids can regulate both the adaptive and innate immune
systems, including the first line of defence: inflammatory responses. The
anti-inflammatory actions of glucocorticoids are due to interactions with blood
vessels, inflammatory cells and mediators of inflammatory responses (Barnes &
Adcock 1993). By altering the transcription of several genes, they decrease
expression of adhesion factors, chemokines, cytokines and their receptors, and
increase the expression of anti-inflammatory mediators such as IL-10 and IL-lra
(Barnes 1998). Therefore, glucocorticoids alter the recruitment of immune cells such
as neutrophils, granulocytes and monocytes to the site of inflammation, cause a
decrease in leukocyte activation and proliferation, and thus suppress the initial
inflammatory response. Furthermore, these hormones modify granulocyte apoptosis
(Meagher et al. 1996), promote the phagocytosis of apoptotic leukocytes (Liu et al.
1999), and regulate the maturation ofmonocytes into highly phagocytic macrophages
(Giles et al. 2001), promoting the resolution of inflammation (Heasman et al. 2003).
It should be noted that glucocorticoids are not exclusively anti-inflammatory agents,
and that at physiological levels they may both suppress and stimulate inflammatory
responses (Yeager et al. 2004). A model has been proposed where physiological
levels of glucocorticoids exert permissive effects on inflammation at low levels, and
stimulatory actions as concentrations increase during normal diurnal variation. At
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high stress levels, or following pharmacological administration, glucocorticoids
inhibit inflammation (Sapolsky et al. 2000). Therefore, the physiological actions of
glucocorticoids are best described as immunomodulatory, rather than
immunosuppressive.
1.2.1.2 Effects on the Cardiovascular System
Observations in patients with adrenal disease have indicated that normal
physiological levels of glucocorticoids are needed to maintain normal blood pressure
and fluid volume. These hormones increase blood pressure and fluid volume in a
homeostatic way, in response to stimuli such as septic shock. However, the exact
mechanisms responsible for regulation of these factors by glucocorticoids are not
clear, since the effects of these hormones on the cardiovascular system are wide
ranging, with cardiac, renal and vascular actions documented. Glucocorticoids can
regulate cardiac output by influencing contractility and work performance of the
heart. They also have an important role in the regulation of fluid and electrolyte
balance, and increase renal sodium retention and plasma volume expansion by the
kidney. This may be mediated via direct influences on sodium handling
(Montrella-Waybill et al. 1991), or in-directly via the regulation of angiotensinogen
production by the liver, arginine vasopressin (AVP) production by the hypothalamus
(Raff 1987) and atrial natriuretic peptide (ANP) production by cardiac myocytes
(Shields et al. 1988). All of these peptide hormones can influence salt and water
handling in the kidney. Glucocorticoids also have direct effects on the tone of the
vessel wall, modulating its sensitivity to vasoconstrictors and the production of
vasodilators (reviewed in (Ullian 1999)). This possible contribution to blood pressure
regulation, and a detailed examination of the effects of glucocorticoids on the blood
vessel wall, is discussed later (section 1.3). Increases in circulating glucocorticoid
levels above physiological concentrations can have adverse effects on the
cardiovascular system (see section 1.2.6).
1.2.2 Regulation of glucocorticoid action
Due to their varied physiological functions throughout the body, the actions of
glucocorticoid hormones are tightly regulated by several mechanisms.
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1.2.2.1 The hypothalamic-pituitary-adrenal axis
Glucocorticoids are released from the adrenal cortex when required, under the
control of the hypothalamic-pituitary-adrenal (HPA) axis. Release of
corticotrophin-releasing hormone (CRH) (Vale et al. 1981) from the hypothalamus
causes the stimulation ofCRH receptors in the anterior pituitary, and the secretion of
adrenocorticotrophic hormone (ACTH) into the systemic circulation (Horrocks et al.
1990). AVP can also stimulate ACTH release (Salata et al. 1988), and there is a
synergistic interaction between CRH and AVP (Rivier & Vale 1983). ACTH acts on
adrenal cells to stimulate steroid hormone biosynthesis, catalysed by members of the
cytochrome P450 oxidative enzyme family, resulting in glucocorticoid secretion. It
does so by regulating the first, rate-limiting step in the steroid biosynthetic pathway:
the conversion of cholesterol to pregnenolone.
There is a basal release of glucocorticoids which shows a normal diurnal variation,
with concentrations at a peak at the beginning of the active period. Stimulation of
glucocorticoid release can also be produced by physiological stimuli such as stress,
injury or infection, which increase the secretion of CRH. Glucocorticoids provide a
negative feedback loop to regulate their own release and maintain physiological
plasma levels (de Kloet 1991). They do so by exerting a negative effect on the HPA
axis at the level of both the hypothalamus and the pituitary.
1.2.2.2 Regulation of circulating hormone concentrations
Glucocorticoids are lipophilic, which enables them to pass through cell membranes.
However, circulating glucocorticoids are predominantly bound to
corticosteroid-binding globulin (CBG) and albumin, and only the small proportion of
free hormone in the plasma can enter cells. In this way, glucocorticoid-binding
proteins act to regulate the bioavailability of glucocorticoids in the plasma.
1.2.2.3 Receptor-mediated glucocorticoid action
Glucocorticoids can bind to and activate the glucocorticoid receptor (GR) and the
mineralocorticoid receptor (MR), which are both members of the nuclear hormone
receptor super family of ligand-activated transcription factors (Parker 1993).
However, glucocorticoids exert most of their physiological effects through GR. In
the absence of hormone, GR are present in the cytosol, in association with a complex
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of heat shock proteins which maintain the receptor in an inactive state. Upon ligand
binding, GR dissociates from these proteins, forms homodimers and translocates to
the nucleus. GR homodimers can then bind specific deoxyribonucleic acid (DNA)
sequences, called glucocorticoid-responsive elements (GRE) in target genes to
initiate their transcription. In addition, GR is able to repress the expression of
specific genes by several mechanisms, and can also modulate the expression of target
genes via cross-talk with other transcription factors, including API, cAMP
responsive element- binding protein (CREB) and nuclear factor kB (NFkB) (Auphan
et al. 1995).
GR are ubiquitously expressed but expression levels vary between and within tissues
(Reul & de Kloet 1985; Reul et al. 1989), contributing to tissue-specific sensitivity to
glucocorticoids. GR levels are programmed perinatally, by environmental factors
such as neonatal stress (de Kloet et al. 1990) or prenatal glucocorticoid exposure
(Nyirenda et al. 1998). This process is regulated in a tissue-specific manner by the
existence of alternative promoters/ exons 1 in the GR gene, which generate several
GR messenger RNA (mRNA) variants (McCormick et al. 2000). In the adult,
autoregulation of expression around its predetermined level by glucocorticoids
allows short-term control of GR levels (Rosewicz et al. 1988); this does not involve
differential mRNAs (Freeman et al. 2004).
There is increasing evidence that glucocorticoids can exert non-genomic actions; for
example the rapid activation of eNOS, which is blocked by GR antagonism but not
by inhibition of transcription (Hafezi-Moghadam et al. 2002; Limbourg et al. 2002).
These effects are thought to be mediated by membrane-bound GR (Bartholome et al.
2004), although the associated intracellular signalling pathways have not been
determined, or by cytosolic GR (Croxtall et al. 2002) in association with molecular
chaperones acting as signalling components. However, it remains uncertain whether
non-genomic receptor-mediated responses to glucocorticoids have any physiological
relevance (Tasker et al. 2006).
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1.2.3 Glucocorticoid metabolism
Hormone metabolism provides additional control of glucocorticoid activity. The
peripheral metabolism of glucocorticoids results in conversion of active steroid into
inactive metabolites, and provides a means of clearing these hormones from the
circulation. Metabolism of glucocorticoids (Figure 1.4) occurs mainly in the liver and
involves reduction, oxidation, hydroxylation and conjugation reactions; the resultant
metabolites are then excreted by the kidney. Inter-conversion of corticosterone (B)
with its inactive 11-keto metabolite 11 -dehydrocorticosterone (A) is catalyzed by the
two isozymes of 11 p-hydroxysteroid dehydrogenase (11 P-HSD 1 and 2); the
subsequent metabolism of corticosterone and 11-dehydrocoticosterone then follow
similar paths, leading eventually to their excretion.
1.2.3.1 The 1ip-hydroxysteroid dehydrogenase enzymes
The 11 P-HSDs are microsomal enzymes of the short-chain alcohol dehydrogenase
super family (Stewart & Krozowski 1999). The inter-conversion of active
glucocorticoids with their inert 11-keto forms by lip-HSD was first described over
fifty years ago (Amelung et al. 1953), but its significance has only become apparent
more recently.
The importance of llp-HSD activity was demonstrated in patients with the rare,
congenital 'syndrome of apparent mineralocorticoid excess' (SAME), which occurs
as a result of mutations in the 11P-HSD2 gene (Stewart et al. 1996). The symptoms
of excessive MR activation (severe hypertension associated with sodium retention,
low plasma renin and hypoalkemia) in SAME, despite low circulating concentrations
of its natural ligand aldosterone, were shown to be due to a congenital deficiency of
11P-HSD. This results in impaired inactivation of Cortisol to cortisone (Ulick et al.
1979; Shackleton et al. 1985; Monder et al. 1986) and inappropriate binding of
glucocorticoids to MR in the distal nephron, confirming the link between 11P-HSD
activity and apparent mineralocorticoid excess (Edwards et al. 1988; Funder et al.
1988). Inactivation of Cortisol by 11 P-HSD activity also explained why MR, which
have similar affinities for aldosterone and Cortisol (Funder et al. 1988), preferentially














Figure 1.4: Metabolism of corticosterone
This pathway involves the inter-conversion of active (B) and inactive (A) hormone by the
isozymes of 11[3-hydroxysteroid dehydrogenase (11(3-HSD). Reduction by 5a- or
5p-reductase produces dihydro metabolites (5a/5p-DHB, 5P-DHA) that are then rapidly
converted to tetrahydro metabolites (5a/5p-THB, 5|3-THA) by 3a-hydroxysteroid
dehydrogenase (3a-HSD). These metabolites are then conjugated and excreted from the
body.
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circulating concentrations (Sheppard & Funder 1987). Thus, it was proposed that the
physiological role of lip-HSD was to protect MR from inappropriate activation by
glucocorticoids, by pre-receptor conversion ofCortisol to cortisone.
Subsequent studies identified two isozymes of lip-HSD. The first isozyme to be
cloned (Agarwal et al. 1989) and purified from liver had a Km in the pM range for
both Cortisol and corticosterone (Lakshmi & Monder 1988), and did not co-localise
with MR in the kidney (Edwards et al. 1988; Rundle et al. 1989; Stewart et al. 1991).
This tissue distribution, and the fact that MR have a Kd in the nM range for
glucocorticoids, indicated that this hepatic enzyme could not be responsible for the
protection ofMR from Cortisol in the distal nephron of the kidney. A second isozyme
of lip-HSD, with nicotinamide adenine dinucleotide (NAD)-dependent
dehydrogenase activity and a Km for Cortisol and corticosterone in the nM range,
was later identified in the aldosterone target cells of the kidney (Naray-Fejes-Toth et
al. 1991; Mercer & Krozowski 1992; Rusvai & Naray-Fejes-Toth 1993; Stewart et
al. 1994). Cloning of this lip-HSD type 2 isozyme confirmed limited tissue
distribution consistent with a role in protection ofMR (Agarwal et al. 1994; Albiston
et al. 1994). The first enzyme cloned from rat liver became known as lip-HSDl.
The physiology of both isozymes has subsequently been explored in greater detail,
particularly since the generation of mice with selective transgenic disruption of each
isozyme (Kotelevtsev et al. 1997; Kotelevtsev et al. 1999).
Physiology of 1 If-HSDl. lip-HSDl is a low affinity nicotinamide adenine
dinucleotide phosphate (NADP)-dependent enzyme. It has a wide expression pattern,
being found in many glucocorticoid target tissues including the liver, lung, adipose
tissue, brain, vascular smooth muscle, skeletal muscle, anterior pituitary, gonads and
adrenal cortex (Stewart & Krozowski 1999; Tomlinson et al. 2004). lip-HSDl is
under complex regulatory control. Factors that alter its synthesis and activity in vivo
or in vitro include stress, sex steroids, growth hormone, inflammatory cytokines,
peroxisome proliferator activated receptor agonists and glucocorticoids themselves
(Stewart & Krozowski 1999; Tomlinson et al. 2004). The CAAT/ enhancer-binding
protein (C/EBP) family of transcription factors represent one major mechanism by
which the expression of 1 lp-HSDl is regulated in the liver (Williams et al. 2000). In
addition, its expression may be altered in a tissue-specific manner via the existence
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of at least three alternative promoters in the lip-HSDl gene with differential
expression patterns (Moisan et al. 1992; Bruley et al. 2006).
Original indications suggested that lip-HSDl was bi-directional, with both
dehydrogenase and reductase activities observed in vitro (Monder & Lakshmi 1989).
However, dehydrogenase activity of llp-HSDl is now attributed to release of
enzyme from damaged or dying cells in culture, and dissociation from
hexose-6-phosphate dehydrogenase, which maintains NADP concentrations needed
for reductase activity (Bujalska et al. 2005; Hewitt et al. 2005). In intact cells or
organs in vitro and in vivo (including liver (Jamieson et al. 1995; Jamieson et al.
2000), adipose tissue (Bujalska et al. 1997), neurones (Rajan et al. 1996) and
vascular smooth muscle (Brem et al. 1995)), lip-HSDl acts predominantly as a
reductase, regenerating active hormone from inactive 11-keto metabolites (Figure
1.4). These results are supported by studies in lip-HSDl deficient transgenic mice,
which cannot convert 11-dehydrocorticosterone to corticosterone in vivo
(Kotelevtsev et al. 1997).
lip-HSDl reactivates glucocorticoids in tissues with few MR but abundant GR,
suggesting that the physiological role of 11P-HSD1 is to amplify local glucocorticoid
concentrations in glucocorticoid target tissues (Seckl & Walker 2001). For example,
in the liver this enzyme might be important in maintaining local glucocorticoid levels
even when plasma levels are low. This has been supported by several studies;
lip-HSDl knockout mice show impaired gluconeogenic responses to fasting
(Kotelevtsev et al. 1997) and pharmacological inhibition of lip-HSD in humans
results in enhanced insulin sensitivity (Walker et al. 1995a). In the lung, its other
major site of expression, lip-HSDl plays a role in surfactant production
(Hundertmark et al. 2002), and in the detoxification of substances such as
tobacco-derived carcinogens (Maser & Oppermann 1997). Amplification of
glucocorticoid action by lip-HSDl is also important in the brain. llp-HSDl is
highly expressed in hippocampal neurones (Rajan et al. 1996) and other areas of the
brain (Moisan et al. 1990a; Moisan et al. 1990b; Sakai et al. 1992), where it acts as a
reductase to amplify glucocorticoid action (Rajan et al. 1996). Studies in lip-HSDl
deficient mice have shown that this enzyme has damaging effects on cognitive
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function (Yau et al. 2001) and may also influence negative feedback regulation of
the HPA axis by glucocorticoids (Kotelevtsev et al. 1997; Harris et al. 2001).
In addition to glucocorticoid metabolism, 11(3-HSD1 can catalyse the
inter-conversion of the oxysterols 7-ketocholesterol and 7P-hydroxycholesterol (Hult
et al. 2004). There is evidence that reduction of 7-ketocholesterol to
7(3-hydroxycholesterol by 11P-HSD1 occurs, since in vivo inhibition of 1 lp-HSDl in
rats resulted in accumulation of 7-ketocholesterol in the liver and plasma (Schweizer
et al. 2004). This indicates that substrate competition for enzyme activity between
the oxysterols and glucocorticoids may occur in vivo.
Physiology of 1 lfi-HSD2. 11P-HSD2 is a high affinity NAD-dependent
dehydrogenase, which converts active glucocorticoids into inactive 11-keto
metabolites (Figure 1.4). It is found primarily in mineralocorticoid target tissues,
such as the kidney, sweat glands, salivary glands and colon (Stewart & Krozowski
1999). In these sites 11P-HSD2 is constitutive; its synthesis and activity are not
highly regulated. The major role of 11P-HSD2 in aldosterone target tissues is to
protect MR from illicit occupation by glucocorticoids. Consequently, transgenic
disruption of 11P-HSD2 recapitulates the major features of SAME (Kotelevtsev et al.
1999).
11P-HSD2 is also expressed at sites where MR are not abundant and do not require
protection from Cortisol; for example, in the placenta throughout most of gestation
(Stewart et al. 1995; Waddell et al. 1998). In this site, 11P-HSD2 is thought to
protect the foetus from excessive exposure to maternal glucocorticoids (Brown et al.
1996). This is important, as excessive gestational exposure to glucocorticoids retards
foetal growth and may 'programme' the development of hypertension and
hyperglycemia, and thus an increased risk of diabetes and CHD, in later life (Seckl
1997). 11P-HSD2 is also found in several adult tissues (e.g. lung (Suzuki et al.,
1998), heart (Walker et al. 1991) and blood vessel wall (Walker et al. 1991; Christy
et al. 2003)) that are not classic targets for mineralocorticoids. Cardiac 11P-HSD2
may prevent fibrosis resulting from the stimulation of MR by glucocorticoids
(Konishi et al. 2003). The role of 11P-HSD2 in the blood vessel wall is discussed
later (section 1.3).
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1.2.3.3 Tissue-specific pre-receptor metabolism as a regulatory mechanism
Improved understanding of the roles of the 11P-HSD isozymes has emphasised the
physiological importance of tissue-specific metabolism of glucocorticoids. Indeed, it
is increasingly apparent that the actions of glucocorticoids are not regulated solely by
systemic factors such as circulating plasma concentrations (modulated by hormone
synthesis and peripheral metabolism), binding by plasma proteins (such as CBG),
and receptor expression and density in target tissues. Rather than merely representing
a clearance mechanism, pre-receptor metabolism by 11 P-HSD types 1 and 2 in target
tissues is now recognised to be an essential component in regulating tissue-specific
responses to glucocorticoids (Seckl & Walker 2001). Consequently, in addition to its
role in rare conditions such as SAME, tissue-specific pre-receptor metabolism of
glucocorticoids is now thought to contribute to the pathogenesis of common
conditions such as obesity, insulin resistance, essential hypertension and
cardiovascular disease.
1.2.4 Glucocorticoids and cardiovascular disease
1.2.4.1 Increased glucocorticoids and cardiovascular risk
Excess circulating glucocorticoid levels are associated with metabolic and
cardiovascular complications such as central obesity, insulin resistance,
hyperglycemia, dyslipidemia and hypertension. Indeed, these conditions often limit
the usefulness of glucocorticoid therapy for inflammatory or immune disease, and
are the most important causes of morbidity and mortality in patients with Cushing's
syndrome (Ross & Linch 1982). Activation of the HPA axis with increased Cortisol
secretion can be observed in non-Cushing's patients, perhaps caused by
programming events during early life (Seckl 2004) or psychosocial stress (Bjorntorp
1991). This form of hypercortisolemia has also been associated with hypertension,
hyperglycemia and dyslipidemia in several studies (Walker 2006). Interestingly, the
cluster of metabolic abnormalities caused by elevations in glucocorticoid secretion
and plasma concentration is strikingly similar to features of the metabolic syndrome
(Reynolds & Walker 2003; Wake & Walker 2004). However, patients displaying the
principal feature of the metabolic syndrome, obesity, have normal or low circulating
glucocorticoid levels (Migeon et al. 1963; Ljung et al. 1996). This suggests that if
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glucocorticoids are involved in the aetiology of the metabolic syndrome,
tissue-specific alterations in metabolism and sensitivity may be the contributory
factor, rather than altered circulating hormone levels.
Tissue sensitivity to Cortisol can vary between individuals and between tissues, and
evidence suggests that increased tissue sensitivity to glucocorticoids is associated
with cardiovascular risk factors (Walker et al. 1996; Walker et al. 1998; Panarelli et
al. 1998; Andrews et al. 2002). In addition to differences in GR expression,
increased sensitivity may be due in part to polymorphisms in the GR gene that
change receptor function (van Rossum & Lamberts 2004), or to variations in
11P-HSD activity. For example, obesity is associated with a tissue-specific
dysregulation of 11P-HSD1 activity; studies in obese Zucker rats (Livingstone et al.
2000) and humans (Rask et al. 2001; Rask et al. 2002; Wake et al. 2003) have shown
enzyme activity to be increased in adipose tissue but decreased in the liver.
Furthermore, transgenic mice over-expressing lip-HSDl selectively in adipose
tissue (Masuzaki et al. 2001) or liver (Paterson et al. 2004) display features of the
metabolic syndrome, whilst transgenic deletion of lip-HSDl improves hepatic
insulin sensitivity, glucose tolerance and lipid profiles (Morton et al. 2001). Since
11P-HSD2 deficiency causes hypertension in humans (Stewart et al. 1996) and mice
(Kotelevtsev et al. 1999), milder reductions in renal enzyme activity could contribute
to essential hypertension. A clinical study showed an increased half-life of
11 a3 [H]-Cortisol in a subgroup of patients with essential hypertension (Walker et al.
1993), and investigations into the 11P-HSD2 genotype have revealed a
polymorphism associated with higher cortisokcortisone metabolite ratios that is more
common in men with blood pressure sensitive to salt loading (Lovati et al. 1999).
Therefore, increased glucocorticoid action in humans is associated with the
cardiovascular risk factors of metabolic syndrome, such as obesity. For this reason,
treatments that will reduce glucocorticoid action are being developed. Therapeutic
inhibition of lip-HSDl would lower hepatic and adipose Cortisol concentrations,
enhancing insulin sensitivity, reducing gluconeogenesis and reducing adiposity
(Sandeep & Walker 2001; Seckl & Walker 2001). This may be of benefit in patients
with diabetes or obesity. Indeed, selective inhibitors of lip-HSDl have been tested
in several rodent models, where they have been found to decrease obesity
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(Hermanowski-Vosatka et al. 2005; Berthiaume et al. 2007), and improve
hyperglycemia and insulin sensitivity (Alberts et al. 2002; Alberts et al. 2003;
Hermanowski-Vosatka et al. 2005).
On the basis that glucocorticoids elicit adverse influences on cardiovascular risk
factors, it would seem that the action of these hormones is detrimental to the
development of CVD. On the other hand, the anti-inflammatory effects of these
hormones would be expected to inhibit the development of atherosclerotic lesions.
Hence, the net effect of glucocorticoids on CVD is not predictable.
1.2.4.2 Glucocorticoids and atherosclerosis
Perhaps unsurprisingly, given their anti-inflammatory properties, glucocorticoid
treatment can decrease macrophage accumulation in animal models of atherogenesis
(Asai et al. 1993; Tauchi et al. 2001). In addition, these hormones prevent
incorporation of modified LDL into macrophages in vitro (Asai et al. 1993) and
reduce cholesterol accumulation in the aorta of mice susceptible to atherosclerosis
(Tauchi et al. 2001). This contrasts with the association between glucocorticoid
excess and increased atherosclerosis in humans. Anti-inflammatory glucocorticoid
therapy is associated with atherogenesis in patients with inflammatory disease
(Maxwell et al. 1994; del Rincon et al. 2004; Davis, III et al. 2005); however it is
difficult to attribute this effect solely to glucocorticoids given the underlying
inflammatory conditions (Bernatsky et al. 2005; Davis, III et al. 2007).
Pharmacoepidemiological studies have found a correlation between glucocorticoid
therapy and adverse cardiovascular events, most strongly with the incidence of heart
failure and myocardial infarction (Souverein et al. 2004; Wei et al. 2004). This effect
was not altered by adjustment for the underlying disease, or for components of the
metabolic syndrome. This suggested that glucocorticoids may not only increase
cardiovascular risk through adverse changes in systemic metabolic factors, but also
by actions in the blood vessel wall. Increases in endogenous glucocorticoids have
also been linked to atherosclerosis; studies in Cushing's patients have found intimal
thickening, increased stiffness and a higher incidence of atherosclerotic plaques in
the carotid artery (Faggiano et al. 2003) which remain five years after successful
cure of the disease (Colao et al. 1999). In a recent pilot clinical study, higher plasma
Cortisol levels in response to stress were associated with coronary artery stenosis
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(Alevizaki et al. 2007). Coronary artery disease has also been linked to a
polymorphism in GR that increases sensitivity to glucocorticoids (Lin et al. 2003).
Consistent with the evidence that excess glucocorticoids promote atherosclerosis in
humans, selective inhibition of 11P-HSD1 in ApoE knockout mice fed a high fat diet
significantly delayed the progression of atherosclerotic lesion development
(Hermanowski-Vosatka et al. 2005). Furthermore, there was a suggestion of a direct
protective effect of enzyme inhibition in the blood vessel wall, with a decrease in
vascular MCP-1 expression observed (Hermanowski-Vosatka et al. 2005).
1.2.4.3 Systemic vs. local actions of glucocorticoids in cardiovascular disease
Whilst their anti-inflammatory actions suggest that glucocorticoids would reduce the
development of vascular lesions, they can also cause adverse systemic changes in
cardiovascular risk factors and may contribute to the development of atherosclerosis,
as described above. What remains unclear is whether their influence on atherogenesis
is due to direct interactions with the blood vessel wall, or to indirect changes in
systemic factors, such as blood pressure or circulating lipid levels. It is unlikely that
glucocorticoids promote atherosclerosis solely through adverse effects in the vessel
wall, and components of local glucocorticoid action (e.g. on VSMCs or
inflammatory cells) may prevent lesion formation. Therefore, it would be premature
to assume that reducing glucocorticoid action at all sites, for example via systemic
lip-HSDl inhibition, would be beneficial in the treatment of atherosclerosis. Since
their role in the vascular response to injury remains unclear, a more detailed analysis
of the local actions of glucocorticoids on the blood vessel wall is required.
1.3 Intra-vascular glucocorticoid actions and metabolism
Glucocorticoids can directly alter vascular function and structure, the inflammatory
response to arterial injury, and the growth of new blood vessels (Figure 1.5). These
actions may contribute to the link between glucocorticoids and cardiovascular
disease (Hadoke et al. 2006).
1.3.1 Vascular glucocorticoid receptors and metabolism
The ability of glucocorticoids to interact with the vascular wall is indicated by the
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Figure 1.5: Effect of glucocorticoids on cardiovascular physiology and
disease
Glucocorticoid hormones present within the vasculature have effects on vascular smooth
muscle cells (VSMCs), endothelial cells and macrophages to influence artery function,
structure and the response to inflammation. It is likely that these processes will be modulated
by inter-conversion of active and inactive glucocorticoids in vascular tissue by the isozymes
of 11 (B-hydroxysteroid dehydrogenase (11P-HSD1 and 2). Glucocorticoids can also have
systemic actions on non-vascular organs, such as the liver, adipose tissue and kidney, to
cause adverse changes in cardiovascular risk factors.
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(Kornel et al. 1982; Christy et al. 2003) and in cultured VSMCs (Meyer & Nicholls
1981; Scott et al. 1987) and endothelial cells (Inoue et al. 1999; Golestaneh et al.
2001). Vascular GR are functional, since antagonism with RU38486 blocks
induction of ACE activity in rat aortic endothelial cells (Sugiyama et al. 2005).
Similarly, antagonism ofMR inhibits angiotensin-II-induced hypertrophy of VSMCs
(Hatakeyama et al. 1994) and aldosterone-induced swelling of endothelial cells
(Oberleithner et al. 2003). The distribution of receptors for glucocorticoids may vary
between vascular beds; for example MR has been detected in VSMCs from rabbit
aorta and pulmonary artery, but not in smaller arteries (Lombes et al. 1992). It
remains to be established whether membrane binding sites for glucocorticoids are
present in the vasculature.
As in other tissues, the interaction of glucocorticoids with their receptors in the
vasculature is unlikely to be regulated by circulating concentrations alone. The
expression of both 1lp-HSDl and llp-HSD2 suggests that pre-receptor metabolism
of glucocorticoids may influence steroid action within the vessel wall (Figure 1.5),
although there is some controversy over the cellular localisation of these enzymes
and the direction of their activity (Morris et al. 2003). In the mouse aorta 1 lp-HSDl
is localised to VSMC whilst 11P-HSD2 is present only in endothelial cells (Christy
et al. 2003), however studies in cultured human and rat cells have suggested that
both isoforms exist in VSMCs (Hatakeyama et al. 1999; Cai et al. 2001) and
endothelial cells (Brem et al. 1998). Therefore, the cellular distribution of these
enzymes may vary between species, and with the anatomical location of the vessel
(Hadoke et al. 2006). In addition, there is evidence that 11P-HSD activity varies in
arteries from different vascular beds, with activity increasing as artery diameter
decreases (Walker et al. 1991). Therefore, variations in cellular distribution and
activity suggest that intra-vascular glucocorticoid metabolism is not the same in all
blood vessels, and may vary between species.
1.3.2 Glucocorticoid actions in the blood vessel wall
1.3.2.1 Modulation of vascular tone
Hypertension caused by glucocorticoid excess cannot be entirely attributed to renal
MR agonism, since these hormones can increase blood pressure in rats devoid of
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renal mass (Langford & Snavely 1959), and normalisation of renal sodium handling
with spironolactone in humans does not totally normalise blood pressure
(Williamson et al. 1996). Furthermore, selective GR agonists, such as
dexamethasone, increase blood pressure in the absence of an increase in sodium
retention or plasma volume (Whitworth 1992). This suggests that increased cardiac
output or an increase in peripheral vascular resistance may contribute to the
development and maintenance of hypertension in response to glucocorticoids.
Indeed, enhancement of vascular contractility by glucocorticoids has been implicated
in the development of hypertension (Brem 2001).
Although it is well established that glucocorticoids contribute to maintenance of
vascular tone in vivo (Figure 1.5), the mechanisms involved have yet to be
confirmed. There is much evidence that glucocorticoids directly enhance vascular
contraction, with several possible mechanisms suggested. Glucocorticoid-dependent
potentiation of noradrenaline- and angiotensin II-mediated VSMC contraction
(Pirpiris et al. 1992) has variously been attributed to up-regulation of receptors in
vascular smooth muscle, altered intracellular signalling downstream from receptor
activation and modulation of the activity and synthesis of vasoactive substances
(Walker & Williams 1992; Kornel et al. 1993; Ullian 1999). Alternatively, enhanced
contraction may be secondary to impaired endothelium-dependent relaxation.
Glucocorticoids can impair endothelium-dependent vasodilation to acetylcholine
(Walker et al. 1995b; Mangos et al. 2000), and reduce the release of vasodilators
(e.g. prostaglandins, NO) (Rosenbaum et al. 1986; Wen et al. 2000; Whitworth et al.
2002), whilst increasing the release of vasoconstrictors (e.g. angiotensin II,
endothelin-1) (Mendelsohn et al. 1982; Morin et al. 1998), from endothelial cells.
Whilst 11 |3-HSD2 deficiency in SAME results in glucocorticoid-induced renal MR
activation and severe hypertension, there is also evidence to show that changes in
lip-HSD activity within the vasculature can contribute to alterations in blood
pressure. In most pharmacological studies in vitro, inhibition of lip-HSD
dehydrogenase activity is associated with an enhanced response to vasoconstrictors,
whereas inhibition of the reductase reaction produces attenuated contraction (Morris
et al. 2003). Whilst interpretation of these results may be complicated by the fact that
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some lip-HSD inhibitors can directly influence vascular function by damaging the
endothelium (Ullian et al. 1996), they are supported by the demonstration that
inhibition of 11 P-HSD 1 activity with antisense oligonucleotides diminishes the
ability of 11-dehydrocorticosterone to enhance phenylephrine-mediated contraction
(Souness et al. 2002). In vivo, 11 p-HSD activity is impaired in vessels isolated from
hypertensive rats (Takeda et al. 1993; Takeda et al. 1994), whilst enhanced vascular
contractility to glucocorticoids and catecholamines is observed in humans with
congenital deficiency of 11P-HSD2 (Walker et al. 1992b). Observations in mice with
transgenic deletion of 11P-HSD2 (Kotelevtsev et al. 1999) have further confirmed
the role of glucocorticoid metabolism in the control of blood pressure and vascular
function. llp-HSD2 knockout mice are hypertensive (Kotelevtsev et al. 1999), and
have enhanced vasoconstrictor responses to noradrenaline with impaired
NO-mediated endothelium-dependent vasodilation (Hadoke et al. 2001). The cause
for the changes in vascular reactivity and endothelial dysfunction are unknown, but
are unlikely to be due to renal sodium retention and increased blood pressure since
chronic renal mineralocorticoid excess does not replicate the changes in vascular
function (Hadoke et al. 2001). Data from 11P-HSD2 knockout mice suggested that
the observed changes in vascular reactivity were due to a loss in 11P-HSD2-mediated
protection of GR within endothelial cells and, hence, glucocorticoid-mediated
endothelial cell dysfunction (Hadoke et al. 2001). However, studies in isolated
vessels from these mice failed to confirm this (Christy et al. 2003), suggesting that
some other indirect mechanism causes the vascular abnormality in vivo. On the other
hand, transgenic deletion of 11 P-HSD 1 has no effect on blood pressure (Kotelevtsev
et al. 1997) or vascular contractility (Hadoke et al. 2001), and this enzyme does not
seem to influence vascular reactivity in vivo. Therefore, studies in the 11 P-HSD 1
knockout mouse do not confirm what pharmacological in vitro studies had suggested.
1.3.2.2 Influence on vascular inflammation
The anti-inflammatory effects of glucocorticoids in vivo are mediated through
interactions with both arterial cells and inflammatory cells circulating in the vascular
lumen, and by promoting the resolution of inflammation (see section 1.2.1.1 and
Figure 1.5). GR are present in the inflammatory cells (e.g. macrophages) that are
involved in vascular lesion formation (Liu et al. 1999). The expression of 11 P-HSD 1
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in VSMCs (Cai et al. 2001), T and B lymphocytes (Zhang et al. 2005), and its
induction on the differentiation of monocytes into macrophages (Thieringer et al.
2001), suggests that regeneration of active glucocorticoids in cells of the vessel wall
and lumen may contribute to the regulation of vascular inflammation during lesion
formation. Indeed, pro-inflammatory cytokines have been shown to selectively
up-regulate 1 lp-HSDl activity in cultured VSMCs (Cai et al. 2001) and THP-1 cells,
a human macrophage-like cell line (Thieringer et al. 2001), indicating that a
mechanism for local feedback inhibition of inflammation may exist in the
vasculature. However, studies in intact vessels in vitro and in mice subjected to
inflammatory stimuli did not replicate this finding (Dover et al. 2007). This may be
explained by phenotypic differences between proliferating cells in culture and
quiescent ceils in intact vasculature, anatomical differences, local glucocorticoid
concentrations, or modulation of the inflammatory response by neighbouring tissues
(Hadoke et al. 2006).
The role of 11(3-HSD1-mediated glucocorticoid regeneration in the resolution of
inflammation has been demonstrated in vivo, after the induction of an acute
inflammatory response in mice via thioglycolate injection (Gilmour et al. 2006).
Cells elicited into the peritoneum showed an early and dramatic up-regulation of
11|3-HSD1 activity, which remained high until the resolution of inflammation
(Gilmour et al. 2006). The demonstration that inactive 11-keto glucocorticoids can
promote macrophage phagocytosis of apoptotic neutrophils to the same extent as
active glucocorticoid (an effect which is dependent on 1 lp-HSDl), and the fact that
lip-HSDl"7" mice showed a delayed clearance of exogenous apoptotic neutrophils
after thioglycolate injection (Gilmour et al. 2006), indicated a functional role for this
enzyme in the early resolution of acute inflammation (Chapman et al. 2006). This
idea is supported by a recent investigation which demonstrated that macrophages
from 1 lp-HSDl"7" mice showed increased production of inflammatory cytokines after
LPS stimulation in vitro, and that 1 ip-HSDl"" mice showed an exaggerated response
to LPS challenge in vivo (Zhang & Daynes 2007). Current studies, using a mouse
model of arthritis, have also indicated that regeneration of active glucocorticoids by
11P-HSD1 plays a role during more chronic inflammation (Chapman & Seckl 2007).
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Therefore, macrophage lip-HSDl activity may also be involved in regulating the
inflammatory response to acute and chronic vascular injury.
1.3.2.3 Inhibition of angiogenesis
The growth of new blood vessels (angiogenesis) is essential during embryonic
development. It also occurs physiologically during adult life, in the female
reproductive tract and during wound healing. Excessive angiogenesis contributes to
the pathology of several diseases, such as cancer, certain retinopathies and
rheumatoid arthritis (Carmeliet 2003). It is a complex process, under the control of
various activators and inhibitors, and modulation of angiogenesis represents a
therapeutic target for the treatment of several conditions (Carmeliet 2003).
Glucocorticoids inhibit angiogenesis (Folkman et al. 1983), but the mechanisms by
which they do so remain unclear (Hadoke et al. 2006). A recent study has
demonstrated that generation of endogenous glucocorticoids by 11(3-HSD1 acts to
regulate angiogenesis, and that glucocorticoid-mediated inhibition of angiogenesis is
GR-dependent (Small et al. 2005). Therefore, in addition to well-recognised effects
on artery function and inflammation, glucocorticoids can also act within the vessel
wall to influence its structure, and this process is modulated by the metabolism of
these hormones (Figure 1.5).
1.3.2.4 Neointimal lesion formation
Inhibition of either the inflammatory response to injury (Miller et al. 2001), or
VSMC proliferation and migration (Dzau et al. 2002), inhibits vascular lesion
development in a variety of models. Since glucocorticoids can inhibit both
inflammation, and smooth muscle cell proliferation (Longenecker et al. 1982;
Longenecker et al. 1984; Berk et al. 1988) and migration (Goncharova et al. 2003;
Ribichini et al. 2007) (Figure 1.5), their ability to directly influence neointimal lesion
formation has been examined both in animals and humans. Importantly, as for their
role in atherogenesis, it is likely that the influence of glucocorticoids on neointimal
formation is a balance between their beneficial actions on the vessel wall, and
adverse effects on systemic cardiovascular risk factors.
Glucocorticoid administration prevents neointimal lesion formation in animal models
of acute vascular injury. Glucocorticoids inhibit the response to cuff placement on
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the femoral artery of the mouse (Pires et al. 2005), balloon injury in the carotid
arteries of the rat (Villa et al. 1994; Guzman et al. 1996) and in similar models of
injury in the rabbit (Van Put et al. 1995; Petrik et al. 1998; Valero et al. 1998;
Ribichini et al. 2007). Similarly, dexamethasone release from coated metal stents
inhibited neointimal lesion formation in the dog femoral artery (Strecker et al. 1998).
The mechanisms underlying this inhibition of neointimal proliferation are unclear but
given the central role of inflammation in the response of the vessel wall to injury
(Wainwright et al. 2001), it is likely that intra-vascular glucocorticoid-mediated
inhibition of inflammation could attenuate both the initiation and progression of
neointimal proliferation. Indeed, in a model of balloon arterial injury in
cholesterol-fed rabbits, dexamethasone inhibited early macrophage accumulation in
the vessel wall, possibly by reducing the expression of MCP-1 (Poon et al. 2001).
Glucocorticoid administration has also been shown to reduce cytokine release after
stenting in rabbits (Ribichini et al. 2007). Inhibition of the inflammatory response to
acute vascular injury is consistent with the ability of glucocorticoid treatment to
decrease atherosclerotic lesion development in animal models via effects on
inflammatory cells (Asai et al. 1993; Tauchi et al. 2001). The anti-proliferative
actions of glucocorticoids, which inhibit the growth of VSMCs in culture
(Longenecker et al. 1982; Longenecker et al. 1984; Berk et al. 1988), and their
ability to inhibit VSMC migration (Goncharova et al. 2003; Ribichini et al. 2007),
may also contribute to the reduction of neointimal lesion development. Furthermore,
glucocorticoids can inhibit thrombin-stimulated release of mitogens (PDGF and
heparin-binding epidermal growth factor (HB-EGF)) from human aortic VSMCs
(Nakano et al. 1993). This may be highly relevant since PDGF has been implicated
in both the induction of migration and the expression of inflammatory
chemoattractant molecules by VSMC following vascular injury (Marmur et al.
1992).
It should be noted that glucocorticoids have not inhibited lesion growth in all animal
models. Dexamethasone had no effect on neointimal proliferation in response to
balloon injury in iliac arteries of hypercholesterolemic rabbits (Karim et al. 1997), or
in response to stenting in porcine coronary arteries (Lincoff et al. 1997). These
negative results were reflected in disappointing results from early clinical trails using
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glucocorticoids as anti-restenotics. For example, one large randomised clinical trial
found that a single dose of methylprednisolone did not inhibit restenosis after
coronary angioplasty (Pepine et al. 1990), whereas a small study showed that local
delivery of methylprednisolone acetate before stent implantation did not reduce
neointimal growth in lesions with high risk of restenosis (Reimers et al. 1998).
Furthermore, a study investigating the effect of anti-inflammatory agents on the
vascular response to injury found that patients treated with glucocorticoids, in
combination with colchicine, actually exhibited increased risk of coronary aneurysm
after stent placement (Rab et al. 1991). This was attributed to altered vessel wall
healing in the presence of anti-inflammatory agents. More recently, however, clinical
trials using glucocorticoids to inhibit restenosis after coronary stenting have
demonstrated beneficial results on luminal narrowing (Versaci et al. 2002; Han et al.
2006).
The negative results in early clinical trials could be attributed to differences between
animal models and the clinical condition or, alternatively, to inadequacies in the
clinical trials (e.g. small sample size, inappropriate patient selection, dose, duration
of treatment, route of administration). It is also likely that the well-recognised
adverse systemic effects of increased glucocorticoids on cardiovascular risk factors
(section 1.2.4), may have offset the benefits of their anti-inflammatory and
anti-proliferative actions in the vessel wall. This is supported by positive results from
more recent trials, using stents to deliver dexamethasone locally to the vessel wall
(Han et al. 2006). However, it should also be noted that glucocorticoids possess
properties that can promote vascular cell proliferation. As described above (section
1.3.2.1) glucocorticoids can attenuate the activity of NO (Walker et al. 1995b;
Mangos et al. 2000), itself a potent inhibitor of cell growth, and stimulate release of
growth factors (e.g. endothelin-1) (Morin et al. 1998). Glucocorticoids also stimulate
ACE expression in VSMCs (Fishel et al. 1995) and endothelial cells (Mendelsohn et
al. 1982). Increased ACE activity leads to increased generation of angiotensin II, a
stimulant of VSMC growth both in vitro (Berk et al. 1989) and in vivo (Griffin et al.
1991). The influence of angiotensin II generation on lesion development has been
highlighted by the demonstration that ACE inhibition limits neointimal lesion
formation following balloon injury of the rat carotid artery and aorta (Powell et al.
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1989; Capron et al. 1991). Alternatively, changes in plasma lipids could influence
the ability of glucocorticoids to interact with vascular cells. Lipoprotein (a) can
down-regulate glucocorticoid receptor gene expression in human VSMCs, thus
inhibiting any protective actions of glucocorticoids and, possibly, representing a
novel atherogenic mechanism (Sato et al. 1995).
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1.4 Hypothesis & aims
1.4.1 Hypothesis
Vascular lesions develop as a result of chronic, uncontrolled inflammatory and
proliferative responses to injury in the vascular wall. Pharmacological administration
of glucocorticoids, which have both anti-inflammatory and anti-proliferative
properties, inhibits the formation of neointimal lesions in animal models.
Furthermore, the potential of these hormones to treat restenosis after coronary
interventions in humans is being investigated. It is not known, however, whether the
availability of endogenous glucocorticoids in the vessel wall influences lesion
development after vascular injury. In addition, the interaction between systemic and
local actions of glucocorticoids on the vascular response to injury has not been
determined in detail. Therefore it was proposed that:
(a) endogenous glucocorticoids act in the vessel wall to directly inhibit
neointimal lesion formation, and
(b) this effect is modulated via the regulation of glucocorticoid availability
within the vessel wall by 11P-HSD1.
1.4.2 Aims
In order to address this hypothesis, the aims of this project were:
(i) To develop in vivo and in vitro models of neointimal lesion formation following
femoral artery injury in the mouse.
(ii) To determine whether the inflammatory response to injury influences
glucocorticoid levels by altering 1 lp-HSDl reductase activity in the vessel wall.
(iii) To determine the influence of glucocorticoid administration on the formation of
neointimal lesions.
(iv) To investigate the influence of endogenous glucocorticoids and their metabolism
by 1 lp-HSDl on the formation of neointimal lesions using both an enzyme inhibitor






Surgery: All surgical instruments and equipment were obtained from Fine Science
Tools, Interfocus Ltd., Haverhill, U.K., except the straight sprung angioplasty
guidewire, (Cook Inc., Bloomington, U.S.A.) and Mersilk 6-0 sutures with 15 mm
cutting needle (Ethicon, Livingston, U.K.). Isoflurane was from Merial Animal
Health Ltd., Harlow, U.K. Vetergesic (0.3mg/ml buprenorphine) was from Alstoe
Animal Health, York, U.K. Lignocaine (1% lidocaine hydrochloride) was from
Hameln Pharmaceuticals Ltd., Gloucester, U.K.
Chemicals, drugs and reagents: All chemicals and drugs were from Sigma-Aldrich,
U.K., except the lip-HSDl inhibitor compound 815 which was from Enamine,
Ukraine, and IL-ip which was from R&D Systems, U.K.
All solvents (including HPLC grade) were from Fisher Scientific, U.K. All
histological chemicals and solutions were from Sigma-Aldrich, U.K., except Harris'
haematoxylin (Thermo Shandon, U.K.) and Weigert's iron haematoxylin A and B
solutions (Bios Europe Ltd., U.K.). DPX mounting medium was from VWR
International, U.K.
Monoclonal primary antibody against smooth muscle cell a-actin (clone 1A4) was
from Sigma-Aldrich, U.K. Polyclonal rabbit anti-human primary antibodies against
von Willebrand factor and fibrinogen were from Dako Cytomation, U.K. Monoclonal
rat anti-mouse primary antibody against Mac-2 (clone M3/38) was from Cedarlane,
Canada. Polyclonal rabbit anti-human primary antibody against proliferating cell
nuclear antigen was from Santa Cruz Biotechnology, U.S.A.
Vectastain ABC kits (containing blocking serum, biotinylated secondary antibody
and ABC reagent), avidin biotin blocking kit, levamisole solution, alkaline
phosphatase substrate (VECTOR red) and diaminobenzidine substrate kits were
obtained from Vector Laboratories, U.K. Proteinase K ready-to-use antigen retrieval
solution and normal IgG fraction (rabbit and rat) were from Dako Cytomation, U.K.
All myography drugs were from Sigma-Aldrich, U.K. and salts from V.W.R
International, U.K. All PCR reagents were from Promega, U.K., except primers,
lKbp DNA ladder and lOx TAE buffer, which were from Invitrogen, U.K.
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2.1.1 Buffers and solutions
2.1.1.1 Histology and immunohistochemistry
0.2% acetic acid: 1 ml of acetic acid was diluted in 499 ml distilled water.
Alkaline tap water: 400 ml tap water plus 2-3 drops of ammonia.
Gomori's aldehyde fuchsin: 5 g of pararosaniline base was dissolved in 500 ml of
60% ethanol. To this 1 ml of hydrochloric acid (HC1) and 2 ml of fresh (within 6
months of purchase) paraldehyde were added, and the mixture was allowed to blue at
room temperature for at least two days. Before use the solution was filtered, and each
new batch was tested for optimum staining time.
Gomori's trichrome: 3 g of phosphotungstic acid was dissolved in 500 ml of
distilled water. To this 3 g of chromotrope 2R and 1.5 g of fast green FCF were
added and mixed until dissolved, then 5 ml of acetic acid were added. The solution
was filtered and tested for optimum staining time before use.
3% Hydrogen peroxide (H2O2): A commercial solution of 30% H2O2 was diluted
1:10 in phosphate buffered saline (PBS).
74 O.P.: A solution of 99.5% ethanol and 0.5% methanol.
2% oxalic acid: 10 ml of a commercial 100% solution diluted in 490 ml of distilled
water.
Phosphate buffered saline (PBS): 1 tablet was dissolved per 200 ml distilled water.
5% phosphotungstic acid: 250 ml of a commercial 10% solution was diluted in
250 ml of distilled water.
0.3% potassium permanganate in 0.3% aqueous sulphuric acid: Prepared from
stock solutions of 1% potassium permanganate (5 g dissolved in 500 ml distilled
water) and 3% sulphuric acid (15 ml concentrated sulphuric acid made up to 500 ml
with distilled water), made up to the appropriate volume with distilled water.
lx Tris buffered saline (TBS)/Tween: 61 g Tris base and 90 g NaCl were dissolved
in 1 litre of distilled water and the pH adjusted to 7.6. 5 ml of Tween 20 was added to
give a lOx solution of 0.5M Tris base, 9% NaCl, 0.5% Tween 20. The solution was
then diluted 1:10 before use.
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lOOmM Tris-HCl pH 8.2 : 12.11 g of Tris base was dissolved in 950 ml distilled
water. Concentrated HC1 was used to adjust the pH to 8.2 and the volume made up to
1 litre.
Weigert's iron haematoxylin: Equal volumes of Weigert's iron haematoxylin
solution A and solution B were mixed and filtered before use.
2.1.1.2 Myography
High potassium physiological salt solution (KPSS): KPSS was prepared in the
same way as PSS, except with the omission of NaCl and the addition 9.22 g of KC1,
giving a final concentration of 1M KC1 (125mM K+).
Physiological salt solution (PSS): 6.95 g NaCl, 0.35 g KC1, 0.54 g CaCl2.6H20,
0.29 g MgS04.7H20, 2.10 g NaHC03, 0.161 g KH2P04, 0.0096 g K2EDTA and
0.991 g D-glucose were dissolved in 1 litre of distilled water and the pH adjusted to
7.4. This gave a solution with final concentrations of: lOOmM NaCl, 0.005mM KC1,
0.002mM CaCl2.6H20, O.OOlmM MgS04.7H20, 0.02mM NaHC03, O.OOlmM
KH2P04, 0.00003mM K2EDTA and 0.005mM D-glucose.
2.1.1.3 Enzyme Activity Assays
C buffer: 63 g glycerol, 8.77 g NaCl, 186 mg EDTA and 3.03 g of Tris were
dissolved in 500 ml distilled water and the pH adjusted to 7.7.
Homogenising buffer: 100 g of glycerol, 300 mg of Tris and 186 mg ofEDTA were
dissolved in 500 ml of distilled water. The pH was adjusted to 7.5 and when ready
for use 7.7 mg of Dithiothreitol was added to 50 ml of buffer.
HPLC mobile phase: A mixture of filtered HPLC grade water (60%), acetyl nitrile
(15%) and methanol (25%).
Krebs' buffer: Krebs' buffer with a final concentration of 118mM NaCl, 3.8mM
KC1, 1.19mM KH2P04, 2.54mM CaCl2, 1.19mM MgS04 and 25mM NaHC03 was
prepared and the pH adjusted to 7.4.
Sucrose buffer: 42.79 g of sucrose was dissolved in 500 ml of distilled water to give
a 0.25M solution. The pH was adjusted to 7.5.
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2.1.1.4 Corticosterone radioimmunoassay
Borate buffer: 8.25 g of boric acid, 2.7 g of NaOH and 3.5 ml concentrated HC1
were dissolved in 1 litre of distilled water and the pH adjusted to 7.4. This gave a
solution with a final concentration of 130mM boric acid and 67.5mM NaOH. 5 g of
bovine serum albumin (BSA) were then added, and the final solution stored at -20°C
until use.
2.1.1.5 Polymerase chain reactions
lx Tris acetate EDTA (TAE) buffer: 100 ml of a lOx commercial solution was
diluted in 900 ml distilled water.
2.1.2 Drugs and radiolabeled steroids
Acetylcholine: 55 mg of acetylcholine (Fwt: 181.7) were dissolved in 30 ml distilled
water to give a 0.01M solution (10"2M). 500 pi aliquots were stored at -20°C until
use.
Corticosterone: 345 mg corticosterone (Fwt: 346.5) were dissolved in 1 ml ethanol
to give a stock solution of 995pM corticosterone.
[3H] Corticosterone: Commercial (GE Healthcare, U.K.) stock solutions of [3H]
corticosterone in ethanol with a concentration of 12.6nmol/ml were stored at -20°C
until use.
Cortisol: Cortisol (Hydrocortisone, Fwt: 362.5) was incorporated into silastic
pellets, as described below in section 2.4.2.2.
[ H] 11-Dehydrocorticosterone: [ H] 11 -Dehydrocorticosterone was synthesised
in-house (see section 2.10.1), re-suspended in ethanol to give concentrations of
approximately 10-15nmol/ml and stored at -20°C until use.
Dexamethasone: 5 mg of dexamethasone (Fwt: 392.5) were dissolved in 2 ml of
ethanol, to which 48 ml of 0.9% saline were added. This gave a solution with a final
concentration of O.lmg/ml. In a 30 g mouse, for example, the required dose of
lmg/kg would require 0.03 mg dexamethasone and therefore 0.3 ml of solution; an
appropriate volume for sub-cutaneous injection.
lip-HSDl inhibitor: 216 mg of compound 815 (Fwt: 271.4) were dissolved in
72 ml of 5% cyclodextrin (3.6 g in 72 ml distilled water). This gave a solution with a
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final concentration of 3mg/ml. In a 30 g mouse, for example, the required dose of
30mg/kg would require 0.9 mg of drug and therefore 0.3 ml of solution, an
appropriate volume for oral gavage.
IL-ip: 5 pg of IL-ip were dissolved in 5 ml PBS containing 0.1% BSA, to give a
final concentration of 1 pg/ml. 200 pi aliquots were stored at -20°C.
Noradrenaline: 96 mg of noradrenaline (Fwt: 319.3) were dissolved in 30 ml
distilled water to give a 0.01M solution (10"2M). 500 pi aliquots were stored at -20°C
until use.
Phenylephrine: 61 mg of phenylephrine (Fwt: 203.7) were dissolved in 30 ml
distilled water to give a 0.01M solution (10"2M). 500 pi aliquots were stored at -20°C
until use.
RU38486: RU38486 (Mifepristone, Fwt: 429.6) was incorporated into silastic
pellets, as described below in section 2.4.2.3.
Sodium nitroprusside: 79 mg of sodium nitroprusside (Fwt: 261.9) were dissolved
in 30 ml distilled water to give a 0.01M solution (10" M). 500 pi aliquots were stored
at -20°C until use.
2.2 Animals
Male C57B16 (Harlan Olac, U.K.) and 1 lp-HSDl"7" (bred in-house at the Biomedical
Research Facility, Little France, Edinburgh, U.K.) mice weighing 25-30 grams were
used in all experiments. Animals were maintained under controlled conditions of
light (lights on 0800h-2000h) and temperature (21-22°C), and allowed free access to
standard chow (Special Diet Services, U.K.) and drinking water. Animal experiments
were carried out under Home Office license. Mice were killed by either Schedule 1
or decapitation, according to Home Office guidelines.
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2.3 Models of neointimal proliferation
2.3.1 Intra-luminal wire injury of the femoral artery in vivo
A model of vascular injury and neointimal proliferation was developed in the mouse
femoral artery (chapter 3). The final, refined surgical procedure was carried out as
follows (see also Figures 2.1a and b).
Mice were weighed and then anaesthetised by isoflurane inhalation with suitable
analgesic cover (0.05mg/kg buprenorphine given as 0.03mg/ml Vetergesic by
sub-cutaneous injection). Femoral artery isolation was performed under a surgical
microscope using aseptic technique: all surgical instruments were sterilized by
autoclaving prior to experiments being carried out, and a bead sterilizer was used
between animals.
Femoral artery injury was carried out by adaptation of the method of Sata et al
(2000). After shaving the inner surface of the hind limb and making a small skin
incision at the top of the leg, the rectus femoris and vastus medialis muscles were
separated along the ligament by blunt dissection to expose the femoral bundle. The
femoral artery and vein were isolated from the nerve both proximally and distally to
the branch point of the popliteal artery (which is located between the rectus femoris
and vastus medialis muscles). Blood flow in the femoral artery and vein was
interrupted with temporary ligatures (6-0 silk suture) proximal and distal to this
branch point, and the popliteal artery was isolated and ligated distally with 6-0
suture. After removing connective tissue from the arteries around the branch point
the popliteal artery was dilated with lignocaine (1% lidocaine hydrochloride) and a
flexible angioplasty guidewire (straight sprung 0.014" diameter) was introduced via
an arteriotomy. After loosening the proximal temporary ligature, the guidewire was
advanced 5-10 mm into the common femoral artery towards the iliac artery, left in
place for 1 minute and then removed. The popliteal artery was then ligated with 6-0
suture proximally to the arteriotomy site, and blood flow restored in the common
femoral artery by removing the two temporary ligatures. This induced endothelial
denudation and stretching of the artery wall, followed by reperfusion of blood over
the injured area. The wound was closed using 6-0 sutures and the animal was
allowed to recover.
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Figure 2.1: Surgical model of wire-induced injury to the mouse femoral artery
Temporary ligatures were placed on the isolated femoral artery for vascular control during
the procedure, and the popliteal branch was ligated distally: a (i) and b (i). A flexible wire was
inserted into the popliteal branch via an arteriotomy, and advanced into the femoral artery
towards the iliac artery, causing stretching of the vessel wall: a (ii) and b (ii). After removal of
the wire, the popliteal branch was ligated proximally to the arteriotomy site: a (iii). In some
experiments, drug-releasing silastic pellets were then placed next to the injured artery: c.
Photographs reproduced with kind permission from Dr. M. Sata.
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2.3.2 Ligation-induced injury of the femoral artery in vivo
To induce neointimal proliferation in the femoral artery by side-branch ligation, mice
were anaesthetised and prepared for surgery as described above (section 2.3.1).
After exposing the popliteal artery by separating the rectus femoris and vastus
medialis muscles through blunt dissection, and separating the femoral artery and vein
from the nerve, the popliteal branch was then ligated with 6-0 silk suture
immediately adjacent to the branch point with the main femoral artery (see Figure
la(iii) for site of permanent ligature). The skin incision was closed with 6-0 silk
sutures, and the mice allowed to recover. Ligation-induced injury was used in some
experiments as an alternative model of neointimal proliferation, in the contra-lateral
leg ofmice undergoing intra-luminal wire injury.
2.3.3 In vitro model of neointimal proliferation
An attempt was made to set up a sterile tissue culture model of neointimal
proliferation, in order to allow the influence of local glucocorticoid and 11P-HSD
activity on lesion development to be investigated specifically within the vessel wall.
An adaptation of the method of Guerin et al (2004) was used.
Mice were subjected to intra-luminal wire injury of the femoral artery in vivo, as
described above (section 2.3.1). Immediately following injury, mice were killed by
cervical dislocation and the left (injured) and right (control) femoral arteries were
carefully excised, and placed in sterile tubes containing tissue culture medium (1:1
mixture of medium for smooth muscle cells and endothelial cells; Promocell, U.K.)
at room temperature. Vessels were then transferred to 6 well plates and cultured in
the same medium under sterile conditions at 37°C in a 5% CO2 atmosphere for 21
days. Tissue culture medium was changed every 2 days.
2.4 Administration of drugs
2.4.1 Systemic glucocorticoid administration
To assess the effect of an increase in systemic glucocorticoid on neointimal
proliferation, mice received lmg/kg/day dexamethasone or vehicle alone (4%
ethanol/ 0.9% saline) by sub-cutaneous injection. Dosing was started at least two
hours before wire injury and continued daily. Injections were given in the morning
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for 21 days. The dexamethasone and vehicle solutions were coded, so that drug
administration was carried out under blinded conditions.
2.4.2 Local administration of drugs
To investigate the influence of locally-released compounds on the response to injury,
silastic pellets (Silastic medical grade elastomer base and curing agent; Dow
Corning, U.S.A.) were implanted proximally to the operation site after wire-induced
injury (Figure 2.1c). Such implants release their impregnated contents at a constant
rate in vivo for at least three weeks (Soro et al. 1997) and have been used to
demonstrate the local inhibitory effect of glucocorticoids on angiogenesis in vivo, in
a sub-cutaneous polyurethane sponge implantation model (Small et al. 2005).
2.4.2.1 Vehicle
1 g of silastic elastomer was mixed with 100 mg of curing agent, and centrifuged at
13,000 rpm for 1 minute. This mixture was then taken up into a 1 ml syringe and
injected into fine bore polythene tubing (internal diameter 0.86 mm, outer diameter
1.27 mm; SIMS Portex Ltd., U.K.) using a 19 gauge needle. The elastomer was
allowed to cure for at least 24 hours at 25°C, and was then cut into pellets weighing
approximately 10 mg before being removed from the tubing.
2.4.2.2 Cortisol
275 mg of Cortisol were mixed with 1 g of silastic elastomer and centrifuged at
13,000 rpm for 1 minute. 100 mg of curing agent were added, mixed and centrifuged
again at 13,000 rpm for 1 minute. The rest of the protocol was then followed as for
vehicle pellets. A 10 mg pellet contained approximately 2 mg Cortisol.
2.4.2.3 RU38486
166 mg of the GR antagonist RU38486 were mixed with 300 mg of silastic elastomer
and centrifuged at 13,000 rpm for 1 minute. 33 mg of curing agent were added,
mixed and centrifuged again at 13,000 rpm for 1 minute. The rest of the protocol was
then followed as for vehicle pellets. A 10 mg pellet contained approximately 3.3 mg
RU38486.
2.4.3 11p-HSD1 inhibitor
To assess the effect of systemic inhibition of 11P-HSD1 on neointimal proliferation,
mice were dosed with 30mg/kg of a specific inhibitor (compound 815
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(Hermanowski-Vosatka et al. 2005)) or vehicle alone (5% cyclodextrin) twice daily
by oral gavage. Loading doses were given one day before surgery, and dosing was
then continued in the morning and afternoon for 14 days. The 1 lp-HSDl inhibitor
and vehicle solutions were coded, so that drug administration was carried out under
blinded conditions.
2.5 Preparation of vessels for histological analysis
At the end of experiments in which vessel structure was to be examined, left and
right femoral arteries were carefully cleaned of surrounding tissue and excised, from
the bifurcation of the iliac artery to the branch point of the popliteal artery. Arteries
were fixed in 10% neutral buffered formalin for up to 24 hours, and then stored in
70% ethanol. Arteries were dehydrated through a graded alcohol series and
embedded in paraffin using an automatic tissue processing machine (Shandon, U.K.)
and embedding station (Shandon, U.K.). Transverse sections (4 pm) were cut on a
microtome, and a set of eight serial sections were mounted from a water bath onto
separate slides (Superfrost plus; VWR International, U.K.) every 100 pm along the
entire length of the vessel.
2.6 Histology
2.6.1 Haematoxylin and eosin
Sections were dewaxed in xylene and rehydrated through absolute ethanol and two
changes of 74 O.P. to water. Sections were placed in filtered Harris' haematoxylin
for 5 minutes, or until desired staining was achieved, and then blued in running tap
water for 1 minute. After washing in alkaline tap water for 1 minute, staining of
nuclei was assessed microscopically. Sections were then rinsed in 70% ethanol
before being placed in alcoholic eosin Y for 30 seconds. After washing in tap water,
sections were dehydrated through two changes of 74 O.P. and absolute ethanol,
cleared in xylene and mounted with DPX.
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2.6.2 United States trichrome stain
Staining was carried out either manually or using an automated staining system
(Varistain Gemini; Thermo Shandon, U.K.). Sections were dewaxed in xylene and
rehydrated through absolute and 95% ethanol to water. Freshly prepared 0.3%
potassium permanganate in 0.3% aqueous sulphuric acid was then applied and, after
rinsing in water, sections were decolourised in 2% aqueous oxalic acid. Sections
were washed in tap water, rinsed in 70% alcohol and then immersed in filtered
Gomori aldehyde fuchsin, which stains elastic fibres deep purple. After
differentiating in 70% alcohol and washing well in water, the staining of elastin was
checked microscopically (if slides were being stained by hand), before filtered
Weigert's iron haematoxylin was applied for 5 minutes to stain cell nuclei. The slides
were then left to blue in running tap water, before 5% aqueous phosphotungstic acid
was applied, which prepares the tissue for the trichrome stain. After rinsing in water,
sections were immersed in filtered Gomori trichrome stain for 20 minutes (which
stains platelets light purple, collagen fibres green and muscle red). Finally, the slides
were rinsed in 0.2% aqueous acetic acid and then dehydrated and cleared in xylene,
before coverslipping with DPX mountant.
2.7 Morphometric analysis
In order to measure the extent of neointimal proliferation in injured arteries, images
of stained sections were digitised using a Photometries CoolSnap camera (Tucson,
U.S.A.) coupled to a light microscope (Zeiss Axioskop) via a microcolour liquid
crystal turnable RGB filter (Cambridge Research and Instrumentation Inc., Woburn,
U.S.A.). Microcomputer Imaging Device software (MCID; Imaging Research Inc.,
St. Catharines, Canada) was used to integrate the microscope and camera, and to
carry out image analysis of the digitised images. Analysis was performed on sections
every 100 pm along each artery, and the parameters measured were mean area (pm )
inside the external elastic lamina (EEL), internal elastic lamina (IEL) and lumen.
These measurements could then be used to calculate the area of the media (area
inside EEL - area inside IEL) and the area of any neointima present (area inside IEL
- area inside lumen). The section with the largest area of neointima was chosen to
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represent each artery when calculating the mean neointimal area in a group.
Additional measurements included perimeter (pm) and average diameter (pm) of the
EEL, IEL and lumen. All analysis was carried out under blinded conditions; each
artery sample was coded to conceal the treatment that it had been subjected to.
2.8 Immunohistochemistry
Representative sections were stained immunohistochemically to allow the
identification of the following cell types or proteins.
2.8.1 Smooth muscle cells
Slides were deparaffmised and rehydrated, then mounted in Sequenza cassettes
(Thermo Shandon, U.K.) using lx TBS/Tween. A 1:200 dilution of alkaline
phosphatase-conjugated monoclonal primary antibody against smooth muscle cell
a-actin was made up in lx TBS/Tween, and 200 pL was applied to sections which
were then incubated overnight at 4°C. Sections of mouse aorta incubated with or
without primary antibody served as positive or negative controls, respectively
(Figure 2.2). To visualise sites of antibody binding, an alkaline phosphatase substrate
kit with a red chromagen (VECTOR red) was diluted in lOOmM Tris-HCl pH 8.2;
levamisole was also added to block endogenous alkaline phosphatase activity.
Sections were washed thoroughly in lx TBS/Tween and then tap water. After
counterstaining in haematoxylin and blueing in tap water, sections were then
dehydrated, cleared and mounted in DPX.
2.8.2 Endothelial cells
Sections were deparaffmised and rehydrated, then mounted in Sequenza cassettes
using distilled water. Epitope retrieval was carried out by incubating slides with 4-5
drops of ready-to-use proteinase K solution for 15 minutes at room temperature.
After washing in PBS, sections were blocked with diluted goat serum for 30 minutes
at room temperature and avidin biotin blocking was then carried out using a kit.
Sections were incubated for 1 hour at room temperature with rabbit anti-human
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Figure 2.2: Immunohistochemistry controls
Representative positive (+ve) and negative (-ve) controls, carried out in parallel with
immunohistochemistry experiments. Sections of mouse aorta (smooth muscle cell a-actin,
von Willebrand factor (vWF)) or spleen (Mac-2) incubated with primary antibody acted as
positive controls. Aorta with no primary antibody (smooth muscle cell a-actin) or normal
rabbit IgG (vWF), and spleen with normal rat IgG (Mac-2) served as negative controls.
Scale bar = 100 pm.
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Sections of mouse aorta incubated with primary antibody served as a positive
control, while sections either without primary antibody or incubated with normal
rabbit IgG fraction (diluted to the same concentration as primary antibody) acted as
negative controls (Figure 2.2).
After rinsing with PBS, endogenous peroxidise activity was inhibited by adding 3%
H2O2 to the slides for 10 minutes. Sections were rinsed in PBS and then a goat
anti-rabbit biotinylated secondary antibody was applied for 30 minutes. After
washing and incubating with ABC solution for a further 30 minutes, sites of
immunoreactivity were detected using the horseradish peroxidase substrate
diaminobenzidine (DAB). Sections were washed in tap water, counterstained and
blued, and then dehydrated, cleared and mounted in DPX.
2.8.3 Macrophages
Sections were deparaffinised and rehydrated, incubated with 3% H2O2 for 10 minutes
and then washed in running tap water for 10 minutes. Slides were mounted in
Sequenza cassettes using PBS and then incubated with diluted rabbit serum for 30
minutes. After washing with PBS, sections were incubated overnight at 4°C with rat
anti-mouse primary antibody against Mac-2, diluted to 1:6000 in rabbit serum.
Sections of mouse spleen incubated with primary antibody served as a positive
control, while sections either without primary antibody or incubated with normal rat
IgG fraction (diluted to the same concentration as primary antibody) acted as
negative controls (Figure 2.2). Slides were then washed with PBS and incubated for
1 hour with rabbit anti-rat biotinylated secondary antibody. After washing and
incubating with ABC solution for a further 30 minutes, sites of immunoreactivity
were detected using DAB. Sections were washed in tap water, counterstained and
blued, and then dehydrated, cleared and mounted in DPX.
2.8.4 Proliferating cells
Sections were deparaffinised and rehydrated, incubated with 3% H2O2 for 15 minutes
and then washed in PBS for 5 minutes. Slides were mounted in Sequenza cassettes
using PBS and then incubated with diluted goat serum containing avidin for 30
minutes. After washing with PBS, sections were incubated overnight at 4°C with
rabbit anti-human primary antibody against proliferating cell nuclear antigen, diluted
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to 1:50 in PBS containing biotin. Sections of mouse testis incubated with primary
antibody served as a positive control, while sections either without primary antibody
or incubated with normal rabbit IgG fraction (diluted to the same concentration as
primary antibody) acted as negative controls. Slides were then washed with PBS and
incubated for 1 hour with goat anti-rabbit biotinylated secondary antibody. After
washing and incubating with ABC solution for a further 30 minutes, sites of antibody
binding were detected using DAB. Sections were washed in tap water, counterstained
and blued, and then dehydrated, cleared and mounted in DPX.
2.8.5 Fibrinogen
Sections were deparaffinised and rehydrated, then mounted in Sequenza cassettes
using distilled water. Epitope retrieval was carried out by incubating slides with 4-5
drops of ready-to-use proteinase K solution for 5 minutes at 37°C. After cooling to
room temperature and washing in PBS, sections were blocked with diluted goat
serum for 30 minutes at room temperature. Sections were incubated overnight at 4°C
with rabbit anti-human primary antibody against fibrinogen, diluted to 1:200 in goat
serum. Sections of femoral artery containing thrombus incubated with primary
antibody served as a positive control, while sections either without primary antibody
or incubated with normal rabbit IgG fraction (diluted to the same concentration as
primary antibody) acted as negative controls.
After rinsing with PBS, endogenous peroxidise activity was inhibited by adding 3%
H2O2 to the slides for 10 minutes. Sections were rinsed in PBS and then a goat
anti-rabbit biotinylated secondary antibody was applied for 30 minutes. After
washing and incubating with ABC solution for a further 30 minutes, sites of
immunoreactivity were detected using DAB. Sections were washed in tap water,
counterstained and blued, and then dehydrated, cleared and mounted in DPX.
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2.9 Small vessel wire myography
To determine the functional characteristics of the mouse femoral artery, arterial rings
were mounted on 40 pm, parallel, intra-luminal wires in a small vessel wire
myograph for measurement of isometric force. Myograph chambers contained PSS at
37°C, perfused with 95% O2/ 5% CO2. In some vessels the endothelium was removed
by rubbing the luminal surface with a human hair.
After the length of each arterial ring was measured, normalization was carried out by
stepwise incremental stretches of the vessel and application of the LaPlace relation
(P = T/r, where P is the trans-luminal pressure, T is the wall tension and r is the
internal radius of the vessel) to determine the internal diameter under an
intra-luminal pressure of 13.3kPa (L100). Arteries were then stretched to their
optimum resting level (0.9L100) (Falloon et al. 1995). Before each set of
experiments, arteries were contracted twice with NA-K (a mixture of 10"5M
noradrenaline in KPSS), once with 10"5M noradrenaline alone, once with KPSS alone
and finally once again with NA-K. Cumulative concentration-response curves were
then obtained for phenylephrine (1x10"9M to 3xlO"4M) and KPSS (lOmM K+ to
125mM K+). Vasodilator concentration-response curves were obtained for
acetylcholine (1x10"9M to 3xlO"4M) and the NO donor sodium nitroprusside
(1x10"9M to 3xlO"5M) in vessels pre-contracted with sufficient phenylephrine to
achieve around 80% of the maximum contraction.
Contractions to phenylephrine are expressed as a percentage of the maximum
response to KPSS in that vessel (to control for vessel size), and contractions to KPSS
are expressed as force per unit length of vessel (mN/mm). Relaxation is expressed as
a percentage of the pre-contraction obtained with phenylephrine in that vessel. To
assess sensitivity to agonists, the negative logarithm of the concentration required to
produce 50% of maximum responses was calculated (pD2 for contraction, -log IC50
for relaxation). The maximum response (Emax) and PD2/ -log EC50 for each agonist
was compared between groups.
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2.10 Measurement of 11p-HSD1 activity
In vivo 11 P-HSD 1 acts predominantly as a reductase, catalysing the conversion of
inactive 11-dehydrocorticosterone to active corticosterone (Jamieson et al. 2000).
However, in homogenised cell preparations it is capable of bi-directional activity,
and the dehydrogenase direction predominates (Lakshmi & Monder, 1988).
Traditionally, in vitro activity assays have measured 11 P-HSD 1 activity in the
dehydrogenase direction using homogenised tissue preparations, as described for
liver (section 2.10.4). Using this technique it is possible to determine between the
activities of the two isozymes of 11P-HSD, by exploiting their cofactor preference
for either NADP or NAD. This has been achieved in the rat (Walker et al. 1992a),
but the mouse 11 P-HSD isozymes do not show such selective cofactor specificity
(Hadoke et al. 2001). Therefore, in the intact vessel assay described (section 2.10.2),
activity was measured in the reductase direction.
2.10.1 Synthesis of [3H] 11-dehydrocorticosterone
Two rat placentas were homogenised in 1 ml homogenising buffer, and stored at
-80°C until use. 120 pi of [3H] corticosterone were dried under nitrogen at 60°C and
• • • • T
reconstituted in 50 pi of ethanol. A reaction mixture containing this 50 pi of [ H]
corticosterone, 200 pi of 25mM NAD cofactor, 300 pi placental homogenate and
4.45 ml of C buffer was prepared in a glass vial, vortexed, and incubated at 37°C for
4 hours. Steroids were extracted by three serial additions of 4 ml ethyl acetate to the
reaction mixture, split into eight volumes. After each addition the sample was
vortexed and centrifuged at 1700 rpm for 10 minutes at 4°C. The upper organic layer
was transferred to a fresh glass tube; all eight volumes were dried nitrogen into one
sample, reconstituted in 100 pi of ethanol and then stored at -20°C until use. 1 pi
aliquots of [ H] corticosterone and the [ H] 11-dehydrocorticosterone product were
analysed by high performance liquid chromatography (HPLC) to assess purity and
concentration of the [3H] 11-dehydrocorticosterone. Concentration was calculated by
using the following equation, where [3H] 11-dehydrocorticosterone is A and [3H]
corticosterone is B:
Concentration of [3H] A = (Area of [3H] A peak / Area of [3H] B peak) x
concentration of [3H] B nmol/ml.
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2.10.2 Intact vessels in vitro
11 P-reductase activity was measured in control and injured femoral arteries, and
aortic rings, using an adaptation of the method of Souness et al (2002). Vessels were
incubated at 37°C in 1 ml culture medium (DMEM + 1% antibiotic/ antimycotic mix;
• • • "3 •
Invitrogen, U.K.) containing lOpmol [ H] 11-dehydrocorticosterone. Sections of
mouse liver served as a positive control. As a negative control, [ H]
11-dehydrocorticosterone was incubated in a well without tissue, and medium alone
in a well was included in the experiment as a blank. The entire length of each
femoral artery was incubated in an individual well, while aortic ring incubations
were performed in duplicate for each animal.
Following incubation, the culture medium was removed at several time-points and
stored at -20°C before extraction of steroids (section 2.10.3) and analysis by HPLC
(section 2.10.5). It has been shown previously that aortic rings only retain 2-3% of
the added radioactivity in these experiments (Souness et al. 2002), so only the
supernatant, and not the vessels themselves, was included in the extraction.
At the end of the experiment the tissue samples were blotted on tissue paper to
remove excess medium, and then weighed. Enzyme activity was calculated as the
o
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amount of product ([ H] corticosterone) formed in pmol per mg of tissue over time,
after subtraction of conversion in negative control samples.
2.10.3 Extraction of steroids from culture medium
To extract a purified preparation of steroids from the culture medium collected
during intact vessel activity assays, samples were run through Cis Sep Pak columns
(Waters Millipore, U.K.) under gravity (Small et al. 2005). Firstly the columns were
prepared by using 5 ml ofHPLC grade methanol to separate the Ci8 chains, and 5 ml
HPLC grade water as a wash. The samples were then run onto the column and
washed on with 5 ml HPLC grade water. Samples were eluted from the columns and
collected into glass tubes with 2 ml HPLC grade methanol. This sample was then
dried under nitrogen at 60°C and dissolved in 800 pi HPLC mobile phase.
2.10.4 Liver homogenates
Liver microsomes were prepared by homogenising approximately 300 mg liver in
1 ml sucrose buffer. To remove membrane debris the homogenate was centrifuged at
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1000 rpm for 10 minutes at 4°C. The supernatant was removed into a fresh tube and
centrifuged at 30,000 rpm for 30 minutes at 4°C to remove nuclear debris. This
supernatant was removed into a fresh tube and centrifuged at 55,000 rpm for 60
minutes at 4°C. The resultant microsomal pellet was resuspended in 400 pi of
sucrose buffer. The protein concentration of each sample was determined via the
Bradford method, using a colorimetric protein assay kit (Bio-Rad, U.K.) and a
standard curve constructed from dilutions ofBSA (Bio-Rad, U.K.).
11 ^-Dehydrogenase activity was measured in liver microsomes using an adaptation
of the method of Livingstone et al (Livingstone et al. 2000). Reactions were prepared
in duplicate with a final volume of 250 pi. This contained 180 pi of liver microsomes
(dissolved in Krebs' buffer to a final protein concentration of 20pg/ml), 50 pi of
cofactor mix (dissolved in Krebs' buffer to give a final concentration of 2mM NADP
and 0.2% glucose) and 20 pi of substrate mix (dissolved in 25% ethanol: 75% Krebs'
buffer, to give a final concentration of 2pM corticosterone [lOnM [3H] corticosterone
and 1.99pM corticosterone]). Reactions containing no cofactor served as negative
controls, and tissue blanks were prepared containing only Krebs' buffer, substrate
and cofactor. Reactions were incubated for 2 hours at 37°C, and the reaction was
then stopped by the addition of 10 volumes of ethyl acetate. In this way,
measurements of enzyme activity were carried out in the linear range of product
formation with time (approximately 30% conversion of substrate to product). The
tubes were vortexed and the upper organic phase containing steroids was removed to
a fresh tube and dried down under nitrogen at 60°C. Steroids were then dissolved in
mobile phase and analysed by HPLC as described (section 2.10.5).
Enzyme activity was expressed as reaction velocity: amount of product ([3H]
11-dehydrocorticosterone) formed in pmol per pg protein per minute.
2.10.5 High performance liquid chromatography
The HPLC system consisted of an auto-sampler and mobile phase pump (Waters,
U.K.), a symmetry Cs column (length 15 cm, internal diameter 4.6 mm, pore size
5 pm; Waters, U.K.) and a radioactivity monitor linked to a scintillation fluid pump
(Berthold, U.K.). The system was controlled by the computer programme
Chromeloen v6.7 (Dionex, U.K.). Steroid samples extracted from experiments using
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liver homogenates and intact vessels were re-suspended in 800 pi mobile phase and
50-200 pi of each sample were injected into the HPLC system to give optimal peak
shape and height (Figure 2.3, 2.4). The flow rate of the mobile phase was 1.5ml/min
and the flow rate of the scintillant (Gold Flow, Meridian, U.K.) was 3ml/min to
achieve optimal mixing in the column and counting efficiency. The column
temperature was 40°C to improve peak shape and maintain stability of retention
times. Radioactive standards for corticosterone and 11-dehydrocorticosterone were
injected at the start of each run to confirm peak identity. The approximate retention
time for [ H] 11-dehydrocorticosterone was 10-12 minutes and for [ H]
corticosterone was 15-18 minutes. Peaks were approximately 2 min 30 seconds wide
and peak height was at least 50-fold higher than background. Representative
chromatograms obtained from a typical 11 P-reductase assay (Figure 2.3), and a
typical 11 P-dehydrogenase assay (Figure 2.4), are shown. Following
chromatography, the area under each peak was integrated using the Chromeleon
software and used to quantify the percentage conversion of [ H]
11-dehydrocorticosterone to [ H] corticosterone (11 P-reductase activity) or [ H]
corticosterone to [ H] 11-dehydrocorticosterone (11 P-dehydrogenase activity). Since
the starting concentration of substrate for each reaction was known, the total amount
of product formed in each sample could then be calculated.
2.11 Analysis of plasma steroid levels
2.11.1 Cortisol
Plasma samples from mice implanted with a unilateral cortisol-releasing silastic
pellet and contra-lateral vehicle control were analysed for Cortisol using a
radioimmunoassay kit (ICN Biomedicals Inc, U.S.A.). Cortisol standards of known
concentration (0, 1, 3, 10, 30 and lOOpg/dl) and plasma samples were added in
• ••• • 19S
duplicate to tubes coated with a rabbit anti-cortisol antibody. Following this, [ I]
Cortisol was added to each tube and the mixture was then vortexed and incubated at
37°C for 45 minutes.
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Figure 2.3: Chromatograms from 1ip-reductase activity assay in intact
vessels
Two representative high performance liquid chromatography (HPLC) chromatograms,
showing peaks for [3H] 11-dehydrocorticosterone ([3H] A; retention time 10-12 minutes) and
[3H] corticosterone ([3H] B; retention time 15-18 minutes). The chromatograms show a
negative control experiment (top), where 10pmol [3H] A was incubated for 24 hours with
culture medium alone, and an 11|3-reductase activity assay (bottom), where [3H] A was
incubated under the same conditions with an intact femoral artery. In the negative control
there is no conversion of [3H] A to its 11 |3-reduced metabolite [3H] B. However when vascular





Figure 2.4: Chromatograms from 11(3-dehydrogenase activity assay in liver
microsomes
Two representative high performance liquid chromatography (HPLC) chromatograms,
showing peaks for [3H] 11-dehydrocorticosterone ([3H] A; retention time 10-12 minutes) and
[3H] corticosterone ([3H] B; retention time 15-18 minutes). The chromatograms show a
negative control experiment (top), where 10nM [3H] B was incubated for 2 hours with buffer
and cofactor only, and an 1 ^-dehydrogenase activity assay (bottom), where [3H] B was
incubated with buffer, cofactor and liver microsomes. In the negative control there is no
conversion of [3H] B to its metabolite [3H] A. However when liver microsomes are present
metabolism to [3H] A occurs, indicating the presence of 11|3-dehydrogenase activity.
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The contents of each tube were discarded and the radioactivity remaining was
19S
counted in a gamma counter, to determine the amount of antibody-bound [ I]
Cortisol. Since the radioactive and non-radioactive forms of antigen compete for
antibody binding sites, the more non-radioactive Cortisol in the sample, the less
radioactive Cortisol will remain bound. To calculate the percentage bound [ I]
Cortisol in each standard and sample, the average counts per minute (cpm) was
divided by the average cpm for the zero standard and multiplied by 100. A standard
I'lC
# #
curve of percentage bound [ I] Cortisol against Cortisol concentration was
constructed with results obtained from the standards, and the levels of Cortisol in
each sample could then be determined from this. At 50% displacement on the
Cortisol standard curve, cross reactivity for corticosterone was 3% and cross
reactivity for cortisone was 1.4%.
2.11.2 Corticosterone
Plasma samples from mice implanted with a unilateral RU38486-releasing silastic
pellet and contra-lateral vehicle control, and mice implanted with bilateral vehicle
pellets, were analysed for corticosterone by radioimmunoassay. Plasma samples were
diluted 1:10 in borate buffer, and denatured at 80°C for 30 minutes to release
corticosterone from CBG. In this way, the assay measured total plasma
corticosterone. 20 pi of diluted and denatured sample were then added in duplicate to
a 96 well plate. Corticosterone standards of known concentration (0, 0.3, 0.6, 1.25,
2.5, 5, 10, 20, 40, 80, 160 and 320nM) were also added in duplicate to the plate. A
rabbit anti-corticosterone primary antibody (diluted 1:100 in borate buffer; kindly
provided by C. Kenyon), [ H] corticosterone (3 pi in 6 ml borate buffer and adjusted
to 10,000 cpm) and an anti-rabbit secondary antibody linked to scintillation
proximity assay (SPA) beads (diluted according to manufacturers instructions; GE
Healthcare, U.K.) were then added to each well. The plate was sealed and inverted to
mix the contents of each reaction, then incubated at room temperature for 16 hours in
the dark. Since the SPA beads ensured that only [ H] corticosterone bound to
primary antibody would be detected, there was no need to separate bound from
unbound antigen. The radioactivity in each well was counted in a beta counter and, to
calculate the percentage bound [ H] corticosterone in each standard and sample, the
average cpm was divided by the average cpm for the zero standard and multiplied by
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100. A standard curve of percentage bound [ H] corticosterone against corticosterone
concentration was constructed with results obtained from the standards, and the
levels of corticosterone in each sample could then be determined from this. Finally,
the result was multiplied by 10 to account for the initial dilution of each plasma
sample.
2.12 Genotyping by polymerase chain reactions
To confirm the genotype of 1 lP-HSDl7" mice bred to use in these studies,
polymerase chain reactions (PCR) were carried out. Using primers and the enzyme
Taq polymerase, specific sequences in the genomic DNA from transgenic and
C57B16 mice were amplified in a number of cycles, during which the DNA template
is repeatedly denatured, annealed with the sequence-specific primers and replicated
by Taq polymerase. Primers Exl-3F1 and Exl-3R1 allowed detection of the wild
type 11(3-HSD1 allele, while Exl-3F1 and Yuri2oligo4 allowed detection of the
disrupted transgenic lip-HSDl allele with integrated targeting vector (Table 2.1;
(Kotelevtsev et al. 1997)). Following 36 cycles the amplified DNA was then
separated by size using gel electrophoresis; the wild type lip-HSDl allele product
was approximately 1.7Kbp and the targeted lip-HSDl allele product was
approximately 1.4Kbp. This difference in size between transgenic and C57B16 mice
allowed identification of 1 lP-HSDl"7" mice.
Total DNA was extracted from tail tips removed from lip-HSDl7" and C57B16
animals using a DNeasy Tissue kit (Qiagen, U.K.). PCR reactions containing 1 pi
undiluted DNA, lx Green GoTaq reaction buffer, 6mM MgCl2, lOmM each of
dATP, dCTP, dGTP and dTTP, lpmol/pl each of Ex If, Exlr and Yuri2oligo4
primers and O.lU/pl GoTaq DNA polymerase were made up to a total volume of
20 pi with nuclease-free water.
Reactions were carried out on an Eppendorf Mastercycler Gradient (Eppendorf,
Germany) with a heated lid. Samples were heated to 95°C for 5 minutes for initial
denaturation, and then underwent 36 cycles of PCR amplification (denaturation at
95°C for 1 minute, primer annealing at 61°C for 1 minute, and elongation by Taq at
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Primer Sequence
Ex1-3F1 TTC TTC GTG TGT CCT ACA GG
Ex1-3R1 CCC GCC TTG ACA ATA AAT TG
Yuri2oligo4 CAC TGC ATT CTA GTT GTG GTT TGT CC
Table 2.1: Primer sequences for 11(3-HSD1 genotyping by polymerase chain
reaction
Using the primers above and the enzyme Taq polymerase, specific sequences in the
genomic DNAfrom 11P-HSD1"'" and C57BI6 mice were amplified and then separated by size
using gel electrophoresis. Primers Ex1-3F1 and Ex1-3R1 allowed amplification of the wild
type 11P-HSD1 allele, while Ex1-3F1 and Yuri2oligo4 allowed amplification of the targeted
11P-HSD1 allele in transgenic mice. This allowed identification of 11P-HSD1"'" or wild type
genotype in the mice used in these studies.
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72°C for 2 minutes 10 seconds). Reactions were then maintained at 72°C for a further
10 minutes to ensure elongation of products to full length and cooled to 4°C before
gel electrophoresis.
To prepare a 1% gel, 2 g of agarose were melted in 200 ml lx TAE buffer. After the
addition of 2 pi of ethidium bromide, the gel was allowed to set in a mould at room
temperature. The gel was then placed in a tank containing lx TAE, and 10 pi of
lKbp DNA ladder was loaded into the first well to allow determination of product
size. The total volume of each PCR reaction was loaded into individual wells and the
gel electrophoresed at 140 volts for approximately 1 hour, or until the loading buffer
band was % of the way down the gel. The gel was photographed under UV light at
X260nm to allow visualization of PCR product bands.
2.13 Statistics
All data are expressed as mean ± standard error of the mean (S.E.M). Values quoted
for n refer to the number of different mice used in each experiment. Data were
analysed by unpaired t test or Analysis of Variance (ANOVA) followed by post hoc
tests, as appropriate. p<0.05 was considered significant.
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Chapter 3
Femoral artery injury as a model to study neointimal
proliferation in the mouse
3.1 Introduction
The major aim of the work described in this thesis was to assess the impact of both
exogenous and endogenous glucocorticoids on neointimal lesion development after
vascular injury. In order to allow use of the murine model of genetic 11 (3-HSD1
inactivation, it was necessary to introduce and clearly describe an appropriate model
of neointimal lesion formation in the mouse.
Several well-described models of neointimal proliferation have been developed in
the mouse (see chapter 1.1.4.3), including: wire-induced intra-luminal injury
(Lindner et al. 1993), carotid artery ligation (Kumar & Lindner 1997), electrical
injury (Carmeliet et al. 1997c) and perivascular cuff placement (Moroi et al. 1998).
A model of intra-luminal injury was considered most appropriate for investigating
the influence of exogenous and endogenous glucocorticoids on neointimal lesion
formation. The model of neointimal proliferation developed was adapted from the
method published by Sata et al (2000). This involves inserting a flexible angioplasty
guidewire into the femoral artery via a small muscular side-branch. The wire
stretches and denudes the artery and the injury caused results in rapid medial cell
apoptosis, followed by the growth of a neointimal lesion composed of smooth muscle
cells. It is not known how this vascular injury and subsequent neointimal
proliferation affects contractile and relaxant function of the artery. Furthermore,
since inflammation is critical to neointimal lesion formation (Wainwright et al.
2001), and lip-HSDl activity can be up-regulated by inflammatory stimuli in
VSMCs (Cai et al. 2001), it is possible that intra-vascular injury may influence
11P-HSD1 activity in the vessel wall.
It is also possible to study the growth of neointimal lesions in isolated vessels in vitro
(Pederson & Bowyer 1985; Soyombo et al. 1990; Voisard et al. 1999; Guerin et al.
2004). This allows investigation of the role that cells within the vascular wall, such
as the endothelium and VSMCs, play in the development of vascular lesions. The
introduction of such a model would allow the impact of glucocorticoids, and their
generation by lip-HSDl, on the vascular response to injury to be assessed in
isolation from systemic effects.
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Therefore, the specific aims of this chapter were:
(i) To introduce and develop a model of wire injury to the femoral artery based on
the technique of Sata et al (2000).
(ii) To determine the time-dependent changes in arterial structure, function and
11P-HSD1 activity following intra-luminal injury.
(iii) To generate a model ofneointimal proliferation in vitro.
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3.2 Method development
3.2.1 Wire-induced injury of the mouse femoral artery
3.2.1.1 Animals
Male C57B16 mice (Harlan Olac, U.K.) were used in all studies in this chapter.
Initially, animals were grouped by age and used between 10 and 16 weeks. However,
it was found that some mice in this age-range were too small and insertion of the
wire into the femoral artery was very difficult. Subsequently mice weighing 25-35
grams were used.
3.2.1.2 Surgical procedure
To induce acute intra-luminal vascular injury and produce neointimal proliferation in
the mouse femoral artery, a surgical procedure was set up according to the method of
Sata et al (2000), and then refined (for final method see chapter 2.3). The process
was aided by a video of the operation provided by this group. For all studies in this
chapter unilateral wire injury was carried out in the left femoral artery, with the right
femoral artery acting as an uninjured contra-lateral control. Sham operation was
performed in a group of mice (n= 3), by carrying out every part of the injury
procedure except insertion of the flexible guidewire.
Methodological modifications. Initially, general anaesthesia was induced by
inhalation of either halothane or isoflurane. Isoflurane was chosen for the refined
method, as it induced a more rapid and stable anaesthesia, and reduced mortality
during the operation. Surgery was performed on cork matting to reduce heat loss, and
mice were allowed to recover in a heated chamber.
When placing the proximal temporary ligature used for vascular control, it was found
that the most effective position was above the superficial caudal epigastric artery,
which descends from the common femoral artery proximally to the popliteal artery.
This not only halted blood flow in the main femoral artery but also helped to retract a
large fat pad near the inguinal ligament, improving access to the femoral artery. In
contrast to the method of Sata et al (2000), it was found that separation of the
femoral artery from the vein was not necessary and this was discontinued in later
studies to reduce damage to the vessel wall (particularly the adventitia).
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3.2.1.3 Effect of vascular injury surgery on mice
Surgery was generally well tolerated, although mice occasionally died under
anaesthesia (5/ 67 during model development). This problem was virtually abolished
by switching from halothane to isoflurane anaesthesia. Mice quickly regained
consciousness (recovery time < 20 min) with few side-effects (some limping was
evident for a few days after surgery). Only two out of 67 mice died spontaneously
after recovery, with no obvious cause of death. A tendency to chew sutures did not
prevent the skin from healing well in most animals.
3.2.1.4 Collection of arteries for histological analysis
To assess the time-course of neointimal proliferation and the composition of
neointimal lesions after wire injury of the femoral artery, mice were killed by
cervical dislocation either immediately or 2, 7, 14, 21 or 28 days after surgery
(n= 5-6 per time-point). Sham operated animals were killed after 28 days (n= 3). Left
and right femoral arteries were carefully excised and fixed in 10% neutral buffered
formalin for up to 24 hours. After this time arteries were stored in 70% ethanol. The
arteries were then dehydrated in a graded alcohol series, embedded in paraffin and
cut into transverse sections: sets of eight 4 pm serial sections were taken at 100 pm
intervals along the entire arterial segment.
3.2.1.5 Histological staining
Histological staining (haematoxylin and eosin or United States trichrome) confirmed
the development of neointimal lesions following wire injury of the femoral artery
(Figure 3.1). Initially, serial cross sections were stained with haematoxylin and eosin
using an established protocol (chapter 2.6.1). In order to improve distinction of the
IEL and EEL for quantitative analysis of neointimal lesion size, a trichrome staining
method was then introduced. The United States trichrome stain (chapter 2.6.2)
differentiates elastin, collagen and muscle in tissue samples (Hadoke et al. 1995).
Identification and quantification of the neointima, media and adventitia was more
straightforward in sections stained with the United States trichrome stain than in
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UST H & E
Figure 3.1: Comparison of histological staining methods
Representative serial sections of control (uninjured) femoral artery, and arteries immediately
(Od) and 28 days after injury, stained with either United States trichrome (UST; a,c,e) or
haematoxylin and eosin (H & E; b,d,f). Distinction of the internal elastic lamina (IEL) and
external elastic lamina (EEL), and so identification of the layers of the artery wall, is easier in
sections stained with UST than in those stained with H & E. Immediately after injury (c,d) the
artery wall shows signs of stretch- the I EL is less convoluted and the medial layer is thinner.
28 days after injury (e,f) neointimal proliferation has occurred and a large neointimal lesion
occludes the lumen. Red blood cells can also be seen in the lumen of the vessels.
A: adventitia, M: media, Nl: neointima. Arrow heads indicate IEL. Scale bar = 100 pm.
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those stained with haematoxylin and eosin, as it provided clear staining of the IEL
and EEL (Figure 3.1). Once this method was established it was used to analyse serial
sections in all samples, either manually or using an automated staining system
(Varistain Gemini Thermo Shandon, U.K.).
3.2.1.6 Effects of wire injury on morphology of the femoral artery wall
To measure changes in artery morphology after injury, images of sections stained
with the United States trichrome stain were digitised using a light microscope
coupled to a colour camera (chapter 2.7). To quantify neointimal lesion size, image
'j
analysis software was used to make measurements of mean area (pm ) inside the
EEL, IEL and lumen, in sections every 100 pm along each artery. Due to variation in
the distance of wire advancement into the femoral artery during surgery (5-10 mm),
the length of neointimal lesions induced by injury was variable between animals
(data not shown). Therefore, the total lesion area was not quantified; instead the
section with the largest area of neointima was chosen to represent each arterial
sample. Additional measurements made included perimeter (pm) and average
diameter (pm) of the EEL, IEL and lumen.
Femoral arteries isolated immediately after injury (Od) showed evidence of severe
stretch, with the perimeters of the EEL and IEL increased compared with uninjured
controls (Table 3.1). The IEL was no longer as convoluted as in an uninjured artery
and the lumen was larger, although this did not become significant until 7 days after
injury (Figures 3.2, 3.3 and Table 3.1). While the EEL of the vessel wall remained
intact after injury, some damage to the IEL was observed. Small breakages were seen
in all arteries at Od. Furthermore, removal of the IEL was seen in 3/ 5 arteries at Od,
always in areas near to the site ofwire insertion (Figure 3.4).
Two days after injury, the artery wall remained stretched (Table 3.1). There was
evidence of damage to the IEL in 3/ 5 arteries at this time-point. Insertion of the wire
also caused medial thinning, which was evident 2d and 7d after injury (Figures 3.2,
3.3) but this did not reach significance (Table 3.1).
Neointimal lesions formed as a result of injury in a time-dependent manner, first
becoming evident at 7d, and continuing to increase in size until 2Id, when growth
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EEL circumference (Mm) IEL circumference (Mm) Luminal area (Mm2) Neointimal area (Mm2) Medial area (Mm2)
Control 952 ± 61 866 ± 71 26176 ±4855 0±0 34123 ±2254
Od 1461 ± 101* 1405 ±92* 66611 ±26620 0±0 35262 ± 2854
2d 1488 ± 195* 1410 ±198 * 49635±19753 0±0 21384 ±3106
7d 1649 ±50 ** 1583 ±39*** 83243±11314* 45901±11621 28488 ±4138
14d 1792 ±69 *** 1663 ±75 *** 50348±10733 111605 ± 19733** 54032 ± 7693
21 d 1854 ±175 *** 1762 ± 141 *** 26475 ± 6747 * 167654 ±40486*** 59226 ± 783 *
28d 1679 ±56*** 1612 ±31 *** 16641 ±5482* 143203 ± 10332*** 42548 ±2136
Table 3.1: Morphometric analysis of wire-injured femoral arteries
Femoral arteries, collected at various time-points after injury, were analysed using digitised
cross sections and image analysis software. Injured arteries were compared with uninjured
contra-lateral controls at Od. The measurements made indicated that wire injury caused an
increase in external elastic lamina (EEL) and internal elastic lamina (IEL) circumference
which was maintained up to 28d, and that luminal area became larger at early time-points.
Data are mean ± S.E.M, n= 6 for control, 7, 14, 21 and 28 days, n= 5 for 0 and 2 days. Each
parameter analysed by one way ANOVA with Tukey's post hoc test: * p< 0.05, ** p< 0.01,
*** p<0.001 vs. control, +p<0.05 vs. 7d.
N.B. Luminal, neointimal and medial area at each time-point are also shown in Figure 3.3.
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Control
Figure 3.2: Neointimal proliferation after wire injury of the mouse femoral
artery
After injury, arteries were excised at the time-points indicated and stained with the United
States trichrome stain. A control uninjured vessel is also shown for comparison. Immediately
(Od) and 2d after injury the internal elastic lamina is stretched and the medial layer is thinner
than in the control. An absence of nuclei suggests that the endothelium has been denuded.
Neointimal proliferation is first observed at 7d and continues until lesions peak in size at 21 d.
Neointimal lesions stain strongly for elastic fibres. Remodelling of the adventitia can also be





Figure 3.3: Quantification of luminal, neointimal and medial size overtime
After wire injury of the femoral artery, morphometric analysis was carried out on digitised
cross sections at the time-points shown. The graph shows that neointimal proliferation
begins 7d after injury, becoming significant from 14d onwards. Luminal area is larger than
uninjured controls at early time-points, and then decreases in parallel with lesion growth.
Medial area shows an initial trend towards a decrease which is not significant, and then
becomes larger than controls at 21d. Data are mean ± S.E.M, n= 6 for control, 7, 14, 21 and
28 days, n= 5 for 0 and 2 days. Analysed by one way ANOVA with Tukey's post hoc test:
*
p< 0.05, ** p< 0.01, *** p< 0.001 vs. control, +p< 0.05 vs. 7d.
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Figure 3.4: Damage to internal elastic lamina caused by wire insertion
Representative sections of arteries immediately after injury, showing types of potential
damage caused to the internal elastic lamina (IEL) by wire insertion. Indicated by arrows,
IEL breaks (a), partial stripping (b) and complete removal (c) were all observed, close to the
site of wire insertion. Thrombosis (Th) in response to IEL removal can be seen in (b) and (c).
Scale bar = 100 pm.
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peaked (Figures 3.2, 3.3). In parallel to neointimal proliferation, medial size
gradually increased and was significantly larger than control after 21 days (Figure
3.3 and Table 3.1). Luminal size decreased as neointimal lesion size increased
(Figure 3.3 and Table 3.1). Expansion of the femoral artery, as assessed by an
increase in the perimeter of the IEL and EEL, persisted over the time-course of these
experiments (Table 3.1).
3.2.1.7 Thrombosis after wire injury of the femoral artery
Occlusive thrombus, which completely blocked the lumen of the vessel, was seen in
18% of the arteries studied from 0 to 28 days during the model development (6/ 34).
Since there was minimal reperfusion in the arteries collected immediately after
injury, only a very slight thrombotic response was seen. Thrombosis was usually
associated with areas of IEL breakage or removal (Figure 3.4). Vessels 2d after
injury had been reperfused, and in two cases this resulted in the formation of an
occlusive thrombus over the area of IEL damage (Figure 3.5). In both arteries this
was seen in areas near to the site ofwire insertion and branch ligation, leaving traces
ofmoderate thrombus in proximal sections before disappearing further up the vessel.
In the third artery with IEL damage, the IEL had been removed in areas near to the
site of wire insertion but this resulted in mural thrombus rather than occlusion
(Figure 3.5). In areas of the vessels without IEL damage, evidence of platelet
adhesion to the stretched artery wall could be seen (Figure 3.5).
At later time-points some evidence of thrombosis could still be seen. As at earlier
time-points, extensive damage and IEL removal were sometimes observed where the
wire was inserted into the artery. This could be associated with occlusive thrombus
(one at 7d, one at 14d and two at 2Id) or more often with mural thrombus, which
became organised into fibro-proliferative neointimal lesions. However neointimal
lesions which were not of thrombotic origin were seen in all arteries, extending
proximally along the vessel, away from the site ofwire insertion.
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Figure 3.5: Types of thrombosis caused by wire insertion
Representative sections of arteries 2 days after injury, showing types of thrombus formed in
response to wire insertion. Occlusive (a) and mural (b) thrombi were observed over areas of
IEL damage, whereas evidence of platelet adhesion (c) was seen in the intact stretched
artery wall. Scale bar =100 pm.
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3.2.1.8 Cellular components of neointimal formation after wire injury
The composition of neointimal lesions in serial sections of injured arteries was
assessed using antibodies against smooth muscle cell a-actin (alkaline-phosphatase
conjugated), von Willebrand factor (vWF), Mac-2 and proliferating cell nuclear
antigen (PCNA). The protocol for each antibody is described in chapter 2.8. An
attempt was also made to identify endothelial cells using an antibody against CD31
(BD Pharmingen, U.K.) but staining was unsuccessful. It is likely that this was due to
antigen masking in the formalin-fixed tissue sections used.
The area occupied by immunoreactivity for smooth muscle cell a-actin and Mac-2
was quantified in the neointima and media of injured arteries by measurement on
digitised cross sections at each time-point, and expressed as a percentage of the total
area of the respective vessel layer. The number of nuclei staining for PCNA in the
neointima and media at each time-point was counted under a light microscope, and is
expressed as a percentage of the total number of nuclei in the respective vessel layer.
Neointimal lesions stained positively for elastic fibres (Figure 3.2), whilst staining
for smooth muscle cell a-actin confirmed that VSMCs were a major cellular
component of advanced neointimal lesions (Figure 3.6). Smooth muscle cells were
first evident in lesions at 14d and peaked in area at 21d (Figures 3.6, 3.7). Injury also
caused a dramatic reduction in medial smooth muscle cells, which was first apparent
at 2d and persisted across the time-course of neointimal development (Figures 3.6,
3.7).
vWF is a glycoprotein present in blood plasma and produced by the endothelium,
megakaryocytes (in the a-granules of platelets) and subendothelial connective tissue.
An absence of cellular nuclei and a lack of strong staining for vWF indicated that the
endothelial layer had been denuded in arteries at Od and 2d after injury (Figures 3.2,
3.8). Granular staining was observed on the luminal surface of arteries at 2d,
suggesting the adherence of platelets after injury (Figure 3.8). Expression of vWF
over the luminal surface of neointimal lesions was first observed at 7d, when
coverage was patchy and limited to individual cells. Lesions from 14d to 28d showed
94
Figure 3.6: Expression of smooth muscle cell a-actin after vascular injury
Representative sections of wire-injured femoral arteries at the time-points shown stained
with primary antibody against smooth muscle cell a-actin, and detected with VECTOR red.
Immunoreactivity in neointimal lesions was first detected at 14d, and indicated that smooth
muscle cells are a major component of advanced lesions at 21 d and 28d. Staining also
showed that there is a dramatic loss of smooth muscle from the media of the artery wall 2d
after injury which persisted over the course of neointimal proliferation. Inserts at higher
magnification confirm an absence of cellular nuclei in the media at 2d and 7d, and
re-appearance of medial nuclei from 14d onwards. Box indicates area shown in insert at high


















Figure 3.7: Quantification of neointimal and medial smooth muscle cell
a-actin
The area stained for smooth muscle cell a-actin in the neointima and media of injured
arteries was measured on digitised cross sections at each time-point, and expressed as a
percentage of the total area of the respective vessel layer. Measurements confirmed that
smooth muscle cell a-actin was first expressed in neointimal lesions at 14d and peaked at
21 d. Immunoreactivity in the media showed a dramatic reduction at 2d, a partial recovery at
14d and a further reduction at 28d. Data are mean ± S.E.M, n= 6 for 7, 14, 21 and 28 days,




Figure 3.8: Expression of von Willebrand factor after wire-induced injury of
the femoral artery
Wire-injured femoral arteries were collected at the time-points shown and representative
sections (n= 3 per time-point) were stained with primary antibody against von Willebrand
factor (vWF), detected with DAB. A control uninjured vessel is also shown for comparison.
No cellular staining for vWF was observed at Od, indicating the endothelium had been
removed by wire injury. Immunoreactivity was detected in a granular pattern at 2d, indicating
the adherence of platelets to the vessel wall after injury. Cells expressing vWF were first
detected on the luminal surface of neointimal lesions at 7d, and from 14d onwards strong
expression was observed in a thickened layer on the luminal surface of advanced lesions.
Scale bar =100 pm.
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strong expression of vWF in a thickened layer of cells over the luminal surface
(Figure 3.8).
Immediately after injury, no staining for macrophages was seen in the vessel wall or
lumen; however, by 2d sites ofMac-2 expression (a macrophage cell surface antigen)
could be seen exclusively in the cells of the adventitia (Figure 3.9). At 7d a large
proportion of cells within the neointima stained positively for Mac-2, and
occasionally cells on the luminal surface of lesions showed positive staining (Figures
3.9, 3.10). Macrophages could also be seen in the media at this time-point, and were
still observed in the adventitia. At 14d smaller sites of Mac-2 expression were
observed in the adventitia, media and neointima than at 7d (Figures 3.9, 3.10).
Advanced neointimal lesions at 21d and 28d showed small and discrete areas of
Mac-2 expression, with staining also seen in certain areas of the media immediately
under the IEL, and in some cells in the adventitia (Figures 3.9, 3.10).
PCNA, a marker of cellular proliferation, is expressed in the Gi and S phases of the
cell cycle. No PCNA expression was seen in the vessel wall immediately after injury,
and by 2 days expression was detected in the cells of the adventitia only (Figure
3.11). PCNA was first seen in the neointima and media 7 days after injury, and
reached maximal levels in the neointima at 14 days (Figures 3.11, 3.12). PCNA was
also expressed in the cells of the adventitia at these time-points. After this time,
PCNA expression decreased in all layers of the vessel wall (Figures 3.11,3.12).
Evidence of adventitial remodelling was seen after wire-induced injury, with a large
number of cellular nuclei, smooth muscle cells, macrophages, proliferating cells and





Figure 3.9: Expression of Mac-2 in the vessel wall after wire-induced injury
Wire-injured femoral arteries were collected at the time-points shown and representative
sections stained with primary antibody against Mac-2, detected with DAB. No staining for
Mac-2 was observed at Od, and staining was detected exclusively in the cells of the
adventitia at 2d after injury. Immunoreactivity was detected in a large proportion of cells in
the neointima at 7d, after which time expression was limited to small discrete sites in
neointimal lesions. Mac-2 was also detected in the media from 7d onwards, with high levels




















Figure 3.10: Quantification of neointimal and medial Mac-2 content overtime
The area stained for Mac-2 in the neointima and media of wire-injured femoral arteries was
measured on digitised cross sections at each time-point, and is expressed as a percentage
of the total area of the respective vessel layer. Measurements confirmed that Mac-2 was
highly expressed in neointimal lesions at 7d, after which time expression decreased, and
occurred in small areas only in advanced lesions. Immunoreactivity was also detected in the
media from 7d onwards. Data are mean ± S.E.M, n= 4. Analysed by one way ANOVA with
Tukey's post hoc test: *** p<0.001 vs. 7d.
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Figure 3.11: Detection of PCNA in the vessel wall after wire-induced injury
Representative sections of wire-injured femoral arteries collected at the time-points shown
were stained with primary antibody against proliferating cell nuclear antigen (PCNA), and
detected with DAB. No staining for PCNA was observed at Od, and staining was detected in
nuclei in the adventitia at 2d after injury. PCNA was first seen in the neointima and media 7
days after injury, and was more abundant at 14 days. After this time, PCNA expression
decreased in all layers of the vessel wall. Scale bar = 100 pm.
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Figure 3.12: Quantification of neointimal and medial PCNA expression over
time
Nuclei stained for proliferating cell nuclear antigen (PCNA) in the neointima and media of
wire-injured femoral arteries were counted under a light microscope at each time-point, and
expressed as a percentage of the total number of nuclei in the respective vessel layer.
Quantification confirmed that PCNA was first detected in neointimal lesions at 7d, peaked at
14d and then decreased. Immunoreactivity was also detected in the media from 7d onwards.
Data are mean ± S.E.M, n= 4. Analysed by one way ANOVA with Tukey's post hoc test:
** p<0.01 vs. Od.
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3.2.1.9 Effect of sham procedure on femoral artery structure
Animals that underwent sham surgery also developed large neointimal lesions in the
common femoral artery after 28 days (Figure 3.13a). These lesions were restricted to
sites immediately proximal to the branch of the popliteal artery. There was no
evidence of IEL damage or thrombosis in these arteries and the endothelium
appeared to be intact. Although the lesions formed in sham operated arteries were
sizeable, they were significantly smaller than those which formed 28 days after
wire-induced injury (Figure 3.13b).
3.2.2 Neointimal proliferation induced by sham operation
3.2.2.1 Surgical protocol
In order to determine which aspect of the sham procedure was causing neointimal
lesion development, groups of mice (n= 3 per group; one treatment in each leg of six
mice) were subjected to different components of the operation, as follows:
(a) isolation of femoral bundle from surrounding tissue,
(b) as (a), then isolation ofmain femoral artery and vein from the nerve and
placement of temporary ligatures for 1 minute,
(c) as (b), then popliteal artery isolated and ligated distally,
(d) as (c), then popliteal artery ligated proximally (see also Figure 3.14).
All arteries were collected after 28 days and fixed in 10% neutral buffered formalin
for 24 hours. A series of transverse paraffin sections (4 pm) from each artery were
stained with the United States trichrome stain and neointimal area measured on
digitised cross sections.
3.2.2.2 Permanent ligation causes sham-induced neointimal proliferation
Isolation of the femoral bundle (Group a) did not cause neointimal lesion
development (Figure 3.15). Isolation of the femoral artery from the nerve and
placement of temporary ligatures to interrupt blood flow for 1 minute (Group b)
















Figure 3.13: Neointimal lesion development in sham operated arteries
(a) Two representative sections showing extensive neointimal lesions formed in sham injured
arteries 28 days after operation. Scale bar = 100 pm.
(b) Quantification of vessel layer area in digitised cross sections, showing the growth of
neointimal lesions in both sham and injured arteries at 28d. Lesions after wire injury are
significantly larger than those in sham operated arteries. Data are mean ± S.E.M, n= 6 for
control and 28 days, n= 3 for sham. Analysed by one way ANOVA with Tukey's post hoc
test: ** p< 0.01, *** p<0.001.
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Figure 3.14: Assessment of components of the sham operation on neointimal
proliferation
A schematic representation of the procedures carried out to determine which stage of the
sham wire-induced injury operation induced neointimal proliferation in the femoral artery.
Exposure of the femoral artery (a), placement of temporary ligatures for 1 minute (b), distal
ligation of the popliteal artery (c) or proximal ligation of the popliteal artery (d) were carried
out in four different groups. The site where the flexible wire would normally be inserted




Figure 3.15: Sham-induced neointimal proliferation is caused by permanent
ligation of the popliteal artery
(a) Representative sections from each sham treatment group: (a) isolation of femoral bundle,
(b) placement of temporary ligatures for 1 minute, (c) distal and (d) proximal ligation of the
popliteal artery. Neointimal proliferation is most extensive in (d). Scale bar= 100 pm.
(b) Quantification of neointimal area in each group, which increases from (a) through to (d).
Data are mean ± S.E.M, n= 3. Analysed by one way ANOVA with Tukey's post hoc test:
**
p< 0.01 vs. a.
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In contrast, permanent ligation of the distal popliteal artery (Group c) produced
intermediate-sized neointimal lesions in 3/ 3 femoral arteries. The addition of a
permanent proximal ligature on the popliteal artery (Group d) caused the
development of large neointimal lesions in 3/ 3 femoral arteries (Figure 3.15).
The results of this experiment prompted the inclusion of a ligation-induced
neointimal proliferation model in subsequent investigations (chapter 2.3.2), where
tying off the popliteal artery at its branch can be used to induce neointimal lesion
development in the femoral artery. These studies also indicated that neointimal lesion
growth after wire-induced injury is a complex process that involves responses not
only to the wire, but also to the temporary and permanent ligatures used during the
operation.
3.2.3 In vitro model of neointimal proliferation
An attempt was made to induce the growth of neointimal lesions in tissue culture, to
allow the influence of local glucocorticoid and 11 (3-HSD activity on lesion
development to be investigated specifically within the vessel wall (chapter 2.3.3). At
the end of the culture period arteries were fixed in 10% neutral buffered formalin,
dehydrated and embedded in paraffin. Transverse serial sections were cut at 4 pm,
every 100 pm along the entire length of the arterial segment.
Left femoral arteries cultured under sterile conditions for 21 days following
intra-luminal wire injury showed no evidence of neointimal lesion development
(Figure 3.16). Indeed, the histological appearance of these arteries was similar to
those assessed immediately after injury (Od; Figure 3.2). The arterial wall appeared
stretched, the artery had collapsed and there appeared to be few endothelial cells
lining the luminal surface.
It is possible that the extent of injury caused to the vessel wall by wire injury in vivo
was too severe to allow neointimal proliferation to occur in vitro. Also, since the
method which this experiment was based on used human mammary arteries (Guerin
et al. 2004), species differences may account for the fact that it was not successful.
Further factors, such as the type of culture medium used, may have also contributed.
It is clear that more research and methodological development would be needed to
allow this model to be used in the future.
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Figure 3.16: In Vitro model of neointimal proliferation
Representative sections of two different arteries cultured for 21 days in vitro after wire
induced intra-luminal injury of the femoral artery. The walls of the vessels are stretched and
appear to be denuded of endothelial cells. No neointimal proliferation was seen.
Scale bar =100 pm.
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3.2.4 Vascular function studies
These investigations were designed to assess the impact of vascular injury and
neointimal proliferation on arterial contraction and relaxation. Since there was little
information in the literature at the time, an attempt was made to study the effect of
intra-luminal injury on endothelial function in the mouse femoral artery. The aim
was to study vascular function both immediately after injury, when it was
hypothesised that endothelium-dependent responses would be abolished, and also in
arteries at later time-points, in order to determine if a functional endothelium is
regenerated over advanced lesions. In order to do this, functional responses were
determined by mounting arterial rings (~2 mm in length) in small vessel wire
myographs for measurement of isometric force (chapter 2.9). Firstly, the functional
characteristics of the normal mouse femoral artery were established. Experiments
were designed (n= 3-7 per group) to determine:
(a) whether functional responses were similar in left and right femoral
arteries, to allow further study with no need to discriminate between the two
sides,
(b) the effect of endothelial cell removal on function,
(c) the effect of storing arteries overnight on function, to assess if it is
necessary to use only freshly dissected vessels in functional studies.
To denude arterial rings, the luminal surface was rubbed with a human hair after
mounting in the myograph. For storage, arteries were placed in PSS at 4°C overnight.
The effect of vascular injury on arterial function was assessed using arteries isolated
immediately, 2 and 14 days after wire-induced injury of the femoral artery (n= 2 for
each time-point).
3.2.4.1 Functional characterisation of the normal mouse femoral artery
Contraction to the ai-adrenoceptor agonist phenylephrine in the mouse femoral
artery began at a concentration of approximately 1x10"7M, showed a clear
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Figure 3.17: The impact of endothelial cell removal on functional responses
of mouse femoral artery
Contractile responses to phenylephrine (a) and high potassium physiological salt solution
(b), and relaxation to acetylcholine (c) and sodium nitroprusside (d) were measured using a
small vessel myograph. Concentration-response curves to phenylephrine and sodium
nitroprusside were unaffected by endothelial denudation. In contrast, the Emax to
acetylcholine was significantly decreased in denuded arteries, and there was a trend towards
a decrease in Emax to high potassium (p= 0.068). Data are mean ± S.E.M, n= 6 for intact,
n= 3 for denuded. Analysed by unpaired t test: ** p< 0.01.
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Contraction to phenylephrine was identical in the left and right femoral arteries
(Table 3.2) and in intact and denuded arteries (Figure 3.17a and Table 3.2). Although
the Emax for phenylephrine in fresh and stored arteries was not significantly different,
the pD2 in stored arteries was decreased when compared to fresh arteries (Table 3.2).
The maximum contraction in response to high potassium appeared diminished in
denuded arteries compared with intact arteries, although this did not quite reach
significance (Figure 3.17b and Table 3.2, p= 0.068). The Emax in response to high
potassium also appeared decreased in stored arteries compared with fresh arteries,
although again this did not reach significance (Table 3.2, p= 0.073).
After pre-contraction with 1x10~5M phenylephrine (not significantly different
between groups, data not shown), relaxation in response to acetylcholine in the
femoral artery began at concentrations as low as 1x10"9M (Figure 3.17c), and then
showed concentration-dependent increases in magnitude, until the relaxant response
reached an Emax- Similarly to acetylcholine, relaxation in response to the
endothelium-independent vasorelaxant drug sodium nitroprusside began at 1x10"9M
and then showed a concentration-response relationship (Figure 3.17d). There was no
significant difference in relaxation to either acetylcholine or sodium nitroprusside
between the left and right femoral arteries (Table 3.2). Acetylcholine-mediated
relaxation was abolished by removal of the endothelium (Figure 3.17c and Table 3.2)
whereas responses to sodium nitroprusside were unaffected (Figure 3.17d and Table
3.2). Relaxation in response to acetylcholine in stored arteries was severely blunted,
and the maximum relaxation reached was significantly less in stored arteries than in
fresh samples (Table 3.2). In contrast, the response to sodium nitroprusside in stored
arteries was not significantly affected (Table 3.2).
These experiments provided the basis for a protocol to assess contraction and
endothelium-dependent and -independent relaxations in wire-injured femoral
arteries. They also confirmed that there are no functional differences between the left
and right mouse femoral artery, and indicated that overnight storage can have



























LFA 5.72 ±0.12 91.33 ±6.06 33.50 ±1.37 4.12 ± 1.01 7.32 ±0.18 96.77 ±7.79 7.85 ±0.19 108.29 ±2.09
RFA 5.64 ±0.09 79.30 ± 9.75 34.38 ± 2 3.15 ±0.52 7.51 ±0.29 108.19 ±5.59 7.81 ±0.24 106.50 ±3.69
Intact 5.78 ±0.05 84.20 ± 5.87 34.57 ±1.63 4.48 ±1.14 7.38 ±0.22 105.5 ±5.56 7.99 ±0.16 108.91 ±2.5
Denuded 5.92 ± 0.07 91.21 ± 14.71 37.9 ± 3.84 1.96 ±0.26 8.21 ±0.35 59.81 ± 19.85** 7.85 ±0.06 112.94 ±6.07
Fresh 5.78 ±0.05 84.2 ± 5.87 34.57 ±1.63 4.48 ± 1.14 7.38 ±0.22 105.5 ±5.56 7.99 ±0.16 108.91 ±2.5
Stored 5.37 ± 0.09** 80.86 ± 13.35 35.04 ±1.92 2.18 ±0.45 7.09 ±0.13 70.21 ± 8 27** 7.66 ± 0.24 104.2 ±1.82
Table 3.2: Functional properties of agonists in the mouse femoral artery
Small vessel wire myography was used to determine the pD2 (contractile agonists), -loglC50
(relaxant agonists) and maximal response (Emax) to phenylephrine (PE), high potassium
physiological salt solution (KPSS), acetylcholine (ACh) and sodium nitroprusside (SNP).
These parameters were compared between left (LFA) and right (RFA) femoral arteries,
between intact and denuded arteries and between fresh and stored arteries. Significant
differences were found in the Emax to ACh between intact and denuded arteries and between
fresh and stored arteries. There was also a significant difference in the pD2 of PE between




3.2.4.2 Vascular function after intra-luminal wire injury
In a preliminary attempt to study vascular function immediately (Od), 2 and 14 days
after injury, arteries failed to respond to any contractile agonists at all, and did not
even contract during the standard start protocol in response to a mixture of
noradrenaline and high potassium salt solution (data not shown). The process of
mounting the injured arteries on wires in the myograph was technically difficult, as
the artery walls were stretched and did not maintain their shape after injury.
These results indicate that the wire has damaged the vessel wall so that it can no
longer contract in response to any stimulus, and that artery function has not
recovered by 14 days after injury. It is likely that this is due to the loss of medial
smooth muscle cells documented after wire-induced injury.
3.2.5 Effect of vascular injury and cytokine stimulation on 11P-HSD1
activity
It has been suggested that inflammatory stimuli may alter vascular 11 p-HSD activity
in an isozyme selective manner, thus up-regulating the generation of active
glucocorticoids and conferring a mechanism for local feedback inhibition of
inflammation (Cai et al. 2001). However, studies in normal intact vessels have failed
to confirm this finding (Dover et al. 2007). Since local inflammation is a central
component of neointimal proliferation (Miller et al. 2001), vascular injury may alter
11 P-HSD 1 activity in the vessel wall. Furthermore, the change in VSMC phenotype
after injury, from quiescent to proliferating, may influence the sensitivity of
11 P-HSD 1 activity to up-regulation by cytokines. These hypotheses were addressed
using injured and control femoral arteries collected 7 days following surgery. This
time-point was chosen as immunohistochemistry demonstrated that cellular
proliferation is occurring in the neointima; this has also been reported in previous
studies (Sata et al. 2000; Reis et al. 2000). Aortic segments were also collected for
use as additional controls.
11 P-HSD 1 activity was assessed in all arteries following incubation with IL-ip
(lOng/mL) or vehicle (0.1% BSA in PBS) for 16 hours (n= 6). 11 P-reductase activity
was measured by an adaptation of the method of Souness et al (2002) (chapter
2.10.2). Samples of medium were collected 0, 8, 24, 32 and 48 hours after addition of
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[ H] 11-dehydrocorticosterone, to allow the time-course of [ H] corticosterone
generation to be studied (n= 6 for 24 hours, n= 3 for all other time-points). The
section of femoral artery used in these experiments extended from the popliteal
artery, where the wire is inserted, up to the bifurcation of the iliac artery and
therefore contained the entire length of any lesion present.
Initial experiments (n= 3) measured the time-course of lip-HSDl activity in aorta,
injured and uninjured femoral arteries. Conversion of [ H] 11-dehydrocorticosterone
•2 # . #
to [ H] corticosterone progressed linearly over 48 hours in the aorta (Figure 3.18a)
and femoral arteries (Figures 3.18b and c). These experiments confirmed that
performing enzyme activity assays after 24 hours of substrate incubation in further
studies would give a measurement within the linear range of product formation with
time, and not after activity had reached a plateau.
■y
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After 24 hours of [ H] 11-dehydrocorticosterone incubation, 11 [3-reductase activity
was not changed in wire-injured femoral arteries when compared with uninjured
controls (Figure 3.19, p=0.33). Therefore, the hypothesis that vascular injury would
act to up-regulate 11P-HSD1 activity in the vessel wall was not confirmed. To assess
whether the sensitivity of vascular lip-HSDl activity to up-regulation by cytokines
is altered under conditions of VSMC proliferation, enzyme activity was measured in
injured arteries incubated with IL-ip. Exposure to IL-ip did not change lip-HSDl
activity in injured arteries (p= 0.20) or uninjured arteries (p= 0.43) compared with
respective vehicle-treated controls (Figure 3.19). However, IL-ip significantly
down-regulated 11 P-reductase activity in aortic segments taken from the same








Figure 3.18: Time-course of 11(3-HSD1 activity in isolated vessels
Segments of (a) aorta, and (b) uninjured or (c) injured femoral arteries were incubated for 16
hours with 10ng/ml interleukin-1 p or vehicle, and then with [3H] 11-dehydrocorticosterone.
1ip-reductase activity over time is expressed as the amount of [3H] corticosterone formed
per mg of tissue during each time interval. Generation of [3H] corticosterone progressed
linearly with time over 48 hours in aorta and femoral arteries. Cytokine incubation caused a
trend towards a decrease in 1ip-reductase activity that did not reach significance, as





Figure 3.19 Effect of injury and inflammation on vascular 11 (3-HSD1 activity
Control (uninjured) and injured femoral arteries, and aortic segments, were incubated for 16
hours with 10ng/ml interleukin-1 (3 or vehicle, and then for a further 24 hours with [3H]
11-dehydrocorticosterone. 1ip-Reductase activity is expressed as the amount of [3H]
corticosterone formed per mg of tissue over 24 hours. Wire injury of the femoral artery did
not cause any change in 1 ip-reductase activity. Cytokine incubation did not significantly alter
1ip-reductase activity in control and injured femoral arteries; however it induced a decrease
in activity in aortic segments. Results are mean ± S.E.M, n= 6 per group. Differences
between groups measured by unpaired t test, ns: non significant, * p<0.05.
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3.3 Discussion
This chapter describes the introduction and development of a model of wire-induced,
intra-luminal vascular injury in the mouse femoral artery (Sata et al. 2000). This
technique induces stretching and denudation of the artery wall, followed by the
time-dependent formation of neointimal lesions. Neointimal lesion formation is
associated with early macrophage infiltration and cellular proliferation. Advanced
lesions are elastin and smooth muscle cell-rich, and show evidence of a
re-endothelialised luminal surface. Wire-induced injury causes loss of medial smooth
muscle cells and abolishes vascular contractile function, but has no effect on
lip-HSDl activity. These studies also demonstrated that permanent ligation at the
branch of the popliteal artery induces neointimal proliferation in the femoral artery.
Choosing a model ofvascular injury in the mouse
Although experiments using transgenic mice represent an effective way to clarify the
mechanisms of neointimal lesion formation during post-angioplasty restenosis,
currently there are no balloons available which can be inserted into small muscular
mouse arteries (Sata et al. 2000). The main advantage of a wire-induced
intra-luminal model of vascular injury over perivascular approaches available in the
mouse (Carmeliet et al. 1997c; Kumar & Lindner 1997; Moroi et al. 1998) is that the
wire stretches the vessel wall and removes the endothelium; two key mechanisms of
the vascular injury induced during balloon angioplasty and stenting. Therefore, it is
more relevant to use this model in the study of pathways and factors that may
contribute to the pathogenesis of neointimal lesion formation.
The first model of wire injury in the mouse was developed by Lindner et al in 1993.
In this method a wire is inserted via the external carotid artery into the common
carotid artery to denude the endothelium. Smooth muscle cells are first seen in the
intima 8 days after injury, and by two weeks neointimal lesions contain a similar
number of smooth muscle cells as the media. There are two main advantages of wire
injury in the femoral artery over the carotid. The first is that neointimal lesions
produced in the carotid artery are not very extensive, and usually only grow to two or
three cell layers in thickness (Lindner et al. 1993; Kumar & Lindner 1997). In
contrast, those seen after four weeks in wire-injured femoral arteries are much larger,
with intima/ media ratios comparable to those seen in larger animal models (Sata et
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al. 2000; Roque et al. 2000). The second is a technical consideration: since the
surgery required is relatively challenging with a high chance of vascular
complications, there is more possibility of accidental death by stroke when using the
carotid arteries. The femoral artery also offers the advantage of bilateral injury, and
the time-course of neointimal proliferation is similar to that found in the rabbit
(Doomekamp et al. 1996), pig (Schwartz et al. 1990) and baboon (Geary et al.
1994).
Shortly before the method of Sata et al (2000) was published, a similar model was
reported by another group (Roque et al. 2000). This method involves inserting a
slightly smaller wire into the femoral artery to cause endothelial denudation, rapid
neutrophil accumulation and neointimal proliferation. However, this model is
somewhat different from that of Sata et al (2000) since the wire is inserted through
an arteriotomy in the main femoral artery, distal to the epigastric branch. After wire
insertion and removal the main femoral artery must be ligated proximally to the
arteriotomy site; therefore, blood flow to the injured artery is only partially restored.
This raises the possibility that the observed neointimal proliferation may be a result
of restriction of blood flow, as seen in the carotid artery ligation model (Kumar &
Lindner 1997), and not of the denuding injury caused by the wire. In contrast, by
inserting the wire through a small side-branch which can be tied off, blood flow to
the femoral artery is completely restored using the model of Sata et al (2000).
The experimental model ofwire- induced vascular injury
This surgical model can be carried out routinely after practice, is generally well
tolerated by the animals and induces reproducible neointimal proliferation consistent
with published reports. The persistence of femoral artery expansion observed over
the duration of the current experiments has been reported previously by Sata et al
(2000). The time-course of neointimal proliferation also followed a similar pattern to
that seen in published models (Sata et al. 2000; Roque et al. 2000). Although
neointimal lesion formation was not assessed beyond 28 days in the current
investigations, previous studies have shown that lesion growth does not continue
after this time in mice (Sata et al. 2000; Zou et al. 2007).
118
The observation that advanced neointimal lesions contained predominantly smooth
muscle cells, and the indication that endothelial cell regeneration occurred over their
luminal surface, is consistent with descriptions of lesion composition made by other
groups (Sata et al. 2000; Roque et al. 2000). The detection of macrophages in the
adventitia of injured vessels, and in small discrete areas of advanced neointimal
lesions, has also been described previously (Sata et al. 2000). The time-course of
cellular proliferation, as determined by PCNA staining, followed a similar pattern to
prior studies (Reis et al. 2000). The adherence of platelets at early time-points to
sections of the artery wall where the IEL was un-damaged has been observed by
another group using a similar model (Roque et al. 2000). The early medial thinning
and dramatic loss of VSMCs from the media of the vessel wall seen in the current
studies were consistent with observations made by other groups (Sata et al. 2000;
Reis et al. 2000), who have described a rapid medial cell apoptosis caused by
vascular injury that occurs independently of the Fas death signalling pathway (Sata et
al. 2001).
The observation that neointimal lesions 7d after injury contained macrophages and
proliferating nuclei, with no expression of smooth muscle cell a-actin, suggests that
early lesion formation occurs via the migration and proliferation of circulating cells
(rather than resident VSMCs) in the arterial wall. In contrast, lesions at 14d contain
smooth muscle cell a-actin positive cells in addition to macrophages and
proliferating nuclei. This implies that cells derived from the circulation are
undergoing proliferation and differentiation into VSMCs. Rapid medial atrophy
observed after injury indicates that, for neointimal VSMCs to have originated in the
arterial wall, they must derive from the adventitia or from uninjured areas of the
vessel. The latter seems unlikely, however, given the extent of injury along the
arterial wall. The suggestion that neointimal cells originate from the circulation
(possibly from vascular progenitor cells) is consistent with the previous observation
that a significant number of neointimal cells are derived from the bone marrow after
wire-induced injury (Tanaka et al. 2003). However, it is contrary to the
classically-described pathogenesis of neointimal lesion formation (Lee et al. 1993),
whereby activation of medial VSMCs results in their migration to, and proliferation
in, the intima. This mechanism of neointimal lesion formation may help to explain
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why wire-injured arteries do not contract at 14d after injury, despite the presence of a
smooth muscle a-actin-rich lesion; these cells are likely to be of a synthetic, rather
than contractile, phenotype and may also not be ideally oriented for normal
contraction of the artery (Kockx et al. 1993).
One limitation of the intra-luminal model of vascular injury described in this chapter
is the damage induced to the IEL of the artery wall, which usually occurred in areas
close to the site of wire insertion. It is likely that this was caused when difficulties
were encountered introducing the wire into the popliteal artery, and more force was
necessary to advance the wire along the femoral artery. The damage, which took the
form of breaks in the IEL, partial stripping of the IEL away from the underlying
media, or even complete removal of the IEL, left the medial layer of the vessel wall
exposed. Exposure of this thrombogenic surface stimulated the formation of several
types of thrombi. The formation of occlusive thrombus in 18% of all vessels studied
during the model development was a higher frequency than that reported by Sata et
al (2000) (about 6%), but falls within the range reported by Roque et al (2000)
(5-21% depending on time-point). Non-occlusive solid thrombus on top of the
exposed media and a fibrin-like mesh containing cells were also observed in vessels
with IEL damage; these types of thrombi are not described in previous reports.
Thrombus which formed as a result of IEL damage at the site of wire insertion often
extended along the artery into areas where the wall remained intact. In addition, solid
and mesh-like thrombi were sometimes seen to be undergoing infiltration by cells
and gradually organising into more fibrous neointimal lesions. Therefore, in arteries
where extensive IEL damage and thrombosis had occurred classification and
measurement of neointimal lesions could be complicated, especially at earlier
time-points (e.g. 7 and 14d) when large advanced neointimal lesions had yet to form.
Additional model ofligation-induced neointimalproliferation
The observation that large neointimal lesions formed in sham-operated arteries
around the branch point of the popliteal artery was unexpected. This prompted
contact with the two groups who had previously published wire-induced injury
models in the mouse femoral artery. The group who developed this model (Sata et al.
2000) revealed that they had seen a similar neointimal response around the branch
point in sham-operated mice but had chosen not to report it. The group who use a
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similar model (Roque et al. 2000) reported that they do not use the area of femoral
artery around the site of wire insertion for histology and start sectioning more
proximally; therefore, they would not observe any response that may occur in
sham-operated mice. By setting up a series of shams to assess the effect of each stage
of the operation on neointimal proliferation, it was found that the permanent ligatures
used during the procedure, in particular the tie placed proximally on the popliteal
artery, induce the formation of neointimal lesions in the femoral artery.
These observations have proved very useful, as they have allowed the introduction of
an alternative model of neointimal proliferation. By simply tying off the popliteal
artery, neointimal lesions can be induced in the main femoral artery, presumably via
a similar mechanism to the model of carotid artery ligation developed by Kumar &
Lindner (Kumar & Lindner 1997). Previous studies have shown that, unlike
wire-induced injury, few bone marrow-derived cells are involved in neointimal
formation after ligation injury (Tanaka et al. 2003). In order to determine whether
early lesions induced in the current model of femoral artery ligation are composed of
circulating cells, arteries would have to be studied at earlier time-points after injury.
This model can be used in the contra-lateral leg of mice undergoing wire-induced
injury, to provide another way to measure the effect of any interventions being
studied.
Conclusions
These studies describe the introduction of a model of vascular injury in the mouse,
which produces structural changes in the artery wall that replicate the method on
which it is based (Sata et al. 2000). The reproducible growth of neointimal lesions
induced by this model will allow the effects of exogenous and endogenous
glucocorticoids on neointimal proliferation to be investigated. The detailed analysis
of the time-course and cellular composition of neointimal lesion formation
performed will allow future experiments to be properly designed and interpreted.
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Chapter 4
Effects of exogenous glucocorticoids on the vascular
response to injury in the mouse
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4.1 Introduction
The influence of glucocorticoids on the vascular response to injury in vivo is hard to
predict, due to their adverse effects on systemic cardiovascular risk factors, and their
beneficial actions locally on the vessel wall. Glucocorticoids can exert profound
anti-inflammatory effects and directly inhibit smooth muscle cell proliferation (see
chapter 1). This gives them the potential to inhibit neointimal proliferation of smooth
muscle cells, which is stimulated primarily by the inflammatory response to vascular
injury. Indeed, administration of these hormones inhibits the response to vascular
injury in a range of different animal models. Glucocorticoids reduced early
inflammation in a rabbit model of balloon injury (Poon et al. 2001), and decreased
neointimal proliferation in the rat (Villa et al. 1994; Guzman et al. 1996; Nagasaki et
al. 2004) and the rabbit (Van Put et al. 1995; Petrik et al. 1998; Valero et al. 1998).
In a rabbit model of established atherosclerosis, oral prednisone after stenting
reduced neointimal formation (Ribichini et al. 2007), and dexamethasone release
from coated metal stents inhibited neointimal formation in the dog femoral artery
(Strecker et al. 1998). In the mouse, one study has shown that dexamethasone
decreased neointimal proliferation caused by cuff placement around the femoral
artery (Pires et al. 2005). In addition, dexamethasone treatment can inhibit vein graft
thickening in hypercholesterolemic ApoE3Leiden transgenic mice (Schepers et al.
2006). However, the effect of glucocorticoids on the arterial response to injury has
not been studied in detail in the mouse.
Human clinical trials investigating the action of systemic glucocorticoid
administration have been performed after balloon angioplasty (Stone et al. 1989;
Pepine et al. 1990) and stent implantation (Rab et al. 1991; Lee et al. 1999; Versaci
et al. 2002). The majority of these studies have yielded disappointing results,
showing no beneficial effect of systemic pulse pre-treatment (Pepine et al. 1990; Lee
et al. 1999), or short-term systemic administration of glucocorticoids (Stone et al.
1989) on restenosis rate. Indeed, one study indicated that treatment with
glucocorticoids after stenting had a detrimental effect on vessel wall healing, leading
to an increased incidence of coronary aneurysms (Rab et al. 1991). In contrast, a
more recent trial reported that systemic administration of prednisone for 45 days
caused a significant decrease in clinical events and restenosis rate after coronary
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artery stent implantation (Versaci et al. 2002). This indicated that a more prolonged
duration of glucocorticoid administration may be beneficial.
Local drug delivery using drug-eluting stents provides the opportunity to administer
therapeutic agents over a prolonged period, while limiting potential systemic side
effects. This is important due to the well-recognised, unfavourable effects of long
term glucocorticoid therapy such as hypertension, impaired glucose tolerance,
immunosuppression and impaired healing after myocardial infarction. A role for
local administration is supported by the demonstration that application of
glucocorticoids at the vessel wall inhibits neointimal proliferation in the rat (Villa et
al. 1994; Guzman et al. 1996) and the mouse (Pires et al. 2005). Release of
methylprednisolone from stents reduced neointimal formation and macrophage
infiltration in a porcine model of coronary stenting (Wang et al. 2005). Pre-clinical
studies using dexamethasone-eluting stents have shown conflicting results, with
inhibition of neointimal formation seen in the dog (Strecker et al. 1998) but no
reduction seen in the pig (Lincoff et al. 1997).
The outcomes of human clinical trials using dexamethasone-coated stents have also
been contradictory. An early feasibility report, the Study of Antirestenosis With the
BiodivYsio Dexamethasone-Eluting Stent (STRIDE) trial, indicated that
dexamethasone release from coated stents may have an inhibitory effect on
neointimal formation (Liu et al. 2003). However, in a separate pilot study, stents
loaded with a high dose of dexamethasone did not significantly reduce neointimal
proliferation (Hoffmann et al. 2004) when compared with previous results reported
for bare metal stents (Kastrati et al. 2001). Importantly, when the effect of high-dose
dexamethasone-eluting stents was evaluated in a randomised and properly controlled
study, an improvement both in clinical outcomes and in restenosis rate was observed
(Han et al. 2006). Most recently, dexamethasone-eluting stents have been shown to
reduce neointimal proliferation when compared to bare metal stents, in patients with
acute coronary syndrome (Konig et al. 2007). Dexamethasone-coated stents have
also been shown to attenuate increases in adhesion molecules (Patti et al. 2005a) and
CRP (Patti et al. 2005b) after stenting.
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Therefore, although glucocorticoids have effects on the cells of the vascular wall that
should inhibit neointimal proliferation, to date the results of studies assessing their
impact on this process have been inconsistent. It is likely that species differences, as
well as the protocol of steroid delivery, have contributed to the variation seen. In
addition, the type of vascular injury induced has differed between studies, with
models of intra-luminal (Petrik et al. 1998; Nagasaki et al. 2004; Ribichini et al.
2007) and perivascular injury (Van Put et al. 1995; Pires et al. 2005) used
interchangeably in animal studies. However, it is also very important to consider the
balance between systemic and local actions of glucocorticoids when interpreting the
influence of these hormones on the vascular response to injury.
We hypothesised that glucocorticoid administration would inhibit neointimal
proliferation in the mouse model of intra-luminal femoral artery injury, and that local
application would avoid the adverse effects associated with systemic steroid
treatment. With this in mind, the specific aims of this chapter were:
(i) To determine whether systemic glucocorticoid administration inhibits neointimal
lesion formation in the mouse model of intra-luminal vascular injury.
(ii) To assess whether neointimal proliferation can be inhibited without confounding




Male C57B16 mice (Harlan Olac, U.K.) weighing 25-35 grams were used in all
studies. To allow collection of trunk blood, animals were killed by decapitation,
according to Home Office guidelines.
4.2.2 Wire-induced injury of the femoral artery
Intra-luminal vascular injury was induced in the femoral artery of mice using a wire
to induce stretching and denudation of the artery wall (see chapter 2.3.1), followed
by the development of neointimal lesions (see chapter 3). Wire-induced vascular
injury was carried out both in the left and in the right femoral arteries of all animals.
4.2.3 Administration of drugs
4.2.3.1 Systemically-administered glucocorticoid
To increase systemic glucocorticoids and investigate the effect on neointimal
proliferation, mice (n= 8 per group) received sub-cutaneous injections of lmg/kg/day
dexamethasone or vehicle (4% ethanol/ 0.9% saline; chapter 2.4.1). Dosing was
started at least two hours before bilateral wire injury and continued daily (in the
morning) until the end of the experiment. Body weight was recorded each day.
4.2.3.2 Locally-released glucocorticoid
To assess the action of locally-released glucocorticoid on neointimal proliferation,
silastic pellets (chapter 2.4.2) were placed next to the femoral artery immediately
following wire-induced injury. A pocket was created at the operation site; pellets
were inserted into this pocket and kept in place when the skin incision was closed
with sutures at the end of the operation. During bilateral, wire-induced injury a pellet
containing Cortisol was implanted in one leg, and a contra-lateral vehicle pellet
(silastic elastomer only) was implanted in the other leg (n= 9). Cortisol or vehicle
pellets were implanted randomly in either the right or the left leg. Each 10 mg pellet
contained 2 mg Cortisol (20% w/w). In an additional control group, animals
underwent bilateral femoral artery injury, and vehicle pellets were placed in both legs
(n= 8). To assess whether pellet implantation alone would cause neointimal
proliferation, bilateral pellet implantation without any manipulation of the femoral
artery was carried out in a third group ofmice (n= 3).
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4.2.4 Tissue collection
21 days following surgery all mice were weighed for a final time and then trunk
blood was collected into heparinised tubes on wet ice. Blood samples were
centrifuged at 3000 rpm for 5 minutes, and the plasma (supernatant) was removed
into fresh eppendorf tubes. Organs (adrenals, thymus, spleen, kidneys, heart and
liver) were removed, cleaned of connective tissue and weighed. Plasma and organs
were then snap frozen on dry ice and stored at -80°C. Due to loss of samples during a
freezer failure, the number of adrenal and plasma samples in the group of animals
treated with a unilateral Cortisol pellet was reduced from n= 9 to n= 6.
Left and right femoral arteries were cleaned of connective tissue and veins, and
excised from the bifurcation of the iliac artery to the branch with the popliteal artery.
Femoral arteries were immediately placed in 10% neutral buffered formalin, fixed
for up to 24 hours and then stored in 70% ethanol if necessary. The arteries were
dehydrated through graded alcohols, embedded in paraffin and cut into transverse
sections: sets of eight 4 pm serial sections were taken at 100 pm intervals along the
entire arterial segment.
4.2.5 Measurement of neointimal proliferation
To assess the extent of neointimal proliferation in these experiments, transverse
sections every 100 pm along injured arteries were stained with the United States
2 • • •trichrome histological stain (chapter 2.6.2). The area (pm ) of any neointima in each
section was measured using a light microscope coupled to a colour camera and image
analysis system (chapter 2.7). The extent of luminal narrowing was also calculated
for each section (% luminal narrowing = neointimal area/ area inside IEL x 100). The
section with the largest area of neointima (and therefore maximal luminal narrowing)
was chosen to represent each arterial sample. All analysis was performed with the
investigator blinded to which group the sample belonged to. Analysis of slides from
the systemic dexamethasone experiment was performed by two independent
investigators.
4.2.6 Assessing neointimal lesion composition
In arteries from animals treated with systemic dexamethasone, the United States
trichrome stain suggested that neointimal lesions had a different structure than those
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from vehicle-treated controls. Therefore, the cellular composition of neointimal
lesions in these two groups was investigated further. Smooth muscle cell content was
assessed using an alkaline-phosphatase conjugated monoclonal primary antibody
against smooth muscle cell a-actin (chapter 2.8.1). A polyclonal rabbit anti-human
primary antibody was used to determine the fibrinogen content of lesions (chapter
2.8.5).
4.2.7 Measurement of plasma Cortisol levels
Cortisol levels in plasma samples from mice implanted with a unilateral
cortisol-releasing pellet and contra-lateral vehicle control were analysed using a
radioimmunoassay kit (n= 6 due to loss of 3 samples; chapter 2.11.1).
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4.3 Results
4.3.1 Effect of systemic glucocorticoids on animals
Daily sub-cutaneous injections of lmg/kg dexamethasone had obvious effects on
mice; at the end of the study the group treated with glucocorticoid appeared
considerably smaller and thinner than the group treated with vehicle. This
observation was confirmed when body weights were compared (Figure 4.1). As
expected, mice treated with vehicle showed an early weight loss after surgery, then
gained weight over the 21 days of the study. In contrast, animals treated with
dexamethasone failed to gain weight during the experiment and weighed
significantly less than the vehicle group from 15 days onwards.
In the group treated with systemic dexamethasone, incisions made on the surface of
the leg during surgery had not healed fully after 21 days. The skin around the
operation site was scarred and, in some cases, the wound was not completely closed.
In contrast, skin had healed fully in animals treated with vehicle. Fur re-growth was
also impeded in the dexamethasone treatment group.
Upon dissection, it was apparent that certain organs which are known to change in
size in response to glucocorticoids (adrenal glands, thymus and spleen) were much
smaller in mice administered systemic glucocorticoid. This was verified when organ
weights were compared between dexamethasone and vehicle treated groups (Figure
4.2). The adrenal glands, thymus and spleen all weighed significantly less in animals
treated with systemic glucocorticoid, whereas there was no difference in weight of
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Figure 4.1: Weight change induced by systemic glucocorticoid administration
Mice were randomised to receive sub-cutaneous injections of 1mg/kg/day dexamethasone
(Dex) or vehicle, for 21 days after bilateral wire-induced femoral artery injury. Vehicle-treated
controls showed early weight loss after surgery, and then gained weight over the course of
the experiment. In contrast, mice treated with dexamethasone failed to gain weight. Data are
mean ± S.E.M, n= 8 per group. Analysed by two way ANOVA with Bonferroni post hoc test:
*























Figure 4.2: Effect of systemic dexamethasone administration on organ
weights
The weight of adrenal glands, thymus and spleen were expressed as a percentage of total
body weight, in animals treated with 1mg/kg/day dexamethasone (Dex) or vehicle for 21
days after bilateral wire-induced femoral artery injury. There was a significant reduction in
the weights of all three organs in animals treated with systemic dexamethasone. Data are
mean ± S.E.M, n= 8 per group. Organ weights compared between groups by unpaired t test:
**
p<0.01, *** p<0.001 vs. vehicle.
131
4.3.2 Influence of systemic dexamethasone on the vascular response to
injury
United States trichrome staining indicated that fibrous neointimal lesions developed
after 21 days in all animals from the vehicle-treated control group (Figure 4.3a); in
some arteries lesions developed over areas where the IEL had been removed during
wire insertion. In the dexamethasone-treated group areas of IEL removal were also
seen. In one animal a small, cellular neointima formed over thrombus generated in
response to IEL removal. No neointimal proliferation was seen in the remaining 7
animals from the dexamethasone group (Figure 4.3b). Therefore, when fibrous
neointimal area was quantified there was a highly significant decrease seen in the
animals administered systemic glucocorticoid (Figure 4.4).
Although very little neointimal proliferation was observed in animals treated with
dexamethasone, organised lesions that occluded the lumen of injured vessels were
still observed in this group. United States trichrome staining indicated that these
lesions were very different in composition from the fibrous lesions seen in
vehicle-treated controls (Figure 4.5a). They appeared smooth, contained very few or
no cells, and did not stain positively for elastin (Figure 4.5b). Whilst lesions in
vehicle-treated control arteries stained positively for smooth muscle a-actin, as
expected (Figure 4.5c), lesions in animals treated with systemic glucocorticoid did
not contain cells expressing this marker (Figure 4.5d). Instead, lesions in the
dexamethasone group stained strongly and uniformly for fibrinogen (Figure 4.5f);
immunoreactivity for fibrinogen was much less intense in controls (Figure 4.5e).
Fibrinogen-rich lesions were seen exclusively in the dexamethasone-treated group,
and were observed both over areas of IEL removal, and in sections of arteries where
the IEL remained intact.
The fibrinogen-rich lesions observed in dexamethasone-treated mice still acted to
block the lumen of injured vessels, and therefore no difference was seen in luminal




Figure 4.3: Effect of systemic dexamethasone on neointimal proliferation
after femoral artery injury
Sections of wire-injured arteries from animals treated with 1 mg/kg/day dexamethasone or
vehicle for 21 days, stained with the United States trichrome stain. Extensive neointimal
lesions developed in the vehicle-treated control group (a), but fibroproliferative lesion









Figure 4.4: Neointimal area in animals treated with dexamethasone or vehicle
after femoral artery injury
The area of fibrous neointimal lesions was quantified by image analysis in animals treated
with 1mg/kg/day dexamethasone (Dex) or vehicle. Dexamethasone administration caused a
significant decrease in neointimal area 21 days after wire-induced femoral artery injury. Data
are mean ± S.E.M, n= 8 per group. Analysed by unpaired ttest: *** p<0.001 vs. vehicle.
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Vehicle Dex
Figure 4.5: Composition of lesions formed after femoral artery injury in
animals treated with systemic glucocorticoid
Although administration of 1mg/kg/day dexamethasone (Dex) for 21 days after wire-induced
femoral artery injury reduced fibrous neointimal proliferation in mice, lesions were still
observed in the lumen of arteries from animals in this group (b,d,f). These lesions differed in
composition from vehicle-treated controls (a,c,e). Lesions in dexamethasone-treated animals
were acellular and elastin-deficient as assessed by United States trichrome staining (a,b),
did not contain smooth muscle cells (c,d) and stained strongly for fibrinogen when compared
with controls (e,f). Scale bar = 100 pm.
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Figure 4.6: Luminal narrowing after femoral artery injury in animals treated
with dexamethasone or vehicle
The extent of luminal narrowing after wire-induced vascular injury was determined in animals
treated with 1mg/kg/day dexamethasone (Dex) or vehicle. Luminal narrowing was calculated
as the area of any lesion present in the vessel lumen, as a percentage of the total area
inside the internal elastic lamina. Therefore, this took into account the potential of both
fibrous neointima and fibrinogen-rich lesions to occlude the lumen of the vessel. There was
no difference in luminal narrowing in mice treated with systemic glucocorticoid when
compared with vehicle-treated controls. Data are mean ± S.E.M, n= 8 per group. Analysed
by unpaired t test: ns, not significant.
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4.3.3 Effect of Cortisol pellet implantation on animals
The body weight of mice implanted with cortisol-releasing pellets was compared
with those implanted with bilateral vehicle pellets, at the start and the end of the
experiment. There were no significant differences in weight between mice implanted
with a Cortisol pellet, when compared with the control group implanted with bilateral
vehicle pellets (Figure 4.7). This confirmed the observation that there were no
obvious morphometric differences between treated and untreated mice at the end of
the experiment. Similarly, there were no differences seen in fur re-growth or wound
healing on the surface of the leg around the operation site.
There were no significant differences in the weights of the adrenals, thymus and
spleen (Figure 4.8) or other organs (heart, kidneys, liver; data not shown). However,
upon dissection it was observed that connective tissue remodelling was attenuated at
the operation site in the leg that had received a Cortisol pellet. Furthermore, injured
vessels treated with a Cortisol pellet were considerably easier to clean of adherent
connective tissue and veins when compared with those treated with a vehicle pellet.
When plasma Cortisol was assessed in mice implanted with a unilateral Cortisol
pellet, levels were below the limit of detection in 4/ 6 mice (below the lowest
concentration on the standard curve). The mean plasma Cortisol concentration was
22.22nmol/l; 95% CI (4.97, 39.47).
4.3.4 Influence of local glucocorticoid administration on neointimal
proliferation
In arteries with an adjacent vehicle pellet, extensive fibrous neointimal lesions
developed in 8/ 9 vessels (Figure 4.9a). (In the remaining animal, an exclusively
thrombotic response was observed). In two cases, neointimal proliferation occurred
over areas of IEL stripping and thrombosis but the remaining six neointimal lesions
developed in arteries where the vessel wall remained intact.
In contrast, a very small neointima developed in 5/ 9 arteries treated with a Cortisol
pellet (Figure 4.9b). In the remaining 4 vessels, no neointimal proliferation was
observed, and only a moderate thrombotic response to injury was seen. IEL stripping
was seen in 3/ 9 arteries in this group but this was always associated with thrombosis
only. All neointimal lesions developed over an intact artery wall.
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Figure 4.7: Influence of cortisol-releasing pellet on weight change over 21
days
Following bilateral wire-induced femoral artery injury, mice received either bilateral vehicle
pellets (vehicle), or a unilateral Cortisol pellet and contra-lateral vehicle control (Cortisol) for
21 days. The weights of animals at the start and the end of the experiment were compared.
There were no significant differences between the groups. Data are mean ± S.E.M, n= 8 for
























Figure 4.8: Effect of local Cortisol administration on organ weights
Following bilateral wire-induced femoral artery injury, mice received either bilateral vehicle
pellets (vehicle), or a unilateral Cortisol pellet and contra-lateral vehicle control (Cortisol). The
weight of the adrenal glands, thymus and spleen were expressed as a percentage of total
body weight in each animal at the end of the experiment. There was no significant difference
in any organ weight between the groups. Data are mean ± S.E.M, n= 8 for all organs in
vehicle group; n= 9 for thymus and spleen, n= 6 for adrenals in Cortisol group (due to loss of
samples). Analysed by unpaired ttest: ns, not significant.
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Contra-lateral vehicle Cortisol Bilateral vehicle
Figure 4.9: Action of local Cortisol administration on neointimal proliferation
after femoral artery injury
Sections of wire-injured arteries from animals implanted with a contra-lateral vehicle control
pellet (a) and unilateral Cortisol pellet (b), and a separate group of mice implanted with
bilateral vehicle pellets (c). Extensive neointimal lesions developed in contra-lateral vehicle
control arteries (a), but neointimal proliferation was dramatically inhibited when a Cortisol
pellet was placed next to the artery (b). Neointimal proliferation also occurred in animals
implanted with bilateral vehicle pellets (c), 21 days after injury. Scale bar = 100 pm.
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Quantification of neointimal lesion area indicated that Cortisol release from an
implanted pellet caused a significant decrease in neointimal proliferation after
vascular injury, compared with contra-lateral controls (Figure 4.10). Neointimal
lesions also developed in wire-injured arteries from the group of animals that
received bilateral vehicle pellets (Figure 4.9c); there was no difference in the size of
these lesions when compared with contra-lateral vehicle controls (Figure 4.10). Since
no solid, fibrinogen-rich lesions were observed, Cortisol treatment also decreased
luminal narrowing, compared to contra-lateral controls (Figure 4.11).
In the group of mice which underwent bilateral pellet implantation without femoral
artery manipulation, no vessel remodelling or neointimal proliferation was seen in







Figure 4.10: Decreased neointimal lesion development in arteries treated
with cortisol-releasing pellets
Neointimal area was quantified using an image analysis system, in animals implanted with a
unilateral Cortisol pellet (Cortisol) and contra-lateral vehicle control (contra-lateral vehicle).
Neointimal area was also quantified in a separate group of mice implanted with bilateral
vehicle pellets (bilateral vehicle). The presence of a Cortisol pellet caused a significant
decrease in neointimal area compared with contra-lateral vehicle controls, 21 days after
wire-induced femoral artery injury. There was no difference in neointimal area between
contra-lateral vehicle controls and bilateral vehicle controls. Data are mean ± S.E.M, n= 9 for
contra-lateral vehicle, n= 9 for Cortisol, n= 8 for bilateral vehicle. Analysed by one way
ANOVA with Tukey's post hoc test: *** p<0.001 vs. contra-lateral vehicle; ns, not significant.
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Figure 4.11: Reduced luminal narrowing in arteries treated with a
cortisol-releasing pellet
The extent of luminal narrowing after wire-induced vascular injury was determined in animals
implanted with a unilateral Cortisol pellet and contra-lateral vehicle control. Luminal
narrowing was calculated as the area of any lesion present in the vessel lumen, as a
percentage of the total area inside the internal elastic lamina. There was a significant
decrease in luminal narrowing in arteries treated with a Cortisol pellet when compared with
contra-lateral vehicle controls. Data are mean ± S.E.M, n= 9 per group. Analysed by
unpaired test: *** p<0.001 vs. vehicle.
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4.4 Discussion
These studies demonstrated that glucocorticoid administration inhibits neointimal
proliferation following wire-induced intra-luminal injury of the mouse femoral
artery. Whilst systemic administration of lmg/kg dexamethasone virtually abolished
the formation of smooth muscle-rich fibrous neointimal lesions, organised
fibrinogen-rich lesions formed in their place. This resulted in a similar extent of
luminal narrowing in mice receiving systemic glucocorticoids and in vehicle-treated
controls. In contrast, administration of Cortisol from an implanted pellet significantly
decreased smooth muscle-rich fibrous lesion formation, without the formation of
alternative fibrinogen-rich lesions. As a consequence, local Cortisol administration
reduced neointimal proliferation and luminal narrowing after vascular injury.
Effects of increased systemic glucocorticoid
Systemic dexamethasone was administered sub-cutaneously at a pharmacological
dose of lmg/kg/day, which was chosen as it inhibited neointimal lesion formation in
previous studies (Van Put et al. 1995; Poon et al. 2001). Inhibition of weight gain,
impaired wound healing and a decrease in weight of the adrenal glands, thymus and
spleen were observed in animals treated with this dose of dexamethasone, indicating
that it had significant systemic side-effects. Such side-effects are well recognised in
clinical practice, where prolonged glucocorticoid therapy can lead to altered body fat
composition, muscle atrophy and impaired wound healing, as well as impaired
glucose tolerance, hypertension and increased plasma lipid levels. In addition,
adverse effects associated with systemic glucocorticoid administration have
previously been shown in the mouse (Pires et al. 2005), where the authors reported
weight loss, impaired wound healing and a decrease in fur quality and daily activity.
In the current experiments, the observed side effects confirmed that daily
sub-cutaneous injections of lmg/kg dexamethasone were pharmacologically active in
the animals.
It was hypothesised that glucocorticoid administration would decrease neointimal
proliferation after vascular injury. Therefore, arteries were analysed after 21 days, as
neointimal lesion area was shown to be maximal at this time during development of
the model (chapter 3). The dramatic reduction in fibrous neointimal lesion formation
observed in these studies with systemic dexamethasone treatment is consistent with
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previous reports in a variety of animal models of neointimal proliferation, such as the
rabbit (Van Put et al. 1995; Petrik et al. 1998) and the mouse (Pires et al. 2005;
Schepers et al. 2006).
The formation of alternative lesions that lacked smooth muscle cells but were rich in
fibrinogen, exclusively in animals treated with systemic glucocorticoid, was
unexpected. Since fibrinogen is a principle protein involved in the clotting of blood,
it is likely that these lesions formed as the result of thrombosis in response to
intra-vascular injury. Therefore, although systemic dexamethasone reduced the
formation of smooth muscle-rich neointimal lesions after injury, the formation of
thrombotic lesions occurred instead. This led to the same end point, and luminal
narrowing was similar between dexamethasone-treated animals and vehicle-treated
controls. Differences in lesion composition between dexamethasone- and
vehicle-treated animals were not due to the extent of injury induced, as this was the
same in both groups. During this experiment it was observed that wire-induced injury
caused severe damage to the artery wall, with breaks and stripping of the IEL
observed more frequently than during the model development. Exposure of the
underlying media induced the formation of thrombus in both groups. In
vehicle-treated mice, thrombus was only observed in sections of artery with wall
damage, normally near to the site of wire insertion. However, fibrous neointimal
lesions also developed in this group. In contrast, mice treated with dexamethasone
exhibited an exclusively thrombotic response to injury. It should be noted that only
wire-injured femoral arteries were studied in this experiment; therefore the
possibility that dexamethasone may have acted to induce a general increase in
thrombosis in all areas of the vasculature cannot be excluded. Increased systemic
glucocorticoids might have promoted the formation of thrombotic lesions
independently from any injury caused to the artery wall. To further investigate this
possibility, sections of uninjured arteries from any part of the vasculature could be
studied for the presence of thrombotic lesions in animals treated with the same dose
of dexamethasone as used in the current experiments.
Action oflocally-released Cortisol
Implanted cortisol-releasing pellets were used to deliver glucocorticoid locally to the
vessel wall, and several observations indicated that this was achieved. No systemic
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side effects, such as significant changes in body weight or organ weights, were seen
in mice implanted with cortisol-releasing pellets. Cortisol-releasing pellets reduced
tissue remodelling around the operation site after vascular injury, in comparison with
the contra-lateral leg of animals. Furthermore, the fact that there was no difference in
neointimal lesion size between contra-lateral vehicle control arteries and those from
different animals implanted with bilateral vehicle pellets, demonstrates that Cortisol
only acted to reduce neointimal proliferation within the artery of the leg in which it
was released. Finally, measurement of plasma Cortisol in mice confirmed that levels
of circulating Cortisol after pellet implantation were undetectable or very low.
The current experiments were consistent with a previous study using
dexamethasone-eluting cuffs to investigate the effect of locally delivered
glucocorticoid on neointimal proliferation (Pires et al. 2005). In this study, no
changes in body weight or general well-being were observed in mice, supporting the
idea that glucocorticoids released in the leg do not cause systemic side-effects.
However, in contrast to the current experiments, impaired wound healing was seen in
the skin at the operation site in 2/ 6 mice at the highest concentration used (20%
w/w) (Pires et al. 2005). This discrepancy may be explained by the difference in
steroids used between studies; dexamethasone may have effects on wound healing at
this concentration, while Cortisol may not since it is more rapidly inactivated by
11P-HSD2 (Best et al. 1997). However, since it is unlikely that levels of 11P-HSD2
are high enough in the skin to cause this difference, it is more probable that Pires et
al (2005) achieved a higher concentration of glucocorticoid administration.
Comparison ofglucocorticoids applied via alternative administration routes
In the current studies two different glucocorticoids were administered:
dexamethasone and Cortisol. Dexamethasone was administered systemically to
reproduce previous animal studies investigating the effect of glucocorticoids on the
vascular response to injury (Villa et al. 1994; Van Put et al. 1995; Guzman et al.
1996; Petrik et al. 1998; Poon et al. 2001; Nagasaki et al. 2004; Pires et al. 2005).
Cortisol, rather than dexamethasone, was used for local delivery as it is more readily
metabolised by 11P-HSD2 (Best et al. 1997) and so has a shorter half-life. Therefore,
Cortisol activity was more likely to be restricted to immediately adjacent tissues, and
less likely to reach the systemic circulation. Cortisol was chosen over corticosterone,
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the glucocorticoid endogenous to rodents, so that its plasma levels could be measured
and used as an indicator of systemic glucocorticoid levels achieved by pellet
implantation.
The use of two different steroids prevents an unequivocal conclusion that differences
seen with systemically-applied and locally-applied glucocorticoids were due simply
to the route of administration. Firstly, Cortisol and dexamethasone have different
actions (the former being a selective GR agonist, and the latter able to bind and
activate both GR and MR), and different potencies at GR. Therefore, the effect of
Cortisol on the vascular response to injury may have been due to MR activation (the
influence ofMR on neointimal proliferation is discussed further in chapter 5.4). It is
also possible that dexamethasone had a higher potency within the vessel wall than
Cortisol, as it is relatively resistant to metabolism by 11(3-HSD2 (Best et al. 1997).
The issue of potency is important, as the dose of glucocorticoid reaching the vessel
wall was not matched in these studies. Therefore, the difference in action on the
vascular response to injury seen using dexamethasone and Cortisol could have been
due to differences in the dose of glucocorticoid administered, rather than differences
between systemic and local effects. Thus, it is possible that systemically-applied
dexamethasone at a lower concentration would decrease neointimal proliferation in
the absence of increased thrombosis. Similarly, a higher concentration of
locally-released Cortisol may have increased thrombogenicity in the vessel wall after
injury. The fact that wound healing at the site of the operation was inhibited in
animals administered systemic dexamethasone, but not in mice implanted with
cortisol-releasing pellets, suggests that the extent of local GR activation in the tissues
of the leg may have been higher in animals treated with dexamethasone. However, an
accurate measurement ofGR exposure to glucocorticoids in the vessel wall could not
be obtained; indeed it would be very difficult to design an experiment in vivo where
this would be possible. Subjective observations of connective tissue remodelling and
wound healing at the operation site suggest that both steroids had an
anti-inflammatory effect in the leg. Hence, what can be concluded is that
dexamethasone and Cortisol were both active locally in the tissues of the leg, with
dexamethasone having additional systemic actions.
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Mechanisms ofglucocorticoid action
There are several potential mechanisms by which exogenously applied
glucocorticoids may have reduced neointimal proliferation in these studies. Firstly,
glucocorticoids are potent anti-inflammatory agents. They suppress several
inflammatory pathways by blocking the transcriptional activity of NFkB (De et al.
1997a; McKay & Cidlowski 1999), and so decrease the release of inflammatory
mediators such as cytokines, chemokines and cell adhesion molecules. Inflammation
plays a critical role in neointimal proliferation following vascular injury in animals
(Miller et al. 2001), and elevated systemic markers of inflammation are associated
with a higher risk of restenosis in humans (Gaspardone et al. 1998; Buffon et al.
1999; Walter et al. 2001b). Indeed, glucocorticoid administration has been shown to
reduce macrophage accumulation (Poon et al. 2001) and inhibit the release of several
inflammatory cytokines (Ribichini et al. 2007) after vascular injury in the rabbit.
Stent-mediated glucocorticoid release also reduced the macrophage content of
neointimal lesions in the pig (Wang et al. 2005). Therefore, glucocorticoids may
inhibit neointimal proliferation by suppressing the initial inflammatory response to
vascular injury that is crucial to the formation of neointimal lesions.
Glucocorticoids are also anti-proliferative, and decrease proliferation of vascular
lesion-derived smooth muscle cells in vitro (Longenecker et al. 1984; Berk et al.
1988; Voisard et al. 1994). Results from early studies indicated that high
concentrations of steroid are necessary to inhibit proliferation in vitro, and a more
recent study using concentrations comparable to those used in vivo failed to find an
anti-proliferative effect (Ribichini et al. 2007). However, the authors did report an
inhibition of VSMC migration at this concentration, another important process in
neointimal lesion formation. Therefore, glucocorticoids may suppress neointimal
proliferation through the inhibition of VSMC proliferation and migration. There is
also some evidence that glucocorticoids may suppress collagen synthesis (Krane &
Amento 1984), which would inhibit the ECM deposition and remodelling involved in
neointimal lesion development.
Whilst it is possible that steroids might affect more that one of the aforementioned
processes, it is likely that the most important mechanism of glucocorticoid-mediated
inhibition of neointimal lesion formation is the suppression of vascular inflammation
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after injury (Miller et al. 2001; Poon et al. 2001). Further experiments would be
required to investigate the effect of exogenous glucocorticoids on inflammation after
vascular injury in this model; for example by testing their ability to inhibit the
adhesion of radiolabeled leukocytes to injured arteries ex vivo (Kennedy et al.
2000b). Alternatively, injured arteries could be excised at a chosen time-point,
cultured in vitro with and without glucocorticoids, and cytokine levels in the culture
medium analysed (Ribichini et al. 2007). To determine if the in vivo proliferation of
VSMCs is altered in animals treated with glucocorticoid, immunohistochemical
staining for PCNA could be carried out. Alternatively, injection of the thymidine
analogue 5-bromo-2deoxyuridine (BrdU) would provide a nuclear marker of
proliferating cells in sections of injured arteries.
In addition to inhibiting neointimal proliferation, systemic dexamethasone
administration also promoted the formation of organized lesions with a thrombotic
origin. It has been proposed that neointimal lesions originate as organizing blood
clots that cover the luminal surface after arterial injury (Schwartz et al. 1992a). In
this model, an initial thrombotic stage occurs, in which platelets, fibrin and red blood
cells accumulate at the site of vascular injury. This is followed by a cellular
recruitment stage, during which the thrombus becomes re-endothelialised and
leukocytes infiltrate from the lumen. Finally, during the proliferative stage, VSMCs
form a cap on the luminal surface of the lesion and, through ECM secretion and
continuing recruitment, this cap progressively thickens. Thus, this model is based on
the idea that thrombus plays a fundamental role in neointimal formation, by
providing a scaffold into which VSMCs migrate and proliferate. It is possible that
dexamethasone inhibited recruitment of inflammatory cells, proliferation and/or
migration of smooth muscle cells into the intimal thrombus, resulting in the reduction
of fibrous neointimal lesions but the persistence of organizing thrombus generated by
vascular injury. However, evidence from development of the model of vascular
injury used in the current studies suggests that a thrombotic scaffold is not necessary
for neointimal lesion formation (chapter 3). Therefore, it seems unlikely that
systemic dexamethasone acted to inhibit lesion formation in this way.
There is also some evidence that glucocorticoids increase the thrombogenicity of
blood; in particular by increasing the expression of plasminogen activator inhibitor-1
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(PAI-1). PAI-1 is the principle protein involved in inhibiting fibrinolysis and,
therefore, an increase in its levels would be expected to impede the breakdown of
blood clots. Studies in vitro have shown that glucocorticoids cause an increase in
PAI-1 release (Fukumoto et al. 1992; Reinders et al. 1992; Halleux et al. 1999;
Morange et al. 1999), and there is also evidence that dexamethasone can augment
cytokine-stimulated PAI-1 release (He et al. 2000; Yamamoto et al. 2004).
Glucocorticoids increase PAI-1 in the rat (van Giezen & Jansen 1992; van Giezen et
al. 1994), whilst elevated circulating glucocorticoids in patients are associated with
increased PAI-1 levels and hyper-coagubility of the blood (Ikkala et al. 1985;
Patrassi et al. 1985; Patrassi et al. 1992; Sartori et al. 1999; Fatti et al. 2000; Sartori
et al. 2000; Udden et al. 2002). It is possible that in animals treated with systemic
dexamethasone the resolution of blood clots formed in response to vascular injury
was delayed, leading to inhibition of neointimal proliferation of smooth muscle cells
and alternative formation of organised thrombotic lesions. To examine whether this
mechanism was involved in the observed effects of dexamethasone, separate
investigations into the influence of glucocorticoids on the wide range of factors
involved in blood clotting, such as PAI-1, could be carried out in the mouse.
Comparing effects ofglucocorticoids on the vascular response to injury with other
animal studies
Previous animal studies have shown inhibition of neointimal proliferation following
glucocorticoid treatment (Villa et al. 1994; Van Put et al. 1995; Guzman et al. 1996;
Petrik et al. 1998; Strecker et al. 1998; Nagasaki et al. 2004; Pires et al. 2005; Wang
et al. 2005; Ribichini et al. 2007). However, these papers do not report the organised
thrombotic lesions seen with systemic dexamethasone treatment in these studies.
There may be several reasons for this. Firstly, the arteries in the current experiments
were not perfusion-fixed before collection, so any thrombus generated in response to
injury would remain in the vessel. In contrast, the majority of previous studies used
perfusion fixation under pressure, which is likely to have removed mural thrombi.
Secondly, no anti-coagulants were used in the current experiments, in order to avoid
effects related to administration of additional drugs, and due to the difficulty
associated with giving anti-coagulants to mice while controlling bleeding during
operational procedures. Therefore, thrombosis was allowed to take place. However,
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an anti-coagulation regime was applied in some previous animal studies, particularly
those using rabbits (Van Put et al. 1995; Ribichini et al. 2007), which may have
inhibited the formation of organised thrombotic lesions. A third source of variation
between previous studies is the type of vascular injury induced. Some studies used
models of perivascular injury (Van Put et al. 1995; Pires et al. 2005), where
thrombosis does not play a major role in the response to injury (Moroi et al. 1998).
Finally, differences in the type and dose of steroid administered, or the species used
may have contributed to variation in the thrombotic response. Therefore, the reason
that organised thrombus has not been reported previously may be that the methods
used for inducing and analysing neointimal proliferation after vascular injury exclude
or remove the formation of thrombus.
In the most comparable study to these experiments (Pires et al. 2005), the authors
administered dexamethasone both systemically and locally in mice, and studied its
effect on cuff-induced neointimal proliferation. Although they found that systemic
dexamethasone abolished neointimal lesion formation, as in the current investigation,
they did not report formation of organised thrombotic lesions. However, as
mentioned above, the cuff-induced model of vascular injury does not induce the
generation of thrombus in the artery lumen (Moroi et al. 1998), and so any effects of
systemic glucocorticoids on thrombosis would not be observed. The intra-luminal
method of injury used in the current investigations allows the action of
glucocorticoids on thrombosis after vascular injury to be studied, a process that is
important to the formation of neointimal lesions. In experiments where different
doses of dexamethasone were delivered locally from the cuff to the vessel wall, all
doses strongly reduced or abolished neointimal proliferation (Pires et al. 2005).
However, higher doses also produced a loss of vessel wall integrity and adverse toxic
effects on vascular cells, such as medial atrophy, apoptosis and loss of smooth
muscle cells. Such effects were not observed with systemic dexamethasone treatment
(Pires et al. 2005). Therefore, the authors concluded that although systemic
glucocorticoid administration may be associated with adverse side effects that can be
overcome by local application, this must be carried out in a relatively narrow
therapeutic window above which pathophysiological effects are observed (Pires et al.
2005). This is in contrast to the current studies, where no effects of locally-released
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Cortisol on vessel wall integrity or medial atrophy were obvious when compared with
contra-lateral controls. Again, this difference may be explained by the different
models used to induce vascular injury in the two studies, since wire-induced injury
itself causes vessel wall damage, medial atrophy and cellular apoptosis.
Consequently, any additional effect of locally-released glucocorticoid on these
factors may have been masked.
Clinical significance ofobservations
In the current studies, systemic dexamethasone treatment failed to decrease luminal
narrowing after vascular injury, due to the formation of organised thrombotic lesions.
This is interesting, as it may go some way to explaining the disappointing results of
early clinical trials using systemic glucocorticoids to treat restenosis (Stone et al.
1989; Pepine et al. 1990; Rab et al. 1991; Lee et al. 1999). It is possible that any
beneficial effect of steroids on restenosis in these studies was masked by the
generation of organised thrombus. The quantification of these thrombotic lesions
during angiography could account for the lack of improvement in angiographic
outcome. However, it is important to note that although reduced restenosis may have
been concealed in these studies, glucocorticoids did not improve the functional
end-point of lumen loss, which restricts blood flow to the myocardium. The lack of a
reduction in luminal narrowing in the clinical studies could also be explained by the
association between systemic glucocorticoid excess and cardiovascular risk.
Increased blood pressure, endothelial dysfunction (Mangos et al. 2000) and the risk
of coronary aneurysms (Rab et al. 1991) caused by increases in circulating
glucocorticoids could all be detrimental, causing vasospasm or altered wall healing
after coronary intervention.
The failure of clinical trials using intravenous single pulse pre-treatment or short
term glucocorticoid administration was attributed to non-lasting and insufficient local
effects of steroids (Stone et al. 1989; Pepine et al. 1990; Rab et al. 1991; Lee et al.
1999). However, prolonged treatment with systemic prednisolone did have a
beneficial effect on restenosis (Versaci et al. 2002), and the most recent evidence
indicates that the use of dexamethasone-eluting stents is associated with an
improvement in clinical and angiographic outcomes after coronary intervention (Han
et al. 2006; Konig et al. 2007). Therefore, it seems that prolonged application of
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steroids at the vessel wall represents the most promising way to administer
glucocorticoids for the treatment restenosis. This concept is supported by the results
of experiments using locally-released Cortisol reported here.
Conclusions
These studies have indicated that, whilst glucocorticoid administration inhibits
neointimal proliferation after vascular injury, systemic administration of
dexamethasone is associated with adverse side-effects and the formation of organised
thrombus. Local application of Cortisol at the vessel wall is more beneficial, as it
reduces luminal narrowing after injury and has no associated systemic effects. These
results suggest a balance exists between the beneficial actions of glucocorticoids on
the vascular response to injury when they are acting locally at the vessel wall, and
the adverse effects of increased systemic glucocorticoids on cardiovascular risk
factors such as hypertension, obesity, impaired glucose tolerance and increased
plasma lipid levels. This supports the concept that local application of
glucocorticoids is more favourable than systemic administration in humans. The
availability of drug-eluting stents allows the local application of steroids in clinical
practice, and avoids the undesirable side-effects of oral steroid treatment mentioned
above, which would exacerbate conditions such as diabetes or heart failure.
However, there are also advantages of oral therapy over drug-eluting stents, such as
low cost and the avoidance of long-term anti-platelet therapy after coronary
interventions. In addition, concerns that drug-eluting stents may delay long term
healing of the vessel wall and increase the risk of late stent thrombosis should be
taken into account in future studies.
The successful application of exogenous steroids at the vessel wall as treatment for
neointimal lesion formation raises the possibility that endogenous glucocorticoids
may influence the vascular response to injury. Inhibition of systemic lip-HSDl
activity is currently being developed as a therapeutic strategy to reduce
cardiovascular risk factors. However, the role that modulation of endogenous
glucocorticoid activity by 1 lp-HSDl within the artery wall plays in neointimal




Influence of endogenous glucocorticoids on the vascular
response to injury in the mouse
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5.1 Introduction
The work described in the previous chapter confirmed that glucocorticoid
administration inhibits neointimal lesion formation, and can reduce the vascular
response to injury when carried out locally at the vessel wall. This highlights a
potential role for endogenous glucocorticoid hormones in the regulation of
neointimal proliferation. Glucocorticoid levels are regulated both systemically, by
the HPA axis (chapter 1.2.2.1), and at a local tissue level, by the 1 1 P-HSD enzymes
(chapter 1.2.3.1). Surprisingly, the effect of endogenous glucocorticoids on
neointimal proliferation after vascular injury has not been investigated previously.
Several lines of evidence suggest that endogenous glucocorticoids may act to
influence vascular remodelling (Hadoke et al. 2006). Increased systemic
glucocorticoid concentrations in Cushing's syndrome are associated with a higher
risk of developing atherosclerotic lesions (Colao et al. 1999; Faggiano et al. 2003).
Detection of expression (Walker et al. 1991; Christy et al. 2003) and activity (Small
et al. 2005) of the 11 P-HSD enzymes in the vascular wall suggests that endogenous
glucocorticoid regeneration occurs locally within this tissue. Indeed, local generation
of endogenous glucocorticoids by 11 P-HSD 1 has been shown to modulate
angiogenesis after myocardial infarction in mice (Small et al. 2005). Furthermore,
the suggestion that local inflammation in the vessel wall, a critical process in
neointimal lesion formation, up-regulates 11 P-HSD 1 activity (Cai et al. 2001)
indicates that a negative feedback loop for the control of inflammation via
glucocorticoid generation may exist at this site. However, studies in intact vessels
(Dover et al. 2007), and wire-injured femoral arteries (chapter 3.2.5) have failed to
confirm this idea.
Although the effect of 11P-HSD on the formation of neointimal lesions after acute
injury has not been investigated, the influence of 11 P-HSD 1 activity on
atherosclerotic vascular lesions has been addressed recently. Selective inhibition of
this enzyme was found to prevent the progression of atherosclerosis in ApoE
knockout mice (Hermanowski-Vosatka et al. 2005). In addition, non-specific
inhibition of 11 P-HSD activity with carbenoxolone decreased atherosclerotic lesion
formation in the hyperlipidemic and hyperphagic Agouti protein over-expressing/
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LDL receptor knockout mouse (Nuotio-Antar et al. 2007). Therefore, these studies
indicate that generation of endogenous glucocorticoids by 11(3-HSD1 increases
atherosclerotic lesion formation. However, what remains unclear from these studies
is the mechanism by which 11(3-HSD1 activity influences atherogenesis, and whether
it is via systemic actions on factors such as plasma lipid levels or blood pressure
(mediated by inhibition of 1 lp-HSDl in e.g. liver or adipose tissue), or caused by a
local effect on the cells of the vascular wall.
To begin to explore the influence of endogenous glucocorticoids on neointimal
proliferation during the vascular response to injury, it was hypothesised that the local
generation of these hormones by 1 lp-HSDl would inhibit neointimal lesion
development in the mouse model of vascular injury. This was based on previous
observations that locally-applied exogenous glucocorticoids decrease neointimal
lesion formation in this model, which primarily involves the cells of the vessel wall
and lumen. With this in mind, the specific aims of this chapter were:
(i) To determine whether endogenous glucocorticoids decrease neointimal lesion
formation via local administration of a GR antagonist to oppose this effect.
(ii) To assess if the abolition of 1 lp-HSDl activity increases neointimal proliferation




Male C57B16 (Harlan Olac, U.K.) and 1 lp-HSDl"7" (bred in-house at the Biomedical
Research Facility, Little France, Edinburgh, U.K.) mice weighing 25-35 grams were
used in all studies. Genetic inactivation of lip-HSDl has been described previously
on an MF-1/129 background (Kotelevtsev et al, 1997); for the current experiments
mice were backcrossed onto a C57B16 background over more than 10 generations
(Morton et al, 2004). To allow collection of trunk blood, animals were killed by
decapitation, according to Home Office guidelines.
5.2.2 Femoral artery injury
In experiments investigating the influence of the GR antagonist RU38486 on the
vascular response to injury, wire-induced intra-luminal vascular injury (chapter
2.3.1) was carried out both in the left and the right femoral arteries. In studies
assessing the impact of endogenous glucocorticoid regeneration, 1 lp-HSDl7" mice
and C57B16 controls (n= 8 per group) underwent wire-induced injury of the left
femoral artery, and ligation-induced injury of the right femoral artery (chapter 2.3.2).
Similarly, animals treated with lip-HSDl inhibitor or vehicle underwent
wire-induced injury of the left femoral artery, and ligation-induced injury of the right
femoral artery.
5.2.3 Administration of drugs
5.2.3.1 Locally-released glucocorticoid receptor antagonist
To assess the action of GR antagonism on neointimal proliferation, silastic pellets
(chapter 2.4.2) were placed next to the femoral artery after wire-induced injury.
Pellets were inserted into a pocket created at the operation site and kept in place
when the skin incision was closed with sutures at the end of the operation. During
bilateral, wire-induced injury a pellet containing RU38486 was implanted in one leg,
and a vehicle pellet (silastic elastomer only) was implanted in the other leg (n= 8).
RU38486 or vehicle pellets were implanted randomly in either the right or the left
leg. Each 10 mg pellet contained 3.3 mg RU38486 (33% w/w). Results were also
compared with the additional control group previously described in chapter 4, in
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which animals underwent bilateral femoral artery injury, and vehicle pellets were
placed in both legs (n= 8).
5.2.3.2 Systemically-administered 11|3-HSD1 inhibitor
To investigate the effect of systemic pharmacological inhibition of lip-HSDl on
neointimal proliferation, mice were dosed with 30mg/kg of a selective inhibitor
(compound 815 (Hermanowski-Vosatka et al. 2005)) twice daily by oral gavage
(chapter 2.4.3). A group of control animals received vehicle alone (5% cyclodextrin);
n= 7 per group. Gavaging was performed by staff at the Biomedical Research
Facility, Little France, Edinburgh, U.K. Loading doses were given one day before
surgery, and dosing was then continued in the morning and afternoon for every day
of the experiment. Body weight was recorded each day.
5.2.4 Tissue collection
Tissues from the RU38486 experiment were collected 21 days following surgery, as
this experiment was carried out in parallel with experiments using cortisol-releasing
pellets (chapter 4). Tissues were collected 28 days after surgery from 1 lp-HSDl '"
mice to ensure that advanced neointimal lesions had developed which could be
quantified. In the experiment in which animals were treated with lip-HSDl
inhibitor, tissues were collected after 14 days so that an effect on neointimal lesion
size in either direction could be discerned. However, thrombotic involvement and the
small and cellular nature of lesions at this time-point made interpretation of sections
and accurate measurement of lesion size difficult.
At the end of all experiments mice were weighed for a final time, and then trunk
blood was collected into heparinised tubes on wet ice. Blood samples were
centrifuged at 3000 rpm for 5 minutes, and the plasma (supernatant) was removed
into fresh eppendorf tubes. Organs (adrenals, thymus, spleen, kidneys, heart and
liver) were removed, cleaned of connective tissue and weighed. Plasma and organs
were then snap frozen on dry ice and stored at -80°C.
Left and right femoral arteries were cleaned of connective tissue and veins, and
excised from the bifurcation of the iliac artery to the branch with the popliteal artery.
Femoral arteries were immediately placed in 10% neutral buffered formalin, fixed
for up to 24 hours and then stored in 70% ethanol if necessary. The arteries were
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dehydrated in a graded alcohol series, embedded in paraffin and cut into transverse
sections: sets of eight 4 pm serial sections were taken at 100 pm intervals along the
entire arterial segment.
5.2.5 Measurement of neointimal proliferation
To assess the extent of neointimal proliferation in these experiments, transverse
sections every 100 pm along injured arteries were stained with the United States
trichrome histological stain (chapter 2.6.2). The area (pm ) of neointima in each
section was measured using a light microscope coupled to a colour camera and image
analysis system (chapter 2.7). The section with the largest area of neointima was
chosen to represent each arterial sample. All analyses were performed with the
investigator blinded as to which group the sample belonged to.
5.2.6 Plasma corticosterone levels
Corticosterone levels in plasma from mice implanted with a unilateral RU38486
pellet and contra-lateral vehicle control, and mice implanted with bilateral vehicle
pellets, were analysed using radioimmunoassay (n= 8 per group; chapter 2.11.2).
5.2.7 Genotype analysis by polymerase chain reactions
lip-HSDl"7" mice used in these studies were kindly provided by Dr. M. Holmes.
Animals were bred in an established colony (Biomedical Research Facility, Little
France, Edinburgh, U.K.) by crossing 11P-HSDU " parents. C57B16 controls were
obtained from Harlan Olac, U.K. PCR were carried out to confirm the genotype of
the male offspring used in these studies (chapter 2.12).
5.2.8 Effect of enzyme inhibitor on 11P-HSD1 activity
The effect of systemic administration of an lip-HSDl inhibitor on enzyme activity
was assessed in liver microsomes (chapter 2.10.4). Activity was measured in the
t o o
dehydrogenase direction, with conversion of [ H] corticosterone to [ H]
11-dehydrocorticosterone determined by HPLC (chapter 2.10.5).
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5.3 Results
5.3.1 Effect of RU38486 pellet implantation on animals
When mice implanted with a unilateral RU38486 pellet were compared with those
implanted with bilateral vehicle pellets, there was no difference in body weight
between groups at the start or the end of the experiment (Figure 5.1). Similarly, there
were no significant differences in the weight of organs known to change in size in
response to glucocorticoids (adrenal glands, thymus and spleen; Figure 5.2), or other
organs (heart, kidneys and liver; data not shown), between the two groups at the end
of the experiment.
Plasma corticosterone levels were not significantly different between mice implanted
with an RU38486 pellet and those implanted with bilateral vehicle pellets, despite a
trend (p= 0.16) towards reduced corticosterone levels in the group receiving
RU38486 (Figure 5.3a). Plasma collections were not always performed at the same
time of day, due to practical constraints. To take diurnal variation of corticosterone
levels into account, plasma samples collected in the morning were compared. This
sub-division demonstrated that it was at this time of the day that a trend (p= 0.081)
towards lower corticosterone levels occurred in mice implanted with an RU38486
pellet (Figure 5.3b). In contrast, this effect of RU38486 was not seen in plasma
samples collected in the afternoon (Figure 5.3c, p= 0.45).
5.3.2 Influence of GR antagonism on neointimal proliferation
Femoral arteries were analysed from the group ofmice (n= 8) receiving an RU38486
pellet and a contra-lateral vehicle pellet following bilateral wire-induced injury.
Some damage to the artery wall was caused by intra-luminal wire injury in this
experiment, which took the form of breaks or stripping of the IEL. This was usually
located near to the branch of the popliteal artery, where the wire is inserted.
However, the damage was not sufficient to cause severe or occlusive thrombosis, and
occurred to a similar extent in arteries treated with RU38486 and vehicle pellets,
allowing the two groups to be compared.
Extensive fibrous neointimal lesions developed in arteries treated with RU38486 and
in contra-lateral vehicle controls (Figure 5.4a and b). Neointimal lesions also
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Figure 5.1: Effect of RU38486-releasing pellet on weight change over 21
days after femoral artery injury
Following bilateral, wire-induced femoral artery injury, mice received either bilateral vehicle
pellets (vehicle), or a unilateral RU38486 pellet plus contra-lateral vehicle control (RU38486).
The weights of animals at the start and the end of the experiment were compared. There
was no significant difference in weight between the groups at either time-point. Data are
mean ± S.E.M, n= 8 per group. Analysed by one way ANOVA.
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Figure 5.2: Influence of RU38486 administration on organ weights
Following bilateral, wire-induced femoral artery injury, mice received either bilateral vehicle
pellets (vehicle), or a unilateral RU38486 pellet and contra-lateral vehicle control (RU38486).
The weight of the adrenal glands, thymus and spleen were calculated as a percentage of
total body weight in each animal at the end of the experiment. Despite a trend (p= 0.091)
towards decreased thymus weight in animals treated with RU38486, there was no significant
difference in any organ weight between the groups. Data are mean ± S.E.M, n= 8 per group.
Analysed by unpaired t test: ns, not significant.
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Figure 5.3: Plasma corticosterone levels in mice implanted with an
RU38486-releasing pellet
Following bilateral, wire-induced femoral artery injury, mice received either bilateral vehicle
pellets (vehicle), or a unilateral RU38486 pellet and contra-lateral vehicle control (RU38486)
for 21 days. Plasma corticosterone levels were measured by radioimmunoassay at the end
of the experiment. There was no difference (p= 0.16) in corticosterone levels when all mice
in each group were compared (a). However, samples collected in the morning showed a
trend (p=0.081) towards lower corticosterone in animals treated with RU38486 (b), while
there was no difference (p= 0.45) in samples collected in the afternoon (c). Data are
mean ± S.E.M, n= 8 per group for (a), n= 3 for (b) and n= 5 for (c). Analysed by unpaired t
test (with Welch's correction in (b)): ns, not significant.
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Contra-lateral vehicle RU38486 Bilateral vehicle
Figure 5.4: Influence of the GR antagonist RU38486 on neointimal
proliferation in the mouse femoral artery
Transverse sections of wire-injured femoral arteries stained with the United States trichrome
stain from mice implanted with a contra-lateral vehicle control pellet (a) and unilateral
RU38486 pellet (b), and from a separate group of mice with bilateral vehicle pellets (c).
Extensive neointimal lesions developed in all groups, 21 days after injury.
Scale bar = 100 pm.
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developed in wire-injured arteries from the group of animals that received bilateral
vehicle pellets (Figure 5.4c). When neointimal area was quantified, a trend towards
increased lesion size in arteries treated with RU38486 was not significant when
compared with contra-lateral vehicle controls (Figure 5.5, p> 0.05). There was also
no difference in neointimal proliferation between contra-lateral vehicle control
arteries, and those from separate mice with bilateral vehicle pellets
(Figure 5.5, p> 0.05).
The failure of the trend towards increased neointimal lesion area in arteries treated
with RU38486 to reach significance suggested that the experiment may have been
under-powered. This was addressed by calculating power using the data generated
and appropriate software (GraphPad StatMate v.2.00). Calculations demonstrated
• • 9 S
that the experiment would detect the observed difference (0.24 pm x 10 ) with only
30% power. However, to detect this difference with 90% power would have required
an increase in numbers to n= 60 per group; this was highly impractical due to
practical and time constraints. Furthermore, if a statistically significant result was
documented in this way, the magnitude of difference in means is of dubious
biological significance, and so arguably it would not be an ethically justified
experiment.
5.3.3 Neointimal proliferation in 11p-HSD1"/"mice
Genotype analysis by PCR confirmed that mice used in these studies were
homozygous null for 11|3-HSD1 (Figure 5.6). lip-HSDl"7" and C57B16 control mice
underwent wire-induced injury of the left femoral artery, and ligation-induced injury
of the right femoral artery (n= 8 per group). Again, some damage to the artery wall
was caused by intra-luminal wire injury in both groups; however, the damage was
not sufficient to prevent the growth of fibrous neointimal lesions and occurred to a
similar extent in both groups. In addition, breaks in the IEL were caused by




Figure 5.5: Influence of local GR antagonism with RU38486 on neointimal
lesion development following femoral artery injury
Neointimal area was quantified by image analysis, in wire-injured arteries from mice treated
with a vehicle control pellet in one leg (contra-lateral vehicle) and an RU38486 pellet in the
other leg (RU38486). Neointimal area was also quantified in a separate group of mice
implanted with bilateral vehicle pellets (bilateral vehicle). The presence of an RU38486 pellet
caused a trend towards increased neointimal area compared with contra-lateral vehicle
controls that did not reach significance, 21 days after femoral artery injury. There was also
no difference in neointimal area between contra-lateral vehicle control arteries, and those
from separate mice implanted with bilateral vehicle pellets. Data are mean ± S.E.M, n= 8 per
group. Analysed by one way ANOVA: ns, not significant.
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Figure 5.6: Genotyping of 1ip-HSD1"/_ and C57BI6 mice by polymerase chain
reactions
Genomic DNA isolated from C57BI6 (C57) and 11P-HSD1"'" (KO) mice was used in
polymerase chain reactions with specific primers to detect either the 11P-HSD1 wild type
allele (1.7Kbp) or the transgenic 11P-HSD1 allele with integrated targeting vector (1.4Kbp).
Gel electrophoresis confirmed that only transgenic alleles were detected in the group of
11P-HSD1"'" mice, confirming their genotype as homozygous null for 11P-HSD1.
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Wire-induced femoral artery injury induced the development of fibrous neointimal
lesions in lip-HSDl"7" mice and C57B16 controls (Figures 5.7a and b). A trend
towards increased neointimal lesion area 28 days after surgery in lip-HSDl7" mice
did not reach significance (Figure 5.8a, p= 0.26).
Ligation-induced femoral artery injury also produced the development of fibrous
neointimal lesions in lip-HSDl"7" mice and C57B16 controls (Figures 5.7c and d),
although these lesions were smaller than those induced by wire injury (Figure 5.8).
There was no significant difference in neointimal lesion area induced by ligation
between 1 lp-HSDl"7" mice and controls (Figure 5.8b, p= 0.77).
Again, the trend towards increased neointimal lesion area in 1 ip-HSD1" mice after
wire-induced injury was investigated further by carrying out power calculations. This
demonstrated that the experiment would detect the difference in means between
1 lP-HSDl"7" and wild type mice (0.21 pm2 x 105) with only 20% power. In order to
detect this difference with adequate power (90%) the sample size would have to be
increased to n= 70 per group. Due to practical and time constraints it was not feasible
to increase group size by this extent and, as for experiments with RU38486, the
biological relevance of the magnitude of difference in means is questionable.
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C57BI6 11B- HSD1"/_
Figure 5.7: Neointimal proliferation after wire- or ligation-induced vascular
injury in 11P-HSD1"7" and C57BI6 mice
Transverse sections of femoral arteries stained with the United States trichrome stain.
Fibrous neointimal lesions developed 28 days after wire-induced injury in C57BI6 (a) and
11p-HSD1 + mice (b). Neointimal proliferation also occurred in the femoral artery 28 days
after ligation of the popliteal artery in C57BI6 (c) and 11P-HSD1"'" mice (d).





Figure 5.8: Comparison of neointimal lesion area in C57BI6 and 11P-HSD1"7"
mice
Neointimal area was quantified by image analysis in arteries from C57BI6 and Hp-HSDI"'"
mice 28 days after wire-induced (a) or ligation-induced injury (b). Although there was a trend
(p= 0.26) towards increased lesion area in Hp-HSDI"'" mice after wire-induced injury, there
was no significant difference in the size of neointimal lesions induced by either type of injury
between the groups (p= 0.77 for ligation injury). Wire injury caused the growth of larger
neointimal lesions than ligation injury. Data are mean ± S.E.M, n= 8 per group. Analysed by
unpaired t test: ns, not significant.
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5.3.4 Effects of 11P-HSD1 inhibitor administration on mice
As an extension of studies in 1 lp-HSDT7" mice, a group of animals were given a
selective lip-HSDl inhibitor. In these preliminary experiments, systemic
administration of lip-HSDl inhibitor or vehicle by oral gavage twice a day had
obvious adverse effects on the animals. Mice in both groups became smaller and
thinner during the study, and were less active. There was no difference in weight
between the groups at the start of the experiment (Figure 5.9). A comparison of body
weight during the experiment showed that mice in both groups lost weight initially
after surgery, but then failed to re-gain weight over the course of the experiment.
There was no difference in weight change between animals administered vehicle and
those given llp-HSDl inhibitor (Figure 5.9). There were no differences in the
weight of the adrenal glands, thymus and spleen (Figure 5.10) or other organs (data
not shown) after treatment with the 1 lp-HSDl inhibitor.
To assess the action of the 1 lp-HSDl inhibitor on enzyme activity, the conversion of
[3H] corticosterone to [3H] 11-dehydrocorticosterone was measured in a preparation
of liver microsomes. There was no significant difference in dehydrogenase reaction
velocity between animals treated with lip-HSDl inhibitor and those treated with





Figure 5.9: Weight change in animals during administration of 11P-HSD1
inhibitor by oral gavage
Mice received 30mg/kg 11 (3-HSD1 inhibitor or vehicle by oral gavage, twice a day for 14
days after bilateral femoral artery injury. There was no difference in weight change between
animals administered 11P-HSD1 inhibitor and those that received vehicle. However, both
groups of animals showed a significant failure to gain weight over the duration of the study
(p< 0.001). Data are mean ± S.E.M, n= 7 per group. Analysed by two way ANOVA.
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Figure 5.10: Effect of 11|3-HSD1 inhibitor on organ weights
Following bilateral femoral artery injury, mice received either 30mg/kg 11p-HSD1 inhibitor or
vehicle by oral gavage for 14 days. The weight of the adrenal glands, thymus and spleen
were calculated as a percentage of total body weight in each animal at the end of the
experiment. There was no significant difference in adrenal (p= 0.22), thymus (p= 0.55) or
spleen (p= 0.61) weights between the groups. Data are mean ± S.E.M, n= 7 per group.

















Figure 5.11: Enzyme activity after administration of 11 (3-HSD1 inhibitor
Mice received 30mg/kg 11 (3-HSD1 inhibitor or vehicle twice daily by oral gavage, for 14 days
after bilateral femoral artery injury. 11P-HSD1 activity was measured in the dehydrogenase
direction in liver microsome preparations. There was no significant difference in enzyme
activity between mice administered 11P-HSD1 inhibitor and those given vehicle alone




5.3.5 Influence of 11P-HSD1"'" inhibition on neointimal proliferation
Mice treated with lip-HSDl inhibitor or vehicle underwent wire-induced injury of
the left femoral artery, and ligation-induced injury of the right femoral artery (n= 7
per group). In both groups a similar extent of damage to the artery wall was caused
by intra-luminal wire injury. In addition, breaks in the IEL were caused by
ligation-induced injury in 4/14 animals.
Wire-induced femoral artery injury stimulated the development of small cellular
neointimal lesions in mice treated with lip-HSDl inhibitor and in vehicle-treated
controls (Figures 5.12a and b). Fourteen days after injury there was a trend (p= 0.15)
towards a decrease in neointimal lesion area after wire-induced injury in mice treated
with enzyme inhibitor when compared with vehicle-treated controls (Figure 5.13a)
but this did not reach significance.
Ligation of the popliteal artery produced small neointimal lesions in mice treated
with lip-HSDl inhibitor and vehicle treated controls (Figures 5.12c and d); these
lesions were smaller than those induced by wire injury (Figure 5.13). Again, there
was a trend (p= 0.13) towards a decrease in neointimal lesion area induced by
ligation in mice treated with enzyme inhibitor when compared to vehicle-treated
controls (Figure 5.13b) which did not reach significance.
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Vehicle HSD1 Inhibitor
Figure 5.12: Neointimal proliferation after wire- or ligation-induced vascular
injury in mice administered systemic 11|3-HSD1 inhibitor or vehicle
Transverse sections of femoral arteries stained with the United States trichrome stain. Small
cellular neointimal lesions developed 14 days after wire-induced injury in vehicle controls (a)
and mice treated with 11 (3-HSD1 inhibitor (b). Neointimal proliferation also occurred in the
femoral artery 14 days after ligation of the popliteal artery in vehicle controls (c) and mice





Figure 5.13: Effect of 11 (3-HSD1 inhibition on neointimal lesion area in the
mouse femoral artery
Neointimal area was quantified by image analysis in wire-injured arteries from vehicle
controls and mice treated with 11P-HSD1 inhibitor (a), and after ligation-induced injury in
vehicle controls and mice treated with 11P-HSD1 inhibitor (b). After 14 days, there was no
significant difference in the size of neointimal lesions induced by either type of injury
between the groups, although there was a trend (p= 0.15 for wire injury, p= 0.13 for ligation
injury) towards decreased lesion area in mice treated with enzyme inhibitor. Wire injury
caused the growth of larger neointimal lesions than ligation injury. Data are mean ± S.E.M,
n= 7 per group. Analysed by unpaired t test: ns, not significant.
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5.4 Discussion
The experiments described in this chapter suggested that endogenous glucocorticoid
action has only a small, if any, effect on neointimal proliferation after intra-luminal
injury of the mouse femoral artery. However, there were trends for effects on lesion
size which, if confirmed in further experiments, might imply a role for endogenous
glucocorticoids which was beyond the limit of detection for these studies. There are
also a number ofmethodological concerns to address.
Effects ofantagonising endogenous glucocorticoid action
The GR antagonist RU38486 was applied via release from silastic pellets at a
concentration of 33% w/w. This approach has been used previously to successfully
alter angiogenesis in sub-cutaneous sponges (Small et al. 2005), indicating that
biologically active concentrations of the drug are released from the pellet and do not
exert systemic effects. The time-scale of the current experiment was 21 days; silastic
pellets have been shown to release steroids at a constant rate in vivo for at least three
weeks (Soro et al. 1997; Small et al. 2005). In the current study, pellets were placed
next to the vessel wall, with the aim of administering RU38486 locally, thus avoiding
systemic side effects. The observation that there was no difference in body weight or
organ weights between animals implanted with a unilateral RU38486 pellet when
compared to those implanted with bilateral vehicle pellets, indicates that RU38486
was being administered locally at the vessel wall without having systemic actions in
the animals. This is supported by the fact that there was no difference in neointimal
lesion area between contra-lateral vehicle control arteries and injured arteries from
separate mice implanted with bilateral vehicle pellets, confirming that RU38486 did
not have any systemic effects on neointimal proliferation.
If RU38486 were to act systemically, it would be expected to activate the HPA axis
via central antagonism of GR and so increase corticosterone secretion. Indeed,
clinical use of RU38486 increases plasma glucocorticoids in this way (Byrne et al.
2004), and RU38486 has also been shown to increase plasma corticosterone in
animal studies (Wade et al. 1988). The fact that there was no significant difference in
plasma corticosterone levels between the groups in the current experiment indicates
that RU38486 did not have central actions on feedback to the HPA axis. However,
morning corticosterone measurements in mice treated with RU38486 showed a trend
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towards a decrease, suggesting some systemic effects. This decrease in
corticosterone may be explained by reports that RU38486 inhibits steroidogenic
enzymes in the adrenal gland to reduce steroid production (Albertson et al. 1994), or
by a study showing that RU38486 may impair plasma corticosterone rises in
response to repeated stress (Moldow et al. 2005). Alternatively, the trend towards
decreased corticosterone may have been caused by local actions of RU38486, via
antagonism of GR-mediated inflammatory cell signalling within the artery wall and,
hence, inhibition of cytokine-mediated neuroendocrine activation of the HPA axis
(reviewed in (Eskandari et al. 2003)) and attenuation of the stress response.
Interestingly, the use of RU38486-releasing silastic pellets in mice significantly
decreased plasma corticosterone in previous studies on angiogenesis (Small et al.
unpublished observations).
In the models used in this chapter, neointimal proliferation occurs in response to an
acute, localised injury to the vessel wall. It was proposed, therefore, that endogenous
glucocorticoid activity within the artery wall would inhibit neointimal proliferation
by reducing inflammation, proliferation and migration. Thus, local GR antagonism
would be expected to increase neointimal lesion size. The demonstration that
RU38486 produced a non-significant trend towards increased lesion size suggests
that if endogenous glucocorticoids do play a role during this response, it is not
extensive. However, the small increase seen may become physiologically significant
in combination with other risk factors (such as hyperlipidemia or hypertension). A
major limitation of the study was the inability to confirm that RU38486 was actually
antagonising GR within the vascular wall. Although the trend towards decreased
morning corticosterone levels (see above) indicates that RU38486 was active, this
was not significant and it is not clear whether it was due to systemic or local effects
of the antagonist. In the absence of an effect on lesion development, it is difficult to
suggest appropriate positive controls for local administration and it is worth
emphasising that use of this type of administration has been successful previously
(Small et al. 2005).
RU38486 is also a progesterone receptor antagonist (Yamamoto et al. 1994).
Progesterone attenuates the inhibitory effect of estrogens on neointimal proliferation
of smooth muscle cells in the rabbit (Hanke et al. 1996) and the rat (Levine et al.
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1996). However, it is unlikely that antagonism of progesterone receptors had any
effects in the current study as male mice were used, which have only very low
progesterone levels.
The current experiment investigated GR-mediated actions of endogenous
glucocorticoids, and did not assess the possible influence of these hormones on
neointimal proliferation via MR. Expression of MR has been detected in blood
vessels (Takeda et al. 1997), localised to vascular smooth muscle and endothelial
cells (Lombes et al. 1992). Its natural ligand, aldosterone, can be synthesised by
vascular smooth muscle and endothelial cells (Hatakeyama et al. 1994; Takeda et al.
1996), and is known to be a positive regulator of vascular remodelling. Aldosterone
enhances angiotensin II-induced VSMC proliferation (Ullian et al. 1993;
Hatakeyama et al. 1994; Xiao et al. 2004) and has also been shown to increase
vascular inflammation in the rat coronary artery (Rocha et al. 2002). In line with this,
administration of aldosterone increased neointimal area 28 days after angioplasty of
the pig coronary artery (Ward et al. 2001), whilst high plasma aldosterone levels in
patients correlate with restenosis 6 months after coronary stent implantation (Amano
et al. 2006). The MR antagonist eplerenone reduced neointimal formation after
angioplasty (Ward et al. 2001) and stenting (Wakabayashi et al. 2006) in pig
coronary arteries. Therefore, an alternative possibility is that endogenous
glucocorticoids act through MR to influence neointimal proliferation. If so, it is
likely that they would increase neointimal lesion formation, and that antagonism of
MR would decrease lesion area. To further investigate this hypothesis, separate
experiments administering eplerenone after wire-induced femoral artery injury in the
mouse could be carried out.
Attenuation of endogenous glucocorticoid regeneration by transgenic deletion of
1 lf-HSDl
llp-HSDl"7" mice were studied to determine whether the abolition of endogenous
glucocorticoid generation by 11 P-HSD1 increases neointimal proliferation. It has
been shown previously that 11 P-HSDl"7" mice lack reductase activity in vivo, and fail
to convert inert 11-dehydrocorticosterone to corticosterone (Kotelevtsev et al. 1997).
These mice are resistant to the development of metabolic syndrome; they resist
hyperglycemia induced by obesity or stress (Kotelevtsev et al. 1997), have a
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cardio-protective lipid profile (Morton et al. 2001) and do not gain weight on a high
fat diet (Morton et al. 2004).
A role for 11J3-HSD1 in atherosclerotic lesion development has been indicated by the
demonstration that a selective inhibitor of this enzyme decreases aortic lipid
incorporation in atherosclerotic (ApoE"7") mice (Hermanowski-Vosatka et al. 2005).
This work suggested that the observed decrease in atherogenesis was not solely the
result of changes in plasma lipids, and implied a direct effect of enzyme inhibition on
the arterial wall. However, it is unclear how lip-HSDl inhibition within the
vasculature would protect against lesion development and, indeed, this hypothesis
directly opposes the one proposed in the present studies. The trend towards increased
neointimal lesion size in 1 lp-HSDl"7" mice observed in the current investigations was
more consistent with the proposal that reduction of glucocorticoid action in the
vessel wall would promote lesion development. It is possible that the time-point
chosen to analyse lesion area in 1 lp-HSDl"7" mice (28 days after injury) was too late
to observe any significant difference from C57B16 controls. However, since the goal
of pharmacological manipulations is to reduce chronic arterial occlusion, the clinical
benefit of a treatment that reduced lesion size early during development, but had no
effect on final outcome, would be questionable. It is notable, however, that the data
obtained in 1 lp-HSDl"7" mice are broadly consistent to those obtained with those for
RU38486 and suggest, at best, a limited role for endogenous glucocorticoids in the
regulation of neointimal lesion size.
Given the demonstrable ability of glucocorticoids to inhibit lesion development
(chapter 4), and the observation that endogenous glucocorticoids regulate angiogenic
remodelling of blood vessels (Small et al. 2005), it seems surprising that
glucocorticoids do not influence neointimal lesion development. There are several
possible explanations for the lack of significant effect of lip-HSDl deletion on
neointimal proliferation in the current experiments. Although glucocorticoids inhibit
proliferation of VSMCs in vitro, they also have actions that may increase the
proliferation of these cells. For example, dexamethasone can cause up-regulation of
endothelin-1 expression (Morin et al. 1998), a positive regulator of cell growth, and
Cortisol decreases the activity of NO (Mangos et al. 2000), a potent inhibitor of
cellular proliferation. Dexamethasone and hydrocortisone have also been shown to
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increase ACE activity in vascular cells (Mendelsohn et al. 1982; Fishel et al. 1995),
which would enhance local generation of angiotensin II, and so stimulate VSMC
proliferation. Therefore, although glucocorticoids inhibit proliferation in vitro, it is
possible that in an in vivo setting they also act to stimulate this process. Thus,
inhibiting their regeneration by transgenic deletion of lip-HSDl would decrease
neointimal lesion area by this mechanism, counteracting any increase caused by
reduced anti-inflammatory effects of endogenous glucocorticoids.
Currently, the influence of vascular lip-HSDl on the regulation of intra-vascular
glucocorticoid levels in vivo is not clear. It is possible that, although pharmacological
concentrations of glucocorticoids can influence neointimal proliferation, changes in
endogenous glucocorticoid regeneration by lip-HSDl within the vascular wall are
not sufficient to alter neointimal lesion development. Since previous experiments
have shown that local application of glucocorticoids at the vessel wall is most
beneficial for the reduction of neointimal proliferation (chapter 4), focussing on the
function of lip-HSDl in the vasculature is an important next step. To dissect the
role of local regeneration of endogenous glucocorticoids by lip-HSDl within the
arterial wall, an enzyme inhibitor could be applied at this site via release from an
implanted pellet. However, difficulties may be encountered in confirming inhibition
of enzyme activity using this method. In the future, further development of an in
vitro model of neointimal proliferation would be useful for this purpose. Transgenic
models of tissue-specific lip-HSDl deletion in vascular smooth muscle or
inflammatory cells would also be very interesting to use in this model.
Pharmacological inhibition ofglucocorticoid regeneration by 1 lf-HSDl
As an extension of studies in 1 ip-HSDl"/" mice, an investigation into the effect of
selective lip-HSDl inhibition on neointimal lesion formation was attempted. The
inhibitor of 1 lp-HSDl used in the current experiments has been used successfully to
selectively inhibit lip-HSDl in mice (Hermanowski-Vosatka et al. 2005). The
authors administered the inhibitor at a dose of 30mg/kg for 9 days by oral gavage,
which lowered fasting glucose and improved insulin resistance in a mouse model of
type 2 diabetes. Therefore, this dose and route of administration was chosen for use
in the current studies. Hermanwoski-Vosatka et al (2005) also administered the
inhibitor at 0.01% in a Western-style diet to ApoE knock out mice for 8 weeks, to
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prevent the progression of atherosclerosis. The current experiments had a shorter
time scale, and so administration of the inhibitor by this route may not have achieved
an active pharmacological dose. Furthermore, this method of administration would
have required separate housing of mice, daily preparation of diet and regulation of
the amount eaten by each animal. For these practical reasons, this method of drug
delivery was not used.
After 14 days of dosing, mice in both groups had lost weight, indicating that oral
gavaging was not well tolerated by the animals. When lip-HSDl activity was
measured in the liver, no difference was detected between mice administered
inhibitor and those given vehicle alone. The fact that mice reacted badly to gavaging
may suggest that drug administration by this route was not efficient in achieving an
active dose in the animals. Alternatively, any inhibition of 1lp-HSDl may have been
negated by an increased stress response in animals to twice-daily oral administration
of the drug, via up-regulation of 11P-HSD1 activity induced by excess glucocorticoid
levels. However, methodological reasons may also account for the lack of effect seen
on enzyme activity. It is possible that the drug appeared to have no effect on liver
1 lp-HSDl activity due to the timing of tissue collection at the end of the experiment,
which was not carried out uniformly after drug administration in all animals.
Hermanowski-Vosatka et al (2005) demonstrated the inhibition of lip-HSDl
activity, and studied the pharmacodynamics of the inhibitor, in a group of animals
separate from the disease models used in their study. The authors found that
inhibition of 1 lp-HSDl activity in the liver had nearly disappeared 6 hours after oral
administration (Hermanowski-Vosatka et al. 2005). Therefore, enzyme inhibition
may have been successful over the course of the current experiment, despite not
being demonstrated in liver preparations. Furthermore, the fact that there was no
difference in liver enzyme activity does not exclude the possibility that there were
differences in lip-HSDl activity in other tissues, such as the vessel wall. The
demonstration of an effect of the inhibitor on enzyme activity would necessitate the
design of separate experiments, to recapitulate Hermanowski-Vosatka et al (2005).
This would involve administration of the inhibitor to separate mice and the
measurement of enzyme activity in different tissues at defined time-points after drug
administration.
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Whilst there was no significant difference in neointimal proliferation between mice
treated with 11(3-HSD1 inhibitor and vehicle controls, there was an apparent trend
towards a decrease in lesion size. This result was contrary both to the hypothesis that
inhibition of endogenous glucocorticoid regeneration would increase neointimal
proliferation, and to the trend towards increased lesion size in 1 lp-HSDF" mice.
These results are particularly interesting, given the ability of the 11(3-HSD1 inhibitor
to reduce atherosclerosis (Hermanowski-Vosatka et al. 2005) and may suggest
enzyme-independent actions. It is notable that reduced atheroma in mice receiving
the 11J3-HSD1 inhibitor was attributed to a decrease in vascular expression of the
inflammatory chemokine MCP-1 (Hermanowski-Vosatka et al. 2005). This process
may be less significant in models of mechanical injury involving endothelial cell
removal and also in the absence of a Western-style diet, which is itself an
inflammatory stimulus.
Interpretation of the results in current experiments using the llp-HSDl inhibitor is
made difficult by the fact that there were concerns over the efficiency of drug
administration, the health of the mice during the experiment and the fact that no
difference in enzyme activity was seen between the groups. Additionally, arteries
were collected at an earlier time-point (14 days) during this study than in previous
experiments. This was designed to allow detection of either an increase in lesion size,
in line with our own hypothesis, or a reduction in lesion size, consistent with
Hermanowski-Vosatka et al (2005). Furthermore, the method of drug administration
by twice daily gavage, and the adverse reaction of mice to gavaging, limited the
time-course of the study. However, analysis of arteries at 14 days involved the
measurement of small and cellular neointimal lesions, meaning that lesion
quantification may have been more unreliable and less sensitive than at later
time-points. Overall, it appears likely that this study did not work as intended, due
primarily to a lack of detectable reduction in lip-HSDl activity. Therefore, the
absence of a significant effect in 11P-HSDF " mice on neointimal proliferation gives




The experiments described in this chapter were designed to explore a novel area; the
potential influence of endogenous glucocorticoids and their metabolism by
11P-HSD1 on the vascular response to injury. Initial observations have not shown
that endogenous glucocorticoids significantly influence neointimal proliferation in
response to wire-induced vascular injury in the mouse. In addition, glucocorticoid
metabolism by lip-HSDl has not been shown to play a major role in the
development of neointimal lesions after wire-induced injury of the femoral artery or
ligation of the popliteal artery. With more time, and limitless resources, it would be
interesting to pursue these preliminary results in more detail. The extension of this
work in future studies may confirm a more subtle role for endogenous
glucocorticoids during neointimal proliferation. Overall the current results indicate
that, whilst manipulation of endogenous glucocorticoid action may not represent a
therapeutic target for the treatment of restenosis, use of lip-HSDl inhibitors for
treatment of the metabolic syndrome should not exacerbate neointimal lesion





Cardiovascular disease, and in particular coronary heart disease, represents a major
health burden in the U.K. Therefore, it is highly important to study the processes
involved during the vascular response to injury, which are relevant to the
development of both atherosclerotic and restenotic lesions. The work described in
this thesis used a model of neointimal proliferation to assess the role of
glucocorticoid hormones in regulating the vascular response to injury. The potential
of glucocorticoid administration for the inhibition of atherosclerotic and neointimal
lesions has been demonstrated in several animal models. Their potential as
anti-restenotics has also been addressed in humans, with recent trials focussing on
local application of glucocorticoids at the vessel wall via stent-mediated delivery.
However, the action of glucocorticoids on the vascular response to injury is hard to
predict, since there is evidence to suggest that endogenous glucocorticoids and tissue
lip-HSD activity contribute to the development of several cardiovascular risk
factors, such as central obesity, hypertension, insulin resistance and dyslipidemia.
Furthermore, whilst glucocorticoids can influence certain aspects of vascular
structure and function (Hadoke et al. 2006), the role of endogenous glucocorticoids
and 11P-HSD1 in modulating the neointimal response to vascular injury has not been
investigated. Therefore, the overall objective of these studies was to advance the
understanding of how glucocorticoids influence neointimal lesion formation, using a
mouse model of intra-luminal vascular injury.
6.1 Models of neointimal proliferation in the mouse
Undertaking this project was dependent on introduction of an in vivo model of
neointimal proliferation, to allow the effects of glucocorticoids on artery structure
and function after injury to be assessed. A mouse model was chosen since use of this
species allows study of the mechanisms of neointimal proliferation at a molecular
level, through the use of genetically-modified animals. A well-characterised model
of intra-luminal, wire-induced injury (Sata et al. 2000), which induced stretching and
denudation of the femoral artery followed by time-dependent development of smooth
muscle-rich neointimal lesions, was successfully introduced. Characteristics of the
model, including thrombus formation, medial cell loss, and the vascular and
inflammatory cell types involved in lesion development, were consistent with
previous reports (Roque et al. 2000; Sata et al. 2000). However, the effect of wire
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injury and lesion growth on endothelial cell function could not be assessed, as injury
completely abolished contractile responses in the femoral artery, probably as a
consequence ofmedial smooth muscle cell loss.
The demonstration that large neointimal lesions developed in sham-operated mice
was unexpected, and led to a series of experiments designed to assess the effect of
each stage of the operation on lesion growth. This approach demonstrated that
placement of ligatures during surgery alone could induce neointimal proliferation.
Temporary ligatures occasionally produced limited, focal lesion growth, but this was
inconsistent. In contrast, the permanent proximal ligature on the popliteal artery
consistently induced lesion growth in the femoral artery, although these were less
occlusive than lesions produced by wire injury and did not extend as far along the
artery. This finding was interesting, as it had not been reported previously by the
groups who had developed models of wire injury in the femoral artery. It also gave
added insight into the processes that contribute to neointimal formation after wire
injury, an observation that was exploited to provide a complementary model of
neointimal lesion growth: simply tying off the popliteal artery, close to its branch
point with the femoral artery can induce neointimal proliferation in the femoral
artery. This model does not involve endothelial cell denudation, and does not cause
such severe stretch damage to the media as the model of wire-induced injury.
However, it is likely to include more adventitial remodelling than intra-luminal
models of injury, in response to the presence of the ligature around the artery, and
involve changes in blood flow and shear stress, caused by constriction of the artery.
Therefore, the first aim of the project (to introduce an in vivo model of wire injury
and neointimal proliferation) was achieved, and in addition a second model of lesion
growth was developed. This allowed the use of these two complementary models of
neointimal lesion development in each leg of the same animal, enabling extension of
studies investigating the influence of lip-HSDl on the response to injury. In the
future, the less severe model of injury to medial smooth muscle cells may allow the
study of vascular function after neointimal lesion growth.
An additional aim during the model development was to introduce an in vitro model
of neointimal proliferation. However, an attempt at recapitulating the method of
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Guerin et al (2004) was not successful in inducing neointimal lesion growth in
cultured femoral arteries. This may have been due to problems such as species
differences, severity of vascular injury and culture conditions. It was decided that
addressing these problems would entail a separate project, and that the current
project should focus on use of the in vivo models that had already been developed
successfully.
It has been proposed that local inflammation in the vessel wall may up-regulate
11P-HSD1 activity (Cai et al. 2001). The femoral artery injury model allowed
investigation of the effect of vascular inflammation and VSMC proliferation induced
by artery injury, and stimulation of injured arteries with an inflammatory cytokine,
on 1 lp-HSDl activity. However, enzyme activity was not altered by injury or IL-1(3,
consistent with previous results in intact vessels (Dover et al. 2007). Therefore, the
up-regulation of endogenous glucocorticoid regeneration by 11(3-HSD1 is unlikely to
play a significant role in this setting.
6.2 Effects of glucocorticoid administration on the vascular response to
injury
The in vivo mouse model of neointimal proliferation allowed investigation of the
effects of exogenously-applied glucocorticoids on the vascular response to injury.
Since previous animal studies have consistently shown that glucocorticoids inhibit
neointimal proliferation, this experiment was designed to act as a positive control for
glucocorticoid action, with the hypothesis that these hormones would also decrease
lesion growth in this model. In addition, since human clinical trials have raised the
possibility that there is a difference in the effect of glucocorticoids on the vascular
response to injury depending on their route of application, the effects of
systemically-applied and locally-applied glucocorticoids were compared in the
mouse.
The effects of systemically-applied glucocorticoids on the vascular response to injury
were more complex than initially expected, due to their actions on two different
aspects of this process. Systemically-applied dexamethasone did inhibit smooth
muscle cell proliferation and fibrous neointimal lesion growth after vascular injury,
in line with previous reports in animal models. However, it also promoted the
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formation of organised acellular lesions with a thrombotic origin, which occluded the
lumen of injured vessels, leading to a similar extent of luminal narrowing as seen in
vehicle-treated controls. In contrast, the release of Cortisol locally at the vessel wall
significantly decreased neointimal lesion growth, with no formation of organised
thrombotic lesions. Therefore, this caused significant protection from luminal
narrowing after wire-induced injury, in comparison to contra-lateral vehicle controls.
In conclusion, this set of experiments provided proof of concept that glucocorticoid
administration inhibits neointimal lesion growth in a mouse model of intra-luminal
injury. In addition, they highlighted a potential difference in the effect of
glucocorticoids depending on their route of application, although there may also have
been differences in the action of the two glucocorticoids applied (discussed further
below). With these caveats, the data support the idea that local release at the vessel
wall reduces neointimal lesion growth, without causing adverse changes in systemic
cardiovascular risk factors, i.e. increased thrombosis in response to vascular injury.
6.3 Influence of endogenous glucocorticoids and 11P-HSD1 on
neointimal proliferation
Following the demonstration that locally-applied glucocorticoids inhibit neointimal
lesion formation, the next aim of the project was to investigate the influence of
endogenous glucocorticoids within the vessel wall. This was carried out by local
application of the GR antagonist RU38486, via release from an implanted pellet. It
was hypothesised that endogenous glucocorticoids acting at the vessel wall would
also decrease neointimal proliferation after wire-induced vascular injury and,
therefore, that antagonism of GR would increase lesion area. However, despite a
trend towards increased lesion area, no significant difference was found between
arteries treated with RU38486 and contra-lateral controls. In conclusion, the role of
endogenous glucocorticoid action via GR-mediated signalling at the vessel wall was
addressed, and the experiments carried out did not indicate that these hormones have
a significant effect on neointimal lesion formation after artery injury.
The influence of endogenous glucocorticoid generation by lip-HSDl on neointimal
proliferation was also investigated using lip-HSDl"7" mice, and a selective
lip-HSDl inhibitor. Previous studies have indicated that inhibition of lip-HSDl
activity causes a decrease in atherosclerotic lesion formation (Hermanowski-Vosatka
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et al. 2005; Nuotio-Antar et al. 2007); this may have been mediated by effects of
enzyme inhibition at the vessel wall, or on systemic factors such as plasma lipid
levels or blood pressure. However, in the current studies the model of vascular injury
used involves a response to acute, focal injury of the vessel wall. Therefore, it was
hypothesised that abolishing lip-HSDl activity would increase neointimal lesion
area in this model, via the associated decrease in local active glucocorticoid
generation. However, no significant changes in neointimal proliferation were seen in
11P-HSD1"/" animals or those administered an lip-HSDl inhibitor. In conclusion,
these experiments did not indicate that the generation of endogenous glucocorticoids
by lip-HSDl significantly influences the neointimal response in a model of acute
injury to the vessel wall.
6.4 Potential clinical significance of results
Studies assessing the actions of exogenously-applied glucocorticoids on the vascular
response to injury have implications for the clinical use of steroids in humans for the
treatment of restenosis. Firstly, the observation that systemic pharmacological doses
of glucocorticoid increased thrombosis after injury may provide an explanation for
the failure of early clinical trials using systemic steroid administration to treat
restenosis: an increase in thrombus formation after angioplasty or stenting may have
disguised any decrease in restenosis caused by glucocorticoids. Alternatively, an
increase in thrombosis may have stimulated restenotic lesion formation via the
alternative mechanism that involves thrombus acting as a scaffold for smooth muscle
cell proliferation and migration (Schwartz et al. 1992a). This model of neointimal
lesion formation may involve additional pathways that glucocorticoids do not inhibit,
such as interactions of inflammatory cells with platelets and fibrin. In addition, this
observation provides more evidence to support the concept that increases in
circulating glucocorticoids, seen in patients with Cushing's syndrome or those
treated with exogenous steroids for inflammatory conditions, can have adverse
effects on cardiovascular risk factors.
The decrease in neointimal lesion development and luminal narrowing after
intra-luminal injury caused by the release of Cortisol at the vessel wall also has
clinical implications. This supports the concept that local application of
glucocorticoids reduces neointimal proliferation during the vascular response to
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injury, and that release of these hormones from coated stents represents the most
effective way to deliver glucocorticoids for the treatment of restenosis.
The indication that endogenous glucocorticoids and lip-HSDl activity do not
significantly influence neointimal proliferation after vascular injury is important with
regard to the use of 11|3-HSD1 inhibitors for treatment of the metabolic syndrome.
Recent evidence suggests that increased tissue lip-HSDl activity, and so
intracellular glucocorticoid levels, are associated with symptoms of the metabolic
syndrome (Wake & Walker 2004; Walker & Andrew 2006). This has led to the
proposal that intracellular glucocorticoids may contribute to the aetiology of this
condition, and inhibitors of lip-HSDl have become an important novel therapeutic
target for the treatment of its underlying cardiovascular risk factors (which include
central obesity, hypertension, insulin resistance, dyslipidemia and atherosclerosis).
However, concerns exist relating to the systemic inhibition of tissue lip-HSDl
activity. A reduction in inflammatory cell glucocorticoid levels may have
pro-inflammatory effects and delay the resolution of acute inflammatory responses
(Gilmour et al. 2006), potentially leading to the development of chronic
inflammatory conditions. In the case of vascular remodelling, pro-angiogenic effects
observed in 11 P-HSDl"7" mice may be beneficial in some situations, such as wound
healing after myocardial infarction (Small et al. 2005). However, enhancement of
angiogenesis via lip-HSDl inhibition would be detrimental in other pathological
conditions, such as cancer or diabetic retinopathy. lip-HSDl inhibition has been
shown to delay the progression of atherosclerosis in mice (Hermanowski-Vosatka et
al. 2005). Since the results of the current studies suggest that attenuation of
11P-HSD1 activity will not cause a worsening of the restenotic response, the
potential use of lip-HSDl inhibitors for the treatment of atherosclerosis should not
be contraindicated in patients undergoing PCI for the treatment of this condition.
6.5 Future studies
As well as highlighting important aspects regarding the effects of glucocorticoids on
the vascular response to injury, the work described in these chapters has also
provided a basis for further experiments. The introduction of a mouse model of
neointimal proliferation will allow the study of many other potential factors and
192
pathways in the vascular response to injury. In addition, there are several prospective
studies that could extend the work described here.
6.5.1 Systemic vs. local effects of glucocorticoids
Whilst the current studies showed a clear difference in the effect of
systemically-applied and locally-applied glucocorticoids on the vascular response to
injury, these experiments were carried out using different steroids (dexamethasone
systemically and Cortisol locally), for the reasons described in chapter 4. This raises
the possibility that differences in the action and/ or metabolism of these two steroids
may have contributed to the difference in effect observed. To overcome this
limitation, experiments could be set up giving systemic doses of Cortisol and
administering dexamethasone locally from silastic pellets after vascular injury. To
allow a direct comparison, the dose of glucocorticoid reaching the vessel wall, and
therefore intra-vascular GR exposure, would have to be matched. However, it would
be difficult to design experiments where this could be carried out accurately. In
addition, it would be interesting to carry out dose-response experiments to determine
if, for example, the increase in thrombosis caused by dexamethasone could be
avoided with a lower dose of this glucocorticoid. Unfortunately, it was not possible
to carry out these further experiments during the time-scale of the current project.
6.5.2 Mechanism of glucocorticoid-mediated inhibition of neointimal
proliferation
In the future, it will be important to determine the cellular mechanism by which
exogenously-applied glucocorticoids inhibit neointimal proliferation in this model. A
clear understanding of whether these hormones target inflammatory cells, inhibit
smooth muscle cell proliferation, or both, will aid their development as
anti-restenotic drugs. Since it seems most likely that glucocorticoids act by inhibiting
the early inflammation after vascular injury (Poon et al. 2001) experiments to
investigate this hypothesis are an important next step. Quantification of neointimal
lesion macrophage content (e.g. via immunohistochemical staining for Mac-2,
chapter 2.8.3) in glucocorticoid- and vehicle-treated arteries from the current
experiments could be compared. However, these arteries were collected 21 days after
injury, when only limited Mac2 expression is observed in advanced neointimal
lesions (chapter 3.2.1.8). Testing the ability of glucocorticoids to inhibit the adhesion
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of inflammatory cells to the vessel wall at early time-points (e.g. immediately or 2
days) after injury would be more appropriate. It is possible to measure the adhesion
of radiolabeled leukocytes to injured arteries ex vivo (Kennedy et al. 2000b) and,
therefore, the influence of glucocorticoids on this process could be investigated.
Alternatively, the expression of adhesion factors in the presence and absence of
glucocorticoids could be assessed in injured arteries, either by
immunohistochemistry or using molecular techniques, such as quantitative PCR or
Western blotting, which would allow quantification of expression levels. As well as
the adhesion of leukocytes after injury, the release of inflammatory chemokines and
cytokines is also important in stimulating neointimal lesion formation. Again, the
ability of glucocorticoids to inhibit this process could be assessed, by measuring
chemokine and cytokine levels released from injured arteries cultured in vitro with or
without glucocorticoids.
Glucocorticoids may also directly inhibit the proliferation of VSMCs after injury,
leading to the inhibition of neointimal lesion development. Previous in vitro studies
have used high concentrations of glucocorticoids to demonstrate the inhibition of
smooth muscle cell growth, raising questions as to whether they have the same effect
in vivo. To determine if the in vivo proliferation of VSMCs is altered in animals
treated with glucocorticoid, sections of arteries from the current experiments could
be stained for PCNA (chapter 2.8.4). However, maximal VSMC proliferation does
not occur in the advanced lesions studied in these experiments (chapter 3.2.1.8).
Alternatively, injection of the thymidine analogue BrdU would provide a nuclear
marker of proliferating cells in sections of injured arteries collected at earlier
time-points after injury (e.g. 14 days), when most cellular proliferation occurs.
Finally, the possibility that glucocorticoids may influence ECM remodelling during
the vascular response to injury could be addressed, by measuring the activity of the
MMP enzymes using the technique of zymography.
6.5.3 Glucocorticoid receptor vs. mineralocorticoid receptor stimulation by
endogenous glucocorticoids
In the current studies a GR antagonist was used to determine the effect of
endogenous glucocorticoids on neointimal proliferation. It is possible that
endogenous glucocorticoids, and exogenously-applied Cortisol, may also act through
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MR to influence the development of neointimal lesions. If they do act in this way,
previous studies suggest that they would increase neointimal lesion formation, and
that antagonism ofMR would decrease lesion area (Ward et al. 2001; Wakabayashi
et al. 2006). To investigate this further, a separate project could be carried out using
a pharmacological approach to confirm the role ofMR in neointimal proliferation in
the mouse. Firstly, the MR ligand aldosterone could be administered to animals after
vascular injury, to validate the idea that MR agonism increases lesion area. Next, an
MR antagonist, such as eplerenone, could be used to confirm the influence ofMR on
neointimal proliferation.
6.5.4 Tissue-specific study of 11 (3-HSD1 activity during neointimal lesion
development
The studies described here investigated the effect of attenuating whole-body
1 lp-HSDl activity on neointimal lesion growth; at present the relative activity of
intra-vascular lip-HSDl remains unknown. Experiments using exogenously-applied
glucocorticoids indicated that glucocorticoids reduce lesion development when they
are applied locally at the vessel wall, but that this can be offset by systemic
glucocorticoids causing adverse changes in cardiovascular risk factors. It has been
suggested that an observed delay in the progression of atherosclerosis after
11P-HSD1 inhibition was mediated by direct effects on the vessel wall, perhaps via
decreased expression of MCP-1 (Hermanowski-Vosatka et al. 2005). Therefore, it
would be interesting to start to determine the role of local 1 lp-HSDl activity in the
cells of the vessel wall. To do this, several approaches could be taken. Firstly, an
inhibitor of 1 lp-HSDl could be applied locally at the vessel wall, via release from a
sub-cutaneous minipump or implanted pellet. However, difficulties may be
encountered in confirming if active drug administration has been successful using
this method. Secondly, further development of the in vitro model of neointimal
proliferation would allow study of glucocorticoid and 1 lp-HSDl effects specifically
on the cells of the vessel wall. Finally, development of transgenic tissue-specific
models of lip-HSDl knockout in vascular smooth muscle and macrophages would
allow the dissection of this enzyme's role in each of these cells during neointimal
proliferation. Alternatively, bone marrow transfer from lip-HSDl"7" mice into wild
type animals would achieve attenuation of lip-HSDl activity specifically in
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circulating leukocytes. This would also allow further investigation of the
mechanisms involved in glucocorticoid-mediated changes in neointimal
proliferation, and whether this involves inflammatory cells or VSMCs.
As a result of studies suggesting a role for 11(3-HSD1 in atherosclerotic lesion
development (Hermanowski-Vosatka et al. 2005), lip-HSDl/ ApoE double
knockout mice have been generated recently, to further clarify the role of this
enzyme in atherosclerosis. Performing wire-induced vascular injury in vessels from
these mice with existing atherosclerotic lesions would be a very interesting
experiment to carry out in the future. This would provide a more clinically relevant
model of neointimal lesion formation in the setting of existing atherosclerotic
disease, and give an indication of the role that 11P-HSD1 plays in vascular
remodelling in this context.
6.6 Conclusions
In conclusion, these studies have provided valuable insight into the effects of
glucocorticoids on neointimal lesion formation. The role of endogenous
glucocorticoids, and their metabolism by lip-HSDl, during neointimal lesion
development was investigated for the first time. In addition, these studies have
highlighted that the influence of glucocorticoids on neointimal proliferation depends
on a balance between local and systemic actions. The neointimal proliferation of
VSMCs in response to inflammation during the vascular response to injury is an
important process involved in the formation of both atherosclerotic and restenotic
vascular lesions. Therefore, results obtained in the current studies, using a model of
neointimal proliferation, have relevance to the development of atherosclerosis and
restenosis. For example, the idea that the action of glucocorticoid hormones on
vascular remodelling is a balance between local and systemic effects can be extended
to investigation of their effects on atherosclerosis. In addition, further clarification of
the mechanism of glucocorticoid-mediated inhibition of neointimal lesion formation
may shed light on how these hormones influence restenosis in clinical trials. In the
future, studies should take into account the ability of intra-vascular glucocorticoids to
interact with both GR and MR in cardiovascular tissues, and the contribution of
11P-HSD1 in different cell types during vascular lesion formation.
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Abstract. The ability of glucocorticoids to directly alter
arterial function, structure and the inflammatory re¬
sponse to vascular injury may contribute to their well-es¬
tablished link with the development ofcardiovascular dis¬
ease. Recent studies have emphasised the importance of
tissue-specific regulation of glucocorticoid availability
by the 11/J-hydroxysteroid dehydrogenase (11HSD) iso¬
zymes, which inter-convert active glucocorticoids and
their inactive metabolites. The expression of both type 1
and type 2 1 lHSDs in the arterial wall suggests that pre-
receptormetabolism ofglucocorticoids may have a direct
impact on vascular physiology. Indeed there is evidence
that 1 lHSDs influence glucocorticoid-mediated changes
in vascular contractility, vascular structure, the inflam¬
matory response to injury and the growth of new blood
vessels. Hence, inhibition of 11HSD isozymes may pro¬
vide a novel therapeutic target in vascular disease.
Key words. 11 /J-Hydroxysteroid dehydrogenase; inflammation; vascular contractility; angiogenesis; cardiovascular
disease.
Introduction
There is increasing evidence that direct interaction ofglu¬
cocorticoids with the vascular wall [1,2] contributes to
their association with increased risk of cardiovascular
disease [3,4]. Certainly, glucocorticoids can interact both
with endothelial (EC) and with vascular smooth muscle
(VSMC) cells, and furthermore, glucocorticoid-mediated
enhancement of vascular contractility has been impli¬
cated in the development of hypertension [5]. In addition,
glucocorticoids may directly modify new blood vessel
formation and vascular lesion development by inhibiting
inflammation, proliferation and angiogenic pathways in
the arterial wall [6, 7],
Interaction of glucocorticoids with the vasculature is un¬
likely to be regulated solely by circulating concentrations
of these steroids; pre-receptor metabolism within target
* Corresponding author.
tissues also has a profound influence on glucocorticoid
activity. Such tissue-specific modulation of glucocorti¬
coid activity, regulated by the isozymes of 11 /J-hydroxy-
steroid dehydrogenase (11HSD) [8], has a key role, for
example, in the development ofhypertension, obesity and
the metabolic syndrome [9-11], It is likely that pre-re¬
ceptor metabolism of glucocorticoids influences steroid
action within the vessel wall since both isozymes of
11HSD are expressed in vascular cells [12], This article
reviews the current evidence that vascular 11HSD ex¬
pression influences glucocorticoid-mediated changes in
vascular growth, function, structure and the inflamma¬
tory response to vascular injury.
Glucocorticoid signalling in the vascular wall
Glucocorticoids (Cortisol in man, corticosterone in ro¬
dents) are predominantly synthesised in, and released
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from, the adrenal cortex. Circulating concentrations of
these steroids are under the control of the hypothalamic-
pituitary-adrenal (HPA) axis, whilst their bioavailability
is regulated by interaction with corticosteroid-binding
globulin (CBG) and albumin in the plasma. The small
proportion of unbound, circulating hormone is able to
cross the cell wall and interact with corticosteroid recep¬
tors. Classically, glucocorticoids interact with the cytoso-
lic glucocorticoid receptor (GR, or corticosteroid recep¬
tor type II). As described below, glucocorticoids may also
activate mineralocorticoid receptors (MR, or corticos¬
teroid receptor type I), but this occurs only in a few tis¬
sues. GR and MR are members of the nuclear hormone
receptor superfamily of ligand-activated transcription
factors [13]. Activation ofGR results in binding of recep¬
tor homodimers to glucocorticoid response elements in
target genes, leading to initiation or repression of tran¬
scription. There is also increasing evidence that gluco¬
corticoids exert specific, non-genomic actions. Examples
exist of rapid glucocorticoid-induced changes to phos-
pholipase A, (PLA2) and phosphoinositide-3-kinase-me-
diated endothelial nitric-oxide synthase (eNOS) release
that are blocked by GR antagonism but not by inhibition
of transcription [14, 15]. These non-genomic effects are
thought to be mediated by membrane-bound GR [16]
(mGR; although the specific signalling pathways associ¬
ated with these receptors have not been established) or by
cytosolic GR (cGR) without requirement for either nu¬
clear translocation or effects on transcription. In the latter
case, chaperones or co-chaperones (such as Src) act as
signalling components and, therefore, mediators of glu¬
cocorticoid-induced effects [17].
Corticosteroid receptors are present in the cells of the
vascular wall, supporting the idea that glucocorticoids in¬
teract directly with the vasculature. Cytosolic MR and
GR have both been demonstrated in freshly isolated ves¬
sels [18, 19] and in cultured vascular cells (VSMCs [20,
21] and ECs [22-26]) from a variety of species. The dis¬
tribution of these receptors may vary with vascular terri¬
tory, as MR were detected in rabbit aortic and pulmonary
VSMCs but not in small arteries [27], Vascular GR are
known to be active as antagonism (with RU38486)
blocked dexamethasone-mediated induction of ACE ac¬
tivity in rat aortic ECs [28], Similarly, activity of MR is
demonstrated by their contribution to angiotensin Il-in-
duced hypertrophy of VSMCs [29] and aldosterone-in-
duced swelling of ECs [22]. It has not been established
whether membrane binding sites for corticosteroids are
present, or have a role, in the vascular wall.
The downstream effects ofGR activation within the arte¬
rial wall, and their influence on cardiovascular risk fac¬
tors (such as hypertension), are imperfectly understood
[5]. Glucocorticoids are essential for maintenance of
blood pressure in healthy individuals [1], whilst their
ability to increase peripheral vascular resistance in ani¬
mals devoid of renal mass indicates that a non-renal
mechanism contributes to glucocorticoid-induced hyper¬
tension [30], A considerable body of evidence suggests
that this non-renal mechanism may involve direct gluco-
corticoid-mediated alteration of EC and VSMC function
[1], Consequently, regulation of glucocorticoid availabil¬
ity by 1 lHSDs within the vascular wall may be an impor¬
tant influence on cardiovascular physiology and pathol¬
ogy.
Tissue-specific metabolism of glucocorticoids
by 11/J-hydroxysteroid dehydrogenases
The 1 lHSDs, microsomal enzymes of the short-chain al¬
cohol dehydrogenase superfamily [8], interconvert active
glucocorticoids and their inert 11-keto forms [31]. Two
isozymes, 11HSD1 and 11HSD2, have been identified:
11HSD1 is a low-affinity NADP(H)-dependent, predom¬
inant reductase in vivo. Dehydrogenase activity of this
isozyme is generally not seen in intact cells or organs (in¬
cluding liver [32-34], adipose tissue [35], neurons [36]
and vascular smooth muscle [37]); early suggestions of
11HSD1 dehydrogenase activity in vascular smooth mus¬
cle [38] are probably attributable to I1HSD2 [37].
11HSD1 dehydrogenase activity observed in some prepa¬
rations in vitro [39] is probably attributable to release of
enzyme from damaged or dying cells, with dissociation
from hexose-6-phosphate dehydrogenase, which is
thought to maintain the high NADPH concentrations re¬
quired for reductase activity [40]. 11HSD1 has a Km in
the micromolar range for both Cortisol and corticosterone
[41 ] and is widely expressed in glucocorticoid-target tis¬
sues (including liver, lung, adipose tissue, brain, vascular
smooth muscle, skeletal muscle, anterior pituitary, go¬
nads and adrenal cortex [8]), where its role is to amplify
local glucocorticoid concentrations [42]. Regulatory con¬
trol of 11HSD1 is complex, with its synthesis and activ¬
ity influenced by a variety of factors (such as glucocorti¬
coids [43—45], stress [46, 47], sex steroids [48], growth
hormone [49], cytokines [50] and peroxisome prolifera-
tor-activated receptor agonists [8]) and its activity driven
in the reductase direction through local generation of
NADPH by hexose-6-phosphate dehydrogenase [51],
Other factors that may drive 11HSD1 activity in the re¬
ductase direction include the cellular environment, co-
factor availability, redox potential and substrate concen¬
tration.
11HSD2, by contrast, is a high-affinity NAD-dependent,
exclusive dehydrogenase, which converts active gluco¬
corticoids into inactive 11-ketosteroids and has a Km for
Cortisol and corticosterone in the nanomolar range. It is
found primarily in mineralocorticoid target tissues, such
as the kidney, sweat glands, salivary glands and colon 8],
where it is constitutively active and serves to protect MR
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from illicit occupation by glucocorticoids. Inhibition of
11HSD2 with liquorice or its derivatives results in gluco-
corticoid-dependent 'apparent' mineralocorticoid excess
and hypertension [52]. Similarly, transgenic disruption of
11HSD2 [9] in mice, or congenital deficiency in man
[53], recapitulates the major features of the syndrome of
apparent mineralocorticoid excess (SAME). The impor¬
tance of 11HSD2 in SAME was demonstrated by the de¬
scription of a defect in Cortisol metabolism in children
with this syndrome [54]; this was later shown to be the re¬
sult of mutations in the 11HSD2 gene [55, 56], 11HSD2
is also expressed in tissues which are not classic MR tar¬
gets, including the lung, lymph nodes, heart, blood vessel
wall and placenta) [57-59] In the placenta 11HSD2 acts
to protect the foetus from excessive exposure to maternal
glucocorticoids [60, 61], whereas cardiac 11HSD2 activ¬
ity may have a role in preventing fibrosis resulting from
stimulation ofMR by glucocorticoids [62],
The influence of 1IHSD isozyme activity on cardiovas¬
cular physiology and pathophysiology is well recognised
(see Krozowski and Chai for review [63]), but details of
the role of 1 lHSDs within the vessel wall have emerged
only recently and remain somewhat uncertain.
Intra-vascular glucocorticoid metabolism
Both isozymes of 11HSD are expressed in the blood ves¬
sel wall, suggesting that they could influence vascular
function by regulating local availability of active gluco¬
corticoids [1, 64]. The cellular distribution of vascular
11HSD1 and 11HSD2 is not completely clear. Our stud¬
ies using mouse and rat aorta suggest that 11HSD2 is lo¬
calised to ECs, whereas 11HSD1 is predominantly in the
VSMC (fig. 1) [18,65]. Others, in contrast, have reported
activity of both enzymes in the VSMC [37, 50] and also
in the EC [66], it should be noted that the latter investiga¬
tion [66] demonstrated only 11HSD1 in rat VSMC and
indicated that 11HSD1 was the predominant isozyme in
the endothelium. Direct comparison of studies is often
difficult, given the use of arteries from different species
and anatomical locations combined with a variety of
techniques for detecting IIHSDs. The balance of the
literature suggests that cellular distribution of 11HSD
isozymes differs in vessels from distinct anatomical loca¬
tions and that 11HSD activity increases as artery diame¬
ter diminishes; in the rat 11HSD, activity was greater in
resistance (mesenteric) arteries than in conduit vessels
(aorta) [65] and in the mouse 11 /^-reductase activity was
higher in iliofemoral arteries than in the aorta [A. R.
Dover et al., unpublished data]. These variations in cellu¬
lar distribution and activity suggest that the role of intra¬
vascular glucocorticoid metabolism is not the same in all
blood vessels.
There is increasing evidence that interconversion of ac¬
tive and inactive glucocorticoids by vascular cells may in¬
fluence glucocorticoid-mediated modulation of vascular
function, structure, growth and inflammation.
Glucocorticoids, llHSDs and vascular function
Although it is well established that glucocorticoids con¬
tribute to maintenance of vascular tone in vivo, the mech¬
anisms have been difficult to establish. A variety of inter¬
actions contribute to homeostasis, including glucocorti-
coid-mediated regulation of cardiac output and fluid and
electrolyte balance, with salt and water handling modu¬
lated both directly [67] and indirectly by influences on the
production of angiotensinogen (liver), arginine vaso¬
pressin (AVP; hypothalamus) [68] and atrial natriuretic
peptide (ANP; cardiac myocytes) [69]. It is apparent,
however, that these cardiac and renal effects cannot ac¬
count totally for the glucocorticoid-mediated increase in
blood pressure, and there is evidence that a component of
hypertension arises from enhanced contractility of the
vascular wall [70-72]. For example, reversal of adreno-
corticotophin-dependent hypertension by administration
of 1-arginine (the substrate for nitric oxide synthase) sug¬
gests that nitric oxide deficiency contributes to the eleva¬
tion of blood pressure [73, 74],
Glucocorticoid-dependent potentiation of noradrenaline-
and angiotensin II-mediated vasoconstriction has been at-
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Figure 1. Presence and distribution of 11 HSD isozymes in the vas¬
cular wall. In situ hybridisation (Ai) and immunohistochemistry
(Aii) confirming both expression and activity of 11HSD1 within the
rat aortic wall; the enzyme was predominantly localised to medial
smooth muscle cells (left-hand panel, sense/control; right hand-
panel, antisense/antibody to 11HSD1). Immunohistochemistry de¬
monstrating (B) 11HSD1 in rat mesenteric artery smooth muscle
and (C) 11HSD2 in human intra-renal artery endothelium [unpub¬
lished]. Reproduced from [65] with permission. © The Endocrine
Society. 1991.
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tributed to alterations within the VSMC and the EC (re¬
viewed inWalker and Williams [2] and Ullian [1]). Given
that glucocorticoids can act on both MR and GR, the in¬
creased contractility observed in many studies may be
secondary to increased stimulation of either receptor. Al¬
terations identified within the VSMC (including upregu-
lation of contractile receptors, altered intracellular sec¬
ond messenger activation and modulation of the activity
and synthesis of vasoactive substances) result in a direct
enhancement of contraction [1]. In contrast, changes in
the endothelium can increase contractility in two distinct
ways: by increased release ofvasoconstrictor compounds
(e.g. angiotensin II, endothelin-1 [75, 76]) from the ECs
and by impaired endothelium-mediated relaxation. Loss
of endothelium-mediated relaxation [77], caused by im¬
paired activity of vasodilators (e.g. prostaglandins, nitric
oxide) [78-80], [reduces the ability of the endothelium to
modulate contraction.
An alternative mechanism through which glucocorticoids
may regulate vascular function is 'foetal programming' of
physiological responses [81]. Exposure of the foetus to
excess maternal glucocorticoid (either by direct infusion
or by inhibition of placental 11HSD2) causes reduced
birth weight [82], an outcome associated with increased
risk of cardiovascular and metabolic disease in adulthood
[83]. Two major causes of low birth weight, maternal di¬
etary restriction and maternal stress, may also be gluco-
corticoid-dependent [84, 85], In the ovine foetus, gluco¬
corticoid infusion elevates blood pressure and alters vas¬
cular contractility in foetal sheep [86]; this may be
significant, as one outcome of foetal programming is el¬
evated blood pressure in adult offspring [87]. However,
although enhanced vascular contractility has been
demonstrated in rats with programmed hypertension, it is
not clear whether this contributes to the elevation of
blood pressure [88, 89]. Furthermore, the mechanisms
through which pre-natal exposure to excess glucocorti¬
coid programme enhance contractility in adult offspring
have not been established.
Influence of IlHSDs on vascular function
In SAME, 11HSD2 deficiency results in sodium reten¬
tion and severe hypertension, mediated in part by gluco-
corticoid-dependent activation of MR in the distal
nephron [90], There is, however, a considerable literature
to suggest that changes in 11HSD activity within the vas¬
cular wall also contribute to elevation of blood pressure.
A clear example of this is the demonstration that 11HSD
activity is impaired in arteries taken from rat models of
hypertension [91-93]. A role for altered vascular function
is supported by reports that 11HSD inhibition (with gly-
cyrrhetinic acid) in rats produced an elevation of blood
pressure which, whilst mediated by MR activation, was
blocked by antagonists of the endothelin-1 system [94,
95]. Moreover, studies of dermal vasoconstriction in pa¬
tients exposed to liquorice, and in a single individual with
SAME [53, 96], demonstrated enhanced cortisol-medi-
ated constriction (fig. 2). The possibility that this is due
to changes in glucocorticoid metabolism within the vas¬
cular wall, rather than indirect systemic effects of sodium
retention, gained further credence with in vitro studies
which showed that bile acids (e.g. chenodeoxycholic
acid), which are endogenous inhibitors of 11HSD [97],
pharmacological inhibitors of 11 HSD (carbenoxolone,
glycyrrhetinic acid) [98, 99] and isozyme selective anti-
sense oligonucleotides [100] alter corticosterone-medi-
ated enhancement of vasoconstriction. Furthermore,
11HSD inhibition (with glycyrrhetinic acid) augmented
corticosterone-induced dysfunction in cultured human
ECs, indicating both a role for intra-cellular 11HSD and
independence from blood pressure elevation in vivo [95],
Care is required in interpreting these results, however,
as some 11HSD inhibitors can directly alter contractile
function by damaging the endothelium [101].
These pharmacological studies have been extended by the
use of arteries from 11HSD knockout mice. Aortic func¬
tion (and blood pressure) are unaltered in 11HSD1 '
mice suggesting that intravascular regeneration of active
glucocorticoids has no effect on vascular contractility
[102, 103], This indicates that despite the ability of glu¬
cocorticoids to enhance vascular contraction, impaired
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Figure 2. The effect of congenital and acquired 11HSD deficiency
on dermal vasoconstrictor sensitivity to Cortisol and beclometha¬
sone dipropionate. Inhibition of 11 HSD activity with liquorice-en¬
hanced dermal vasoconstriction (measured by skin blanching) in re¬
sponse to Cortisol but not to beclomethasone diproprionate. A sim¬
ilar result was obtained in a patient (GB) with the syndrome of
apparent mineralocorticoid excess type 1 (11HSD2 deficiency).
These data indicate that local regulation of glucocorticoid activity
in the vascular wall contributes to contractile tone. Bars are s.e. NS,
not significant. Reproduced from [53] with permission. ©The Bio¬
chemical Society, 1992.





Figure 3. Effect of (a) transgenic deletion of 11HSD2 and (6) ex¬
posure to glucocorticoids on mouse aortic endothelial cell function.
In aortic rings isolated from control mice (squares), release of en-
dothelium-derived nitric oxide acts as a physiological antagonist of
noradrenaline-mediated contraction; thus, removal of the endothe¬
lium (open symbols) results in enhanced contraction. In aortae from
11 HSD2~'_ mice (a; triangles) this ability of the endothelium to
modulate contraction has been lost, suggesting glucocorticoid-me-
diated impairment of endothelial cell function. This is contested,
however, by the demonstration that (b) in vitro incubation (24 h, 37
°C; 10-7M corticosterone) ofaortic rings from control animals with
glucocorticoids (circles) did not produce a similar endothelial cell
dysfunction. Values are mean ± s.e. mean; n=8. Adapted with per¬
mission from [103] and [18]. © Lippincott, Williams and Wilkins.
duce contractile function. In contrast, enhanced contrac¬
tility was demonstrated in thoracic aortae from mice lack¬
ing 11HSD2 as a result of impaired endothelium-derived
NO activity [103], rather than changes in the VSMC
(fig. 3a). This suggests that 11HSD2 activity in the en¬
dothelium may serve to protect endothelium-dependent
relaxation from the detrimental effects of glucocorti¬
coids. This appears to be consistent with in vivo studies
which suggest that non-selective inhibitors of both iso¬
zymes of 1 lHSDs, such as liquorice derivatives, potenti¬
ate rather than impair the vascular actions of glucocorti¬
coids, suggesting inhibition of inactivation rather than re¬
activation of steroids within the vessel wall. More recent
data, however, suggest that the concept of protection of
ECs by 11HSD2 may be an oversimplification. In mouse
aortic rings, we could not induce EC dysfunction by in¬
cubating isolated rings with glucocorticoids (fig. 3b),
even in the absence of 11HSD2 [18]; whether dehydroge¬
nase activity of 11HSD1 [38] served to protect the en¬
dothelium is not clear, although our data suggest that
11HSD1 does not act as a dehydrogenase in intact arteries.
This raises the possibility that in vivo differences in vas¬
cular function in 11HSD2 knockout mice are dependent
on indirect mechanisms, e.g. related to hypertension or
sodium retention. Cell-specific manipulation of 1 lHSDs
would be the most attractive means to dissect this biology
further, but has yet to be reported for vascular cells.
Glucocorticoids, UHSDs and vascular inflammation
Whereas studies in transgenic mice have suggested that
11HSD2 activity may influence vascular function, whilst
11HSD1 does not, a much clearer role for 11HSD1 has
been identified in regulation of vascular inflammation.
The anti-inflammatory and immunosuppressive effects of
glucocorticoids, which account for their most common
therapeutic applications, are due to GR-mediated interac¬
tions with blood vessels, inflammatory cells and media¬
tors of inflammatory responses [104]. For example, glu¬
cocorticoids decrease expression of adhesion factors, cy¬
tokines and chemokines, and so alter the recruitment of
immune cells such as neutrophils and macrophages to
sites of inflammation. This also results in a decrease in
leukocyte activation and proliferation. Furthermore, the
glucocorticoid receptor mediates lymphocyte apoptosis
[105] and suppresses the synthesis of inflammatory me¬
diators (e.g. prostanoids), and hydrocortisone stimulates
the synthesis of anti-inflammatory mediators (e.g. lipo-
cortins) [106]. Glucocorticoids, but not mineralocorti-
coids, can also promote the phagocytosis of apoptotic
leukocytes [107], and so contribute to the resolution of
inflammation. The expression of 11HSD1 in VSMCs [50]
and in activated macrophages [108] suggests that genera¬
tion ofglucocorticoid within these cells may contribute to
regulation of inflammation.
Influence of llHSDs on vascular inflammation
The demonstration that pro-inflammatory cytokines se¬
lectively upregulate 11HSD1 activity in human VSMCs
suggests that glucocorticoid generation within the vascu¬
lar wall provides a mechanism for local feedback regula¬
tion of inflammation [50], However, this has not been ex¬
amined in vivo. The ability of inflammatory mediators to
regulate 11HSD activity in VSMCs may be dependent
upon the phenotypic state of the cells (with enzyme ac-
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tivity upregulated in actively proliferating, but not in qui¬
escent, cells), the anatomical origin of a particular vessel,
the prevailing local glucocorticoid concentrations and the
modulation of the inflammatory response by neighbour¬
ing tissues [A. R. Dover et al., unpublished data]. Further
work is required to clarify the significance of cytokine-
mediated regulation of 11HSD1 in arterial cells, particu¬
larly given the importance of inflammation in the vascu¬
lar response to injury [109].
Alternatively, 11HSD I may regulate inflammation by
controlling generation of glucocorticoids within the in¬
flammatory cells. Certainly, the ability of inflammatory
cytokines to upregulate 11HSD1 activity in activated hu¬
man macrophages [108] suggests, as in human VSMC
[50], a means of feedback regulation of inflammation
within these cells.
Glucocorticoids and vascular remodelling
The term 'vascular remodelling' has been used to cover a
range of structural changes in the arterial wall, and its
correct definition is the subject of debate (for review see
Bund and Lee [110]). In this review, the term 'vascular re¬
modelling' encompasses medial hypertrophy (thickening
of the vessel wall caused by increase in cell size) and hy¬
perplasia (thickening of the cell wall caused by an in¬
crease in cell number), as well as the intimal remodelling
seen in neointimal proliferation and the development of
atherosclerotic lesions. It has also been extended to in¬
clude angiogenic growth of new blood vessels.
The relationship between glucocorticoids and arterial re¬
modelling is well-established; for example, one year fol¬
lowing remission, patients with Cushing's syndrome
show reduced intimal/medial thickness and increased lu¬
men diameter in the carotid artery [111]. It should be
noted, however, that remodelling may be the indirect re¬
sult of systemic changes (e.g. increased blood pressure)
rather than direct interactions of glucocorticoids with the
vessel wall. Glucocorticoids may induce vascular remod¬
elling by altering expression of genes for relevant growth
factors or by inhibiting processes that modulate growth
factor activity. For example, dexamethasone induces a
GR-dependent upregulation of endothelin-1 expression
[76], and Cortisol attenuates the activity of nitric oxide
[77] (itself a potent inhibitor of cell growth). Similarly,
dexamethasone- and hydrocortisone-mediated increases
in ACE activity in VSMCs [112] and ECs [75] may en¬
hance local generation of angiotensin II (a stimulant of
VSMC growth both in vitro [113] and in vivo [114]).
Hypertrophy
Vascular hypertrophy in rats exposed to mineralocorti-
coids, predominantly deoxycorticosterone acetate, and
salt [115] has been attributed to upregulation of the en-
dothelin-1 gene [116], Similarly, glucocorticoids (dex¬
amethasone, hydrocortisone) have the ability to induce
vascular hypertrophy by augmenting the production of
[112, 117], and hypertrophic response to [118, 119], an¬
giotensin II. The significance of this hypertrophy is un¬
clear, however, as many investigations that demonstrate
enhanced vascular contractility in response to corticos-
terone involved a duration of exposure that would be in¬
sufficient for vascular hypertrophy to occur [120]. Fur¬
thermore, glucocorticoid-mediated stimulation ofgrowth
in the vascular wall is counterintuitive given that dexam¬
ethasone inhibitsVSMC growth in culture [121-123] and
glucocorticoids prevent neointimal hyperplasia (see be¬
low). Thus, the direct influence ofglucocorticoids on vas¬
cular hypertrophy/hyperplasia is unclear, and any role of
local glucocorticoid metabolism by 1 lHSDs in the pro¬
cess has yet to be investigated.
Neointimal proliferation
The development of neointimal lesions (e.g. in athero¬
sclerosis and in restenosis following revascularisation) is
a consequence of an excessive wound healing response in
the vessel wall [124, 125]. Vascular injury results in infil¬
tration by inflammatory cells and subsequent migration
and proliferation ofVSMCs [109]. Consequently, inhibi¬
tion of either the inflammatory response [126] or VSMC
proliferation/migration [127] inhibits lesion development
in a variety of models. Since glucocorticoids (dexam¬
ethasone) can inhibit inflammation and VSMC prolifera¬
tion [121-123] and migration [128], it is not surprising
that their potential as anti-atherosclerotic [129] and anti-
restenotic agents [130] has been investigated [6]. It is also
possible, however, that the action of glucocorticoids on
the vessel wall is deleterious in patients with vascular dis¬
ease. For example, given that ACE inhibition limits
neointima formation following balloon injury [131, 132],
stimulation of ACE activity by dexamethasone [75, 112]
could exacerbate lesion development. Also, inhibition of
endothelium-derived nitric oxide activity by glucocorti¬
coids could increase both VSMC proliferation and vascu¬
lar contraction. Further, the systemic effects of glucocor¬
ticoids on cardiovascular risk factors (glucose, insulin,
lipids and blood pressure) may offset beneficial effects
within the vessel wall.
Dexamethasone reduces cholesterol ester accumulation
in the aorta [133], and glucocorticoids (dexamethasone,
hydrocortisone) inhibit neointimal lesion formation in
rats [134, 135], rabbits [136-138] and dogs [139] (with a
few contradictory reports [140, 141]). Clinical trials in
humans, by contrast, have proved disappointing (with no¬
table exceptions [130]): methylprednisolone did not in¬
hibit restenosis after coronary angioplasty [142] or stent
implantation [ 143], whilst the combination of a glucocor-
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ticoid with colchicine increased the risk of coronary
aneurysm following stent placement [144], Discrepan¬
cies between clinical studies and animal models could be
attributed to species differences or, more probably, to
methodological variation (e.g. small sample size; inap¬
propriate patient selection, dose, duration of treatment,
route of administration). Exacerbation of lesion develop¬
ment by glucocorticoids could be explained by systemic
effects (e.g. weight gain with elevated blood pressure and
plasma lipids, which may be more prominent in humans
than in other species) or by a net stimulation of vascular
cell proliferation. Alternatively, changes in plasma lipids
could influence the ability of glucocorticoids to interact
with vascular cells. Lipoprotein(a) can downregulate GR
gene expression in human VSMCs, thus inhibiting any
protective actions ofglucocorticoids and, possibly, repre¬
senting a novel atherogenic mechanism [145].
Angiogenesis
Angiogenesis, in which new blood vessels are formed
from an existing vascular network, is a complex process
regulated by a balance between counteracting endoge¬
nous activators and inhibitors [146]. Physiological angio¬
genesis is an essential component of reproduction and
embryonic development. In postnatal and adult life, it is a
discrete process (e.g. in the reproductive tract, wound
healing and exercised skeletal muscle) of relatively short
duration [147]. In contrast, pathological angiogenesis is
usually persistent and unabated and often continues for
months or years [147]. Numerous disorders are charac¬
terised by excessive angiogenesis, including neoplasia,
rheumatoid arthritis and diabetic retinopathy [148]. Con¬
sequently, modulation of angiogenesis is regarded as an
attractive therapeutic goal in a variety of conditions.
A comprehensive review of the mechanisms ofangiogen¬
esis is beyond the scope of this article (for recent reviews
see [146, 149]). For the present purposes it is useful to
consider angiogenesis to be a stepwise process compris¬
ing four distinct phases: (i) basement membrane disinte¬
gration, (ii) endothelial cell migration, (iii) channel for¬
mation and (iv) maturation. Of the numerous factors that
control this process, vascular endothelial cell growth fac¬
tor (VEGF) is widely considered to be of central impor¬
tance, since it is crucial for vascular development both in
the embryo and in adult tissues and it is EC specific.
Since its first demonstration by Folkman and colleagues,
over 20 years ago [150], the ability of glucocorticoids to
inhibit angiogenesis has been confirmed in vitro, in vivo
and in tumour-bearing animals [150]. It was suggested
that inhibition of angiogenesis in the rabbit cornea
was independent of classical GR and MR activity [151].
For example, 17a-hydroxyprogesterone and tetrahydro-
S, which have no glucocorticoid or mineralocorticoid ac¬
tivity, retained an anti-angiogenic capability equivalent
to, or greater than, that of hydrocortisone. Taken together,
these studies demonstrated a class of steroids for which
inhibition of angiogenesis appears to be the principal
function and hence were named 'angiostatic steroids.'
[151].
Despite considerable research, the mechanisms through
which glucocorticoids inhibit angiogenesis have not been
identified. Indeed, the role of GR is still controversial, as
some of the 'angiostatic steroids' may actually have the
ability to stimulate these receptors. For example, we have
recently shown that inhibition of angiogenesis by tetrahy-
drocorticosterone, one of the original angiostatic ster¬
oids, is dependent upon GR activation in mouse aortic
ring explants [G. R. Small et ah, unpublished]. Some in¬
dication of mechanism was provided by early studies
which demonstrated, using nude mice or the non-antico¬
agulant hexasaccharide fragment of heparin, that the
combination of glucocorticoid and heparin was indepen¬
dent of an immune response and anti-coagulant function,
respectively [ 150]. At present, however, there are still sev¬
eral possible pathways through which glucocorticoids
may inhibit angiogenesis: (i) Degradation of extracellular
matrix, (ii) modification of cytokine production, (iii) in¬
hibition of protease activity, (iv) impairment of vessel
maturation and stabilisation, (v) inhibition ofgrowth fac¬
tor activity, (vi) inhibition of the arachidonic acid cas¬
cade, (vii) inhibition of EC-leukocyte interactions and
(viii) non-transcriptional effects. The relative signifi¬
cance of these pathways has not been established.
llHSDs and vascular remodelling
Although the initial focus was on 11HSD2 and vascular
function, the most recent work in the field of intra-vascu-
lar glucocorticoid metabolism has highlighted novel roles
for 11HSD1 in influencing vascular structure and remod¬
elling.
Neointimal remodelling and atherogenesis
The potential link between atherosclerosis and tissue-
specific generation of glucocorticoids by llHSDs has
been underlined by recent demonstrations that selective
upregulation of 11HSD1 in the adipose produces features
of the metabolic syndrome, including central obesity, hy¬
pertension and hypertriglyceridaemia [ 10,152]. This sup¬
ports the concept that similarities between the metabolic
syndrome and Cushing's syndrome are explained by tis¬
sue-specific increases in 11HSD1 activity resulting in tis¬
sue-specific elevation ofglucocorticoid generation [153].
This link between 11HSD1 activity in glucocorticoid-tar-
get tissues and atherosclerotic risk factors is not limited
to the adipose, as hepatic overexpression of 11HSD1 also
results in elevated blood pressure and dyslipidaemia
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[154]. It has been proposed, therefore, that 11HSD1 inhi¬
bition may reduce atherogenesis. Very recently, systemic
administration of a selective 11HSD1 inhibitor was re¬
ported to virtually abolish lipid accumulation in the aorta
of atherosclerotic (apolipoprotein E ') mice. However,
inhibition of 11HSD1 in ApoE ' mice produced only a
relatively modest reduction in serum triglycerides and
cholesterol [155], suggesting that mechanisms over and
above amelioration of systemic cardiovascular risk fac¬
tors may be responsible. It may be that inhibition of
11HSD1 within the vessel wall or within invading macro¬
phages [156] is caicial, but these mechanisms require
further clarification.
1 lHSD2-dependent protection ofMR from inappropriate
occupation by glucocorticoids may also influence athero¬
genesis. The role ofMR activation in the pathogenesis of
atherosclerosis [157] is demonstrated by aldosterone-in-
duced enhancement of lesion development in atheroscle¬
rotic (apolipoprotein E ') mice (probably by increasing
oxidative stress in macrophages and cells of the vascular
wall [157, 158]). This potentiation of lesion development
by aldosterone, which is largely independent of blood
pressure, is attenuated by MR antagonists [157], as is
constrictive remodelling following angioplasty [159],
The potential importance of 11 HSD activity to the devel¬
opment of atherosclerotic lesions was recently extended
by the demonstration that, in addition to glucocorticoid
metabolism, llHSDs catalyse the conversion of the
atherogenic oxysterol 7-ketocholesterol to 7/3-hydroxy-
cholesterol [160]. 7-Ketocholesterol is present in micro-
molar concentrations in human atherosclerotic lesions
and in nanomolar concentrations in the plasma [161], Its
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Figure 4. The influence of 11HSD1 on glucocorticoid-mediated angiogenesis. (A) In mouse aortic rings cultured in Matrigel, corticosterone
and its inactive metabolite 11-dehydrocorticosterone attenuated new vessel growth. Glucocorticoid receptor antagonism (with RU38486,
filled columns) abolished the angiostatic response to both compounds (Ai), but 11HSD1 deletion (hatched columns) selectively prevented
11-dehydrocorticosterone-mediated angiostasis (Aii). Similar results were obtained in vivo, using subcutaneous sponge implants (B), with
11HSD1 deletion (hatched columns) increasing angiogenesis under basal conditions and abolishing cortisone-, but not Cortisol-, mediated
inhibition of vessel growth. This mechanism contributed to regulation of myocardial angiogenesis following coronary artery ligation (C)
with increased vessel growth in 11HSD1 mice (coronary artery ligation, shaded bars; sham, open bars). rtp < 0.05 compared with relevant
vehicle-treated control; **p<0.01 compared with wild-type mice; ***p<0.001 compared with relevant wild-type control or sham-oper¬
ated mouse. Reproduced with permission from [168]. © The National Academy of Sciences of the USA, 2005.
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association with atherosclerosis is demonstrated in the
condition cerebrotendinous xanthomatosis, in which pa¬
tients who have normal circulating cholesterol levels but
increased 7-ketocholesterol develop atherosclerosis pre¬
maturely [162], Conversion of 7-ketocholesterol to 7/3-
hydroxycholesterol by 11 /3-IISD1 may represent the rate-
limiting step in a clearance pathway: in vivo inhibition of
11HSD1 in rats resulted in an accumulation of 7-ketoc-
holesterol in the liver and increased concentrations in the
plasma [163], In addition to these hepatic effects, reduc¬
tion of 7-ketocholesterol by 11HSDI within the vascular
wall may also be important. 7-Ketocholesterol and 7/J-hy-
droxycholetserol are both toxic to cells of the vascular
wall [164] and are potent inhibitors of endothelium-de-
pendent relaxation [165-167]. Consequently, reduction
of 7-ketocholesterol, and subsequent clearance of 7/J-hy-
drocholesterol, by protecting the vascular wall from dam¬
age may have a role in preventing lesion development.
The influence of 11-HSD activity on angiogenesis
Since inflammatory cytokines can promote angiogenesis,
we hypothesised that 11/3-HSD1 in the vessel wall may
regulate new vessel formation by controlling the local re¬
generation of active glucocorticoids. This possibly was
addressed using a combination of in vitro, in vivo and
pathological models of angiogenesis [168], Using a
model of tube formation from mouse aortic rings cultured
in Matrigel [169], we demonstrated (fig. 4A) that angio¬
genesis was inhibited by physiological concentrations of
active glucocorticoid (corticosterone) but also by its in¬
active metabolite (11-dehydrocorticosterone). Both these
responses were blocked by RU38486, but not by spirono¬
lactone, indicating GR dependence. However, whereas
11HSD1-inhibition (with carbenoxolone) or deletion
(aortic rings from 11HSD1 ' mice) had no effect on
the response to corticosterone, they abolished the ability
of 11 -dehydrocorticosterone to inhibit angiogenesis
(fig. 4B). This indicated that 11HSD1-dependent regen¬
eration of active glucocorticoid within the vascular wall
regulates new vessel growth. Application of a model
of angiogenesis in sub-cutaneous sponge implants, con¬
firmed this role for 11HSD1 in vivo, showing that
11HSD1 deletion produced increased angiogenesis in un¬
treated sponges and blocked the ability of cortisone (but
not Cortisol) to inhibit new vessel formation. The patho¬
physiological significance of these observations was em¬
phasised in healing cutaneous wounds and in the myocar¬
dial response to coronary artery ligation (fig. 4C). In both
cases, 11HSD1 deletion resulted in increased angiogene¬
sis, demonstrating that 11HSD1 regulates the growth of
new blood vessels in healing tissues.
Altered angiogenesis in 11HSD1 ' [168] mice could,
conceivably, be the result of changes in macrophage ac¬
tivity. Given that 11HSD1 is expressed in macrophages
[170], and regeneration ofglucocorticoids enhances pha¬
gocytosis of apoptotic neutrophils [107], absence of
11HSD1 may confer a prolonged and enhanced acute in¬
flammatory response, thus stimulating angiogenesis. The
use of ex vivo models such as isolated aortic rings cul¬
tured in extracellular matrices [171] has made it possible
to differentiate between these two intimately related path¬
ways, angiogenesis and inflammation, and specifically
address the effects of glucocorticoids on angiogenesis in
the absence ofa systemic response. This has produced ev¬
idence that glucocorticoids regulate angiogenesis by di¬
rect interaction with the vessel wall [168],
Conclusions
It is apparent that glucocorticoids have the ability to regu¬
late both the structure and the function of the artery wall,
with significant implications for vascular physiology and
pathophysiology. Emerging evidence suggests that pre-re-
ceptormetabolism ofglucocorticoids within vascular ECs
and VSMCs provides a mechanism for regulating these in¬
teractions. Relatively few studies have addressed the role
of intravascular 11HSD activity, and most of those avail¬
able have focussed on vascular function. There is, how¬
ever, a growing body of evidence to suggest that 11HSD
isozymes within the arterial wall modulate vascular con¬
tractility, the angiogenic growth of new blood vessels, and
the atherosclerotic process. Whether these isozymes also
influence the inflammatory response to vascular injury
and the inter-conversion of atherogenic oxysterols in vas¬
cular smooth muscle has still to be determined. Further
clarification of the role of llHSDs in vascular cells is
likely to increase our understanding of the link between
glucocorticoids and a variety of vascular diseases, and to
demonstrate their potential as therapeutic targets for treat¬
ment of these conditions.
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110-Hydroxysteroid dehydrogenases (llffflSDs) catalyze in-
terconversion of 11-hydroxy-glucocorticoids with inactive 11 -
keto metabolites. In blood vessel walls, loss of 110HSD1 is
thought to reduce local glucocorticoid concentrations, reduc¬
ing the progression of atheroma and enhancing angiogenesis.
Conversely, on the basis that 11/JHSD1 is up-regulated ap¬
proximately 5-fold by inflammatory cytokines in cultured hu¬
man vascular smooth muscle cells, it has been proposed that
increased 11/3HSD1 during vascular inflammation provides
negative feedback suppression of inflammation. We aimed to
determine whether inflammation and injury selectively up-
regulate 11/3HSD1 reductase activity in vitro and in vivo in
intact vascular tissue in mice. In isolated mouse aortae and
femoral arteries, reductase activity (converting Il-dehydro-
corticosterone to corticosterone) was approximately 10-fold
higher than dehydrogenase activity and was entirely ac¬
counted for by lljJHSDl because it was abolished in vessels
from 11/SHSD1-'- mice. Although 11/iHSDl activity was up-
regulated by proinflammatory cytokines in cultured murine
aortic smoothmuscle cells, no such effectwas evident in intact
aortic rings in vitro. Moreover, after systemic inflammation
induced by ip lipopolysaccharide injection, there was only a
modest (18%) increase in 11/J-reductase activity in the aorta
and no increase in the perfused hindlimb. Furthermore, in
femoral arteries in which neointimal proliferation was in¬
duced by intraluminal injury, there was no change in basal
11/3HSD1 activity or the sensitivity of 11/3HSD1 to cytokine
up-regulation. We conclude that increased generation of glu¬
cocorticoids by lljSHSDl in the murine vessel wall is unlikely
to contribute to feedback regulation of inflammation. (Endo¬
crinology 148: 166-172, 2007)
THE LINK BETWEEN glucocorticoids and cardiovascu¬lar disease is well established: systemic glucocorticoid
excess (1) and exogenous glucocorticoid therapy (2, 3) are
associated with an increase in cardiovascular risk. Epidemi¬
ological studies have associated higher Cortisol secretion
with risk factors for cardiovascular disease, including hy¬
pertension, insulin resistance, impaired glucose tolerance,
and dyslipidemia (4, 5). Furthermore, the local action of
glucocorticoids within the blood vessel wall may be impor¬
tant because glucocorticoids influence the regulation of vas¬
cular tone (6, 7) and the vascular response to inflammation
and injury (8,9). This may have therapeutic as well as patho¬
physiological significance: for example, glucocorticoid ther¬
apy has been shown to prevent neointimal proliferation after
intraluminal vascular injury (10, 11).
Recent studies demonstrated the importance of tissue-
specific regulation of glucocorticoid concentrations (12,13).
Interconversion of glucocorticoids (corticosterone in ro¬
dents) and their 11-keto-metabolites (11-dehydrocorticoster-
one) is catalyzed in target tissues by the 11 /3-hydroxysteroid
dehydrogenases (ll/3HSDs). 11/311SD type 1 acts predomi¬
nantly as a reductase in vivo, catalyzing the regeneration of
active glucocorticoids and thereby promoting activation of
glucocorticoid receptors in target tissues. 11/3HSD type 2 is
First Published Online September 28, 2006
Abbreviations: FCS, Fetal calf serum; lljSHSD, 11 /3-hydroxysteroid
dehydrogenase; LPS, lipopolysaccharide; MA, murine aortic; SMC,
smooth muscle cell.
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an exclusive dehydrogenase (14-16) and prevents illicit ac¬
tivation of mineralocorticoid receptors by glucocorticoids.
Both isozymes are expressed in the vessel wall (17-20), as are
both mineralocorticoid and glucocorticoid receptors (6, 21).
In mouse, 11/3HSD1 is predominantly localized to the
smooth muscle, whereas 11/3HSD2 is found in the endothe¬
lium (21). 11/3HSD2 prevents glucocorticoids from inhibiting
endothelium-dependent vasodilatation (22), but a role for
11/3HSD1 in the vessel wall has only recently been elicited
and appears to relate to vascular remodeling. By increasing
local glucocorticoid concentrations, 11/3HSD1 amplifies the
angiostatic actions of glucocorticoids (9). Conversely, inhi¬
bition of 11/3HSD1 protects against atherogenesis in
ApoE_/_ mice; this effect is disproportionate to changes in
serum lipid profile and may reflect alterations in local re¬
generation of glucocorticoids within the vessel wall (23).
It has been suggested that 11/3HSD activity is regulated in
diseased blood vessels, contributing to local feedback regu¬
lation of inflammation. This hypothesis is based on the ob¬
servation that proinflammatory cytokines (e.g. TNFa) up-
regulate 11/3HSD1 activity and expression and down-
regulate 11/3HSD2 expression in cultured human aortic
smooth muscle cells (24), favoring increased local glucocor¬
ticoid concentrations. However, whereas cytokines alter
11/3HSD activity in vascular and other cultured cell types
(24-31), the relevance of this observation during inflamma¬
tion in intact blood vessels has not been established. Here we
use models of systemic and local vascular inflammation in
vitro and in vivo to address the hypothesis that exposure to
proinflammatory cytokines selectively up-regulates
11/3HSD1 activity in intact blood vessels.
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Materials and Methods
Mice
Male, C57B6] (Charles River, Kent, UK) and 110HSD l_/_ mice on
a C57B6] genetic background (Harlan Orlac, UK) (32) were maintained
under controlled conditions of light (on 0800-2000 h) and temperature
(21 C) with free access to chow (Special Diet Sendees, Witham, UK) and
water. Animal experiments were carried out under Home Office license
and conformed to standards defined in The Principals of Animal Care
(National Institutes of Health publication 85-23, revised 1985).
Materials
Salts were obtained from BDH (Dorset, UK). l,2,6,7-[3H]4-corticoste-
rone was obtained from Amersham Biosciences (Buckingham, UK).
l,2,6,7-[3H]4-ll-dehydrocorticosterone was synthesized in house from
l,2,6,7-[3H]4-corticosterone using rat placental homogenate (33) and was
more than 99% pure when assessed by HPLC. Murine recombinant
TNTa, II.-l /!, IL-4, and IL-13 (R&D Systems, Abingdon, UK) were stored
in PBS containing 0.1% fetal calf serum (FCS) in aliquots at —20 C until
required. Etanercept (Wyeth, UK) was dissolved in sterile water. Lipo-
polysaccharide (LPS), derived from Escherichia coli (serotype 0111:B4;
Sigma, Poole, UK), was dissolved in sterile 0.9% saline and stored at —20
C. Bioactivity of TNFa was confirmed by means of a neutrophil apo-
ptosis assay (data not shown) (34).
Effects of IL-If on llfHSDl activity in cultured vascular
smooth muscle cells
Mice were killed by cervical dislocation. The thoracoabdominal aor-
tae and the iliofemoral vessels were immediately removed into ice-cold
DMEM F12 (Invitrogen, Renfrewshire, UK) and cleaned of periadven-
titial tissue. Primary murine aortic (MA) smooth muscle cells (SMCs)
were cultured using a modification of the method of Ray et al. (35). The
cells were maintained in DMEM containing 20% FCS, 1% penicillin/
streptomycin, and 1% L-glutamine 200 mM (Life Technologies, Inc.,
Paisley, UK) in a humidified oxygenated (95% Oz-5% C02) atmosphere.
To demonstrate that 11/3HSD1 activity in murine-cultured SMCs is
up-regulated after cytokine stimulation as in human SMCs (24), MA-
SMCs (passage 2) were seeded onto 6-well plates at 1.75 X 10s cells/well
in 2 ml of assay medium. The following day, the medium was replaced
with basal medium [containing 0.5% FCS plus IL-1/3 (20 ng/ml) or
vehicle], and cells were incubated for 48 h. [3H]4-ll-dehydrocortico-
sterone (10 pmol) was then added to the appropriate wells and the cells
incubated for a further 24 h. Steroids were extracted from the culture
medium supernatant using C18 Sep-pak columns (Waters Millipore,
Watford, UK). [3H]4-corticosterone and [3H]4-ll-dehydrocorticosterone
were separated by HPLC and quantified by on-line liquid scintillation
counting. Enzyme activity was expressed as conversion per 1.75 X 105
cells after subtraction of apparent conversion in negative control wells.
Effects of cytokines on llfHSD activity in intact vascular
and hindlimb tissues in vitro
11/3HSD activities were measured in murine aortic rings and iliofem¬
oral vessels by adapting tiremethod of Soilness et al. (36). Briefly, vessels
were incubated (24 h, 37C) in DMEM-F12 (1 ml) containing [3H]4-steroid
and supplemented with streptomycin (100 /xg/ml), penicillin (100
U/ml), and amphotericin (0.25 /xg/ml). 11/3-Reductase activity was de¬
termined in vessels fromwild-type and ll/3HSDl_/_ mice by adding 10
pmol [3H]4-ll-dehydrocorticosterone. 11 ^-Dehydrogenase activity was
determined in vessels from wild-type mice by adding 10 pmol [3H]4-
corticosterone. 11/3-Reductase activity was also determined using the
method described for arteries in hindlimb tissues (dissected pieces of
quadriceps muscle and skin with subcutaneous fat) from wild-type
mice.
To assess the influence of cytokines in vitro on 11/3-reductase activity,
single aortic rings from C57B6J mice were preincubated with murine
recombinant TNFa (10-1000 ng/ml); IL-1/3 (1-100 ng/ml); IL-4 (50 ng/
ml); IL-13 (50 ng/ml); Etanercept [a fusion protein that antagonizes
human andmurine TNFa and that ameliorates the cardiovascular effects
of murine TNFa (37), 0.1-10 /xg/ml]; or vehicle. After 16 h incubation
(24), 10 pmol [3H]4-ll-dehydrocorticosterone was added and incubation
continued for a further 24 h. Control wells without tissue contained
medium alone, [3H]4-ll-dehydrocorticosterone, or [3H]4-ll-dehydro-
corticosterone with cytokines.
To observe the effect of cytokines in vitro on 11/3-dehydrogenase
activity, three to five aortic ringswere preincubated for 16 h with murine
recombinant TNFa, IL-1/3, or vehicle. At 16 h, 10 pmol [3H]4-cortico-
sterone was added and incubation continued for a further 24 h. Control
wells contained [3H]4-corticosterone alone, medium alone, and [3H]4-
corticosterone with cytokines.
After incubation, steroids were extracted from the culture medium
and assayed as described for cultured cells. Aortic ring tissue, which
contains only 2-3% of the added radioactivity (36), was not included in
the extraction.
Effects of LPS in vivo on vascular llfHSDl activity in
aorta and perfused murine hindlimb
As described by Brandes et al. (38), the aorta at the thoracoabdominal
transition was isolated, after cervical dislocation, and a cannula (24-
gauge; Neoflon, Ohmeda, Sweden) introduced (distal to the renal ar¬
teries) and secured at the iliac bifurcation with a 3-0 prolene suture
(Surgical Supplies Ltd., Cumbernauld, UK). The distal inferior vena cava
was also cannulated (18-gauge cannula; Venflon, BD, UK) and secured
with a 3-0 prolene suture. The hindlimb was constantly perfused, via
the aortic cannula, with warmed oxygenated modified Krebs-Henseleit
solution containing 2% BSA (Sigma) at flow rates of between 0.8 and 1.2
ml/min to achieve a perfusion pressure of approximately 40 mm Hg.
Effluent was collected from the venous cannula. After a 10-min equil¬
ibration period, [3H]4-ll-dehydrocorticosterone (for determination of
reductase activity) or [3H]4-corticosterone (for determination of dehy¬
drogenase activity) was added to the perfusion buffer (final concentra¬
tion 5 nM). Perfusion was maintained for up to 60 min and aliquots of
effluent collected at regular intervals. Steroids were extracted from the
effluent and analyzed as described for aortic homogenates. To determine
enzyme kinetics for 11/3-reductase activity, the above procedure was
replicated using concentrations of [3H]4-ll-dehydrocorticosterone be¬
tween 5 and 500 nM.
The effects of inflammation on 11/3HSD1 activity in the perfused
hindlimb were assessed 6 h after ip administration of LPS (10 mg/kg)
or vehicle (physiological saline; 20 ml/kg).
To assess the effects of in vivo LPS on aortic 11/3HSD activities, aortic
rings were obtained from C57B6J mice that had received either LPS (10
mg/kg ip) or vehicle 6 h before the animals were killed. 11/3-Reductase
and dehydrogenase activities were determined, ex vivo, by incubation
with 10 pmol [3H]4-ll-dehydrocorticosterone or [3H]4-corticosterone for
24 h, as described above.
Effects of vascular injury on llfHSDl enzyme activity in
femoral arteries
Femoral artery injury was performed in anesthetized (halothane)
C57B6J mice using the method of Sata et al. (39). Briefly, a guidewire
(0.014 in. diameter; Cook Inc., UK) was advanced from the descending
genual artery to more than 5 mm along the femoral artery, left in place
for 1 min, and then removed. The genual artery was ligated, blood flow
restored to the femoral artery, and the skin incision closed with 6-0 silk
sutures. For histological evaluation, arterieswere excised at various time
points after injury, fixed in 10% neutral buffered formalin, and embed¬
ded in paraffin. Four-micrometer sections were stained with the United
States trichrome stain (40).
To assess the effects of vascular injury on basal 11/3HSD1 activity,
injured and contralateral uninjured femoral arteries (from the descend¬
ing genual artery to the bifurcation of tire iliac artery, therefore con¬
taining the entire injured section of vessel) removed 7 d after surgery
were incubated in vitro with vehicle for 16 h after which 11/3-reductase
activity was assessed as described above. In addition, to examine the
effect of cytokines on 11/3HSD1 activity in injured arteries, injured and
contralateral uninjured femoral arteries were removed 7 d after injury
and incubated in vitro with 1L-1/3 (10 ng/ml) for 16 h after which 11/3-
reductase activity was assessed as described above.
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Data analysis and statistics
III vitro experiments were performed in duplicate or triplicate and the
mean in each experiment used in statistical analyses. Enzyme activity
was expressed per 1.75 X 105 cells or, in the case of intact tissue, per wet
weight of tissue after subtraction of apparent conversion in negative
control samples. Data are expressed as mean ± sem and analyzed by
Student's t test or ANOVA followed by post hoc tests where appropriate.
Results
Effects of IL-lfi on llpHSD activity in cultured mouse
aortic smooth muscle cells
As previously reported in human SMCs (24), IL-1/3 in¬
creased 11/3-reductase activity by approximately 40% (87 ±
2% conversion in 24 h), comparedwith controls (62 ± 3%; P <
0.05, n = 6).
Effects of cytokines on llfiHSD activity in intact vascular
tissue in vitro
11/3-Reductase and dehydrogenase activities were de¬
tected in aortic rings and femoral arteries from C57B6J mice
(Fig. 1). 11/3-Reductase activity was higher in aorta than
femoral artery (P < 0.005), whereas 11/3-dehydrogenase ac¬
tivity was similar in aorta and femoral artery (Fig. 1, P = 0.48;
n = 6). 11/3-Reduction was the predominant reaction direc¬
tion, and was completely abolished in arteries from
ll/3HSDl_/_ mice (<0.1pmol/mg per 24 h, n = 6).
11/3-Reductase activity in aortic rings from wild-type mice
(8.30 ± 1.20 pmol product/mg per 24 h, n = 18) was unaf¬
fected after incubation with the proinflammatory cytokines
IL-1/3 and TNFa or the antiinflammatory cytokines IL-4 and
IL-13 (Fig. 2). To exclude the possibility that 11/3HSD1 in
aortic rings was already maximally induced by endogenous
TNFa, rings were incubated with the TNFa antagonist, Et-
anercept, which had no effect on 11/3-reductase activity (Fig.
2). 11/3-Dehydrogenase activity in wild-type aortic rings
(0.21 ± 0.08 pmol product/mg per 24 h) was unaffected by







Fig. 1. 11/3IISD activities in intact vascular tissues in vitro. 11/3-
Reductase (open bars) and dehydrogenase (closed bars) activities in
intact arteries from C57B6J mice. Reductase and dehydrogenase ac¬
tivities are expressed as the amount of [3H]4-corticosterone or [3H]4-
11-dehydrocorticosterone formed, respectively. Results are mean ±
se, n = 6. 11/3-Reductase activity was higher than dehydrogenase
activity (***, P < 0.0001 for aorta; *, P < 0.05 for femoral artery).
11/3-Reductase activity was higher in aorta than femoral artery (**,
P < 0.005).
C TNFa IL-ip IL-4 IL-13 Etanercept
Concentration (ng/ml)
Fig. 2. Effect of cytokines on 11/3-reductase activity in the mouse
aorta. Aortic rings were incubated for 48 h with TNFa, IL-1/3, IL-4,
IL-13, Etanercept, or vehicle and then for a further 24 h in the
presence of [3H]4-ll-dehydrocorticosterone. 11 /3-Reductase activity is
expressed as [3H]4-corticosterone formed relative to activity in control
incubations without cytokine manipulation. Results are mean ± se.
There were no differences between groups (n = 4-10).
product/mg per 24 h) or TNFa (100 ng/ml; 0.30 ± 0.01 pmol
product/mg per 24 h, P = 0.25, n = 4).
Effect of LPS in vivo on lipHSDl activity in aorta and
perfused murine hindlimb
In perfused murine hindlimb, both reductase and dehy¬
drogenase activities were detected, with reductase predom¬
inating by approximately 10:1 (Fig. 3A). In ll/3HSDl_/_
mice, reductase activity was abolished (Fig. 3A). The appar¬
ent Michaelis constant was 1.064 p\t for 11/3-reductase ac¬
tivity in the perfused hindlimb (Fig. 3B). Ex vivo assays of
hindlimb tissues confirmed reductase activity in the hind¬
limb vasculature (11.4 ± 31.4 pmol/mg per 24 h), which was
substantially greater than in skeletal muscle (0.14 ± 0.02
pmol/mg per 24 h; P < 0.0001) or skin with sc fat (0.27 ± 0.05
pmol/mg per 24 h; P < 0.0001, n = 4).
Intraperitoneal LPS administration to wild-type mice in¬
duced weight loss (1.4 ± 0.2 vs. 0.7 ± 0.2 g, P < 0.05, n = 6)
and splenomegaly (0.12 ± 0.01 vs. 0.08 ± 0.01 g, P < 0.05, n =
6), compared with vehicle. LPS induced a small increase in
11/3-reductase (P < 0.05, n = 6) but not dehydrogenase (P =
0.16, n = 3) activity in aortic rings analyzed ex vivo (Fig. 4A)
but did not significantly increase 11/3-reductase activity in
the perfused hindlimb (P = 0.12 by repeated measures
ANOVA, n = 6; Fig. 4B).
Influence of vascular injury on llfiHSD activity in
femoral artery
Vascular injury produced extensive stretching of the vas¬
cular wall and atrophy of medial SMCs, with subsequent
development of a proliferative, smooth-muscle rich neoin-
tima, evident at 7 d and peaking in size at 21 d (Fig. 5).
11/3-Reductase activity was not altered in femoral arteries
after vascular injury in vivo (P = 0.33, n = 6; Fig. 6). Fur¬
thermore, vascular injury did not alter the effect of in vitro
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Fig. 3. 11/3HSD activities in the perfused murine hindlimb. A, 11/3-
Reductase (closed squares) and dehydrogenase (closed triangles) ac¬
tivities in perfused hindlimbs of C57B6J mice and 11/3-reductase
activity in perfused hindlimbs of 11/3HSD1-'- mice (open circles).
Enzyme activity is expressed as the percentage of [3H]4-corticosterone
or [3H]4-ll-dehydrocorticosterone formed, 11/3-Reductase activity
was abolished in 11/3HSD1-'- mice. Results are mean ± se, n = 3-4;
**,P < 0.005, comparing reductase activity in 11/3HSD1-'- mice with
controls. B, Kinetics of 11/3-reductase activity in perfused hindlimbs
of wild-type C57B6J mice. Using a time point of 11 min after the
commencement of the perfusion, Michaelis constant was calculated
from this Lineweaver-Burke plot as 1.064 pM and maximum velocity
313 pmol/min. Results are mean ± se, n = 3 at each concentration.
A, 11-Dehydrocorticosterone.
incubation with IL-1/3 on 11/3-reductase activity (P = 0.20,
n = 6; Fig. 6).
Discussion
We and others previously established that both isozymes
of 11/3HSD are present in the vascular wall (17-21), in which
they may regulate local glucocorticoid availability and hence
activation of glucocorticoid and mineralocorticoid receptors.
Here we assessed whether vascular inflammation increases
local generation of active glucocorticoid by selectively alter¬
ing the activity of 11/3HSD1. Our results indicate that, in
contrast to cultured SMCs (24), 11/3HSD1 in intact arteries is
not up-regulated by proinflammatory cytokines in vitro or in
vivo or the inflammatory response to injury in vivo. This
suggests that endogenous glucocorticoid generation in the
A
*
Fig. 4. Effects of in vivo LPS on 11/3HSD activity in vascular tissue.
A, Aortic rings from C57B6J mice were incubated for 24 h in the
presence of either [3H]4-ll-dehydrocorticosterone or [3H]4-corticoste-
rone, 6 h after in vivo ip administration of LPS (10 mg/kg) or vehicle.
11/3-Reductase and -dehydrogenase activities are expressed as the
amount of [3H]4-corticosterone or [3H]4-ll-dehydrocorticosterone
formed, respectively. Results are mean ± se. 11/3-Reductase activity
was increased after LPS injection (*, P < 0.05, n = 6). 11/3-Dehydro-
genase activity was similar in both groups (P = 0.16, n = 3). B,
11/3-Reductase activity in perfused hindlimbs of C57B6J mice 6 h
after in vivo ip administration of LPS (10 mg/kg, closed circles) or
vehicle (open squares). 11/3-Reductase activity is expressed as the
amount of [3H]4-corticosterone formed. Results are mean ± se. There
were no differences between groups (P = 0.12 by repeated-measures
ANOVA, n = 6).
murine arterial wall does not provide a mechanism for feed¬
back regulation of inflammation.
Although both isozymes of 11/3HSD are expressed in mu¬
rine vessels (21, 22), the net balance between active 11-OH
and inactive 11-keto steroids was unpredictable. Whereas
11/3HSD2 is an exclusive dehydrogenase and 11/3HSD1 a
predominant reductase, 11/3HSD1 might operate as a dehy¬
drogenase in the absence of cofactor generated by the neigh¬
boring hexose-6-phosphate dehydrogenase in the endoplas¬
mic reticulum (41, 42). Here we show that the predominant
reaction direction, by approximately 10-fold, in intact vessels
is the reductase and that this can be accounted for entirely by
11/3HSD1 because it is absent in ll/3HSDl~/~ mice. More¬
over, the kinetics of reductase activity in the perfused hind-
limb are consistent with the 11/3HSD1 isozyme (43). Further¬
more, whereas dehydrogenase activity was similar in all
vessels examined, regional differences in basal 11/3-reductase
activity (44) were suggested, with activity higher in aortae
than femoral arteries. Our studies of regulation during in¬
flammation were therefore focused on the reductase activity
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Control
Fig. 5. Development of neointimal lesions over time after intraluminal injury of the femoral artery. After wire injury of the femoral artery,
arteries were excised at the time points indicated and stained with the United States trichrome stain. This indicated initial stretching of the
vessel wall, followed by the time-dependent formation ofneointimal lesions, which are first observed at 7 d and peak in size after 21 d. A control
uninjured vessel is also shown. Scale bar, 100 /xm. Arrowheads indicate internal elastic lamina.
Consistent with a previous report in human cultured
SMCs (24), 11/3-reductase activity in cultured murine vas¬
cular SMCs was up-regulated after exposure to the proin¬
flammatory cytokine, IL-1/3. The extent of up-regulation
(40% increase in activity), however, was less dramatic than
the 5-fold enhancement reported with human SMCs (24) and
was difficult to replicate at later passages (data not shown).
This may be indicative of a species difference in the regu¬
lation of 11/3HSD1 activity by cytokines in cultured SMCs.
In contrast to cultured MA-SMCs, vascular 11/3HSD1 re¬
ductase activity was not up-regulated by several different
cytokines (IL-1/3, IL-4, IL13, TNFa) in intact arteries in vitro.
This lack of effect was not due to preexisting up-regulation
of 11HSD1 activity because the TNFa antagonist, Etanercept,
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Fig. 6. Influence of injury and inflammation on 11/3-reductase ac¬
tivity in femoral arteries. Whole injured and uninjured femoral ar¬
teries obtained 7 d after surgery were incubated for 16 hwith 10 ng/ml
IL-1/3 or vehicle and then for a further 24 h in the presence of [3H] 11-
dehydrocorticosterone. 11/3-Reductase activity is expressed as the
amount of [3H]corticosterone formed. Results are mean ± se. There
were no differences between groups (P = 0.33 for effect of injury, P =
0.20 for effect of cytokine, n = 6).
also had no effect on glucocorticoid generation. In addition,
IL-1/3 and TNFa failed to produce the down-regulation of
11/3-dehydrogenase activity reported in human SMCs (24).
In contrast to our in vitro findings, there was a small (18%),
selective increase in 11/3-reductase activity in aortic rings
from mice that had received LPS in vivo. Thus, although
individual cytokines were ineffective at enhancing 11/3HSD1
activity in intact tissue, the result of in vivo LPS may be to
produce an altered inflammatory milieu that favors a modest
increase in 11/3-reductase activity. Although this effect of LPS
was not evident in perfused hindlimbs, there was a similar
trend toward an increase in 11/3-reductase activity, raising
the possibility that there is a small effect of LPS on hindlimb
vascular 11/3HSD1 activity, which may be masked by the
contributions from other tissue types within the regional
perfused territory. Additionally, there may be regional dif¬
ferences in the inflammatory regulation of vascular
11/3HSD1 activity. It is uncertain whether the resultant
change in glucocorticoid availability after these modest ef¬
fects would have physiologically relevant consequences, but
importantly the magnitude of effect is substantially smaller
than that observed in cultured cells (24).
The majority of reports detailing regulation of 11/3HSD1
activity by inflammatory cytokines (in a variety of different
cell types) demonstrate a selective increase in 11/3-reductase
activity and/or expression (24-31). This effect is not univer¬
sal, however, because TNFa has no effect on 11/3-reductase
activity in cultured human hepatocytes (28). Furthermore, in
circulating monocytes, 11/3HSD1 expression is not up-regu¬
lated by TNFa or IL-1/3 but is induced during differentiation
into macrophages and after exposure to IL-4 and IL-13 (25).
All studies reported to date used cell culture systems, which
undoubtedly alter the natural cell phenotype. The differences
that we observed in the ability of cytokines to up-regulate
11/3HSD1 activity in cell culture but not intact tissue prep¬
arations suggests that the regulation of 11/3HSD1 by inflam¬
matory stimuli may not only be tissue specific but may also
depend on the degree of cell proliferation and/or differen¬
tiation. In vascular lesions, contractile SMCs dedifferentiate
and take on a proliferative phenotype (45). Thus, the absence
of inflammatory up-regulation of 11/3HSD1 in healthy intact
arteries cannot be extrapolated to arteries undergoing pro¬
liferative remodeling. This issue was addressed using the
model of injury/proliferation in the mouse femoral artery.
Insertion of a wire in the femoral artery produces extensive
stretching of the vascular wall followed by acute inflamma¬
tion and the temporal development of a proliferative, smooth
muscle-rich neointima (39). In our hands small lesions are
first evident 7 d after injury and peak in size after 21 d. This
is consistent with the pattern of remodeling reported by Sata
et al. (39), in which significant medial and neointimal SMC
proliferation was demonstrated at 7 d. Even under these
circumstances, however, 11/3HSD1 activity was not in¬
creased in the femoral artery wall. Furthermore, the remod¬
eling process did not increase the sensitivity of 11 /3HSD1 to
up-regulation by IL-1/3. This supports the concept that in¬
flammatory regulation of ll/3HSDs in whole-tissue prepa¬
rations, even during extensive inflammatory and prolifera¬
tive remodeling, does not mirror that found in cell culture.
We conclude, therefore, that increased local generation of
endogenous glucocorticoids by 11/3HSD1 in vascular SMCs
does not contribute to regulation of vascular lesion devel¬
opment by feedback inhibition of inflammation in mice.
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